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Currently over one million humans are estimated to fulfill the criteria for chronic kidney 
damage in the Netherlands. More than 60.000 have serious kidney problems, ranging from 
renal failure to end stage renal disease (ESRD). Of these, 16.000 patients need lifelong 
renal replacement consisting of either dialysis or renal transplantation and this number 
is increasing every year. Dialysis treatment is associated with high mortality and reduces 
quality of life of the patients dramatically. One out of six patients dies every year because 
of this high mortality. Moreover, the health system costs associated with dialysis treatment 
per patient are very high. Currently over 6500 patients are treated with dialysis with an 
average annual cost of €75.000 per patient. The other option; renal transplantation became 
available in the Netherlands since 1966, but is limited by availability of donor organs. By 
the end of the year 2012, 855 patients were on the waiting list for a renal transplantation 
and every year 200 patients die because the shortage of donor organs. In 2012, 961 
kidneys were transplanted and 50% of the donor organs were from a life donor [1–3]. 
Following transplantation immunosuppressive therapy is needed to prevent the recipient’s 
immune system of rejecting the graft. The last two decades the rejection rates have been 
significantly reduced to 10–20% with the introduction of the calcineurin inhibitors 
regimens. However, despite the low acute rejection rates and successful treatment in the 
first year after transplantation long term outcome after renal transplantation remains 
poor [4]. Optimal survival of the transplanted kidney depends on a number of factors; 
the donor and transplant procedure characteristics such as living versus deceased donor, 
cold ischemic time, donor age, HLA matching as well as co-morbidities of the recipient 
and optimal immunosuppressive therapy [5–8]. Immunosuppressive agents have a small 
therapeutic window and have often highly variable pharmacokinetics which makes 
therapeutic drug monitoring (TDM) of immunosuppressive drug concentrations essential 
for individualizing the dose and thereby preventing serious toxicity or rejection [9–12]. 
Suboptimal use of immunosuppressive medication such as under-immunosuppression 
and calcineurin-inhibitor toxicity plays a central role in the shortened long-term graft 
survival. Recent studies indicate that chronic antibody-mediated rejection is another 
important barrier to improve long term outcome [13]. Maintaining adequate overall 
immunosuppression is essential for prevention of chronic antibody-mediated rejection. 
Currently the most used immunosuppressive regimen consist of: induction therapy with 
an interleukin-2 blocking agent such as basiliximab, and maintenance therapy using a 
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1calcineurin inhibitor (tacrolimus), mycophenolic acid and corticosteroids (prednisolone)
[14]. Since the introduction of mTOR inhibitors the search to find the most optimal 
immunosuppressive regimen has further increased and different calcineurin inhibitor 
sparing regimens are emerging in an attempt to further improve long term outcome [15,16]. 
Although TDM has proven its effectiveness, still some patients experience toxicity and or 
rejection, therefore further optimization is warranted. In addition finding biomarkers, 
such as polymorphisms in genes coding for proteins involved in metabolism and dynamics 
of immunosuppressive drugs, which can predict altered pharmacokinetics or dynamics 
could further improve outcome for renal transplant recipients. Pharmacometrics; which 
uses mathematical models based on physiology, pharmacology and disease for quantitative 
analysis of interaction between drugs and patients [17] as used throughout this thesis can 
be a helpful tool to find such biomarkers.
Aim and Scope
The general aim of this thesis is to optimize immunosuppressive therapy, especially 
everolimus therapy in renal transplantation recipients by identifying pharmacological 
and pharmacogenetic risk factors influencing pharmacokinetics, and dynamics such 
as side effects and patient outcome. Chapter 2 describes the knowledge of clinical 
pharmacokinetics and dynamics of mTOR inhibitors in renal transplantation at the 
start of this PhD project and functions as an introduction for this thesis. TDM of oral 
immunosuppressive agents is essential to prevent toxicity and/or rejection. Therefore 
it is very important to use a reliable and accurate bioanalytical assay. In Chapter 3 the 
differences between the most used analytical assays of measuring everolimus in whole 
blood and its effect on dosing advice are investigated. TDM is performed based on 
either trough or AUC monitoring and pharmacogenetics might be a valuable addition 
to TDM to get the drug as soon as possible on target concentration. In Chapter 4 the 
population pharmacokinetics of everolimus in a calcineurin free regimen and the search 
for predictive factors such as pharmacogenetics as well the development of a limited 
sampling model is described which enables physicians to accurately predict everolimus 
exposure with limited patient discomfort. MTOR inhibitors are known for a variety of 
side effects and high discontinuation rates. Chapter 5 evaluates potential risk factors for 
the most severe side effect of mTOR inhibitors, interstitial pneumonitis, in a case control 
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study. Furthermore Chapter 6 describes a comprehensive analysis identifying risk factors 
for discontinuation and a number of side effects in a population of renal transplant 
patients on a regimen of everolimus and prednisolone dual therapy. In Chapter 7 the most 
promising polymorphisms in renal transplantation are in investigated for influence on 
pharmacokinetics on the main stay immunosuppressive drugs cyclosporine, everolimus 
and tacrolimus. In addition Chapter 8 reports the findings of the effect of peroxide 
reductase (POR) and CYP3A5 polymorphisms and their combination on everolimus 
pharmacokinetics. Finally Chapter 9 aims at identifying risk factor associated with delayed 
graft function, acute rejection and subclinical rejection in patients on a cyclosporine based 
immunosuppressive regimen. This thesis ends with a general discussion in Chapter 10 
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Clinical pharmacokinetics and 
pharmacodynamics of mTOR inhibitors 
in renal transplantation





The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus 
are a relatively new therapeutic group in renal transplantation and have shown their 
efficacy in recent trials. Their main advantage compared to the calcineurin inhibitors 
cyclosporine and tacrolimus are their relative lack of nephrotoxicity. Sirolimus differs 
from everolimus mainly in pharmacokinetic characteristics such as elimination half-life 
and bioavailability. The oral mTOR inhibitors exert both highly variable inter- and intra-
individual pharmacokinetics. They are metabolized by CYP3A4, CYP3A5 and CYP2C8 
enzymes and are substrates for P-glycoprotein and share similar pharmacodynamics. 
Polymorphisms in genes coding for these enzymes might be of interest for optimizing 
immunosuppressive therapy. The most important side effects of sirolimus and everolimus 
are thrombocytopenia, leukopenia, hypercholesterolemia, diarrhea and although rare but 
potentially life threatening interstitial pneumonia. The narrow therapeutic window of 
mTOR inhibitors, together with high variability in pharmacokinetics, makes therapeutic 
drug monitoring essential for individualizing the dose and thereby preventing toxicity 
or rejection. The main future challenge is to further optimize mTOR inhibitor based 
immunosuppressive therapy.
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Introduction
In the last 30 years considerable progress has been made in the field of renal transplantation 
with regard to immunosuppression, since the calcineurin inhibitors (CNIs) cyclosporine 
and later on tacrolimus came available to the clinic. However, despite this success, 
calcineurin inhibitors are also associated with severe toxicity such as acute and chronic 
nephrotoxicity [1,2]. In an effort to find new immunosuppressive drugs without or 
less nephrotoxicity mTOR inhibitors were introduced in renal transplantation. The 
mTOR inhibitors sirolimus (Rapamune®) and everolimus (Certican®) are potent orally 
administered immunosuppressive agents. Both are derived from a macrocyclic lactone 
produced by streptomyces hygroscopicus recovered from Easter Island [3,4]. Similarities 
exist between other macrocyclic lactones such as erythromycin and tacrolimus with regard 
to their chemical structures. Although highly active against Candida Albicans sirolimus 
was commercially launched for its immunosuppressive potency discovered in animals 
[5,6] and later suggested for clinical renal transplantation [7]. Everolimus is a derivative of 
rapamycin (sirolimus) and was developed for prevention of acute and chronic rejection of 
solid organ transplants. Instead of a hydrogen atom at position 40 it has a 2-hydroxethyl 
chain (Figure 1a en 1b) substitution which improves the solubility and bioavailability of 
the drug [4]. 
Figure 1: Chemical structure of Sirolimus and Everolimus.
In the past years mTOR inhibitors were only prescribed in combination with cyclosporine 
and steroids since a synergistic effect and different mechanism of action is present 
compared to CNIs [8,9], but as a result of the damaging effects of cyclosporine on the 
donor kidney everolimus is now tested in absence of cyclosporine in clinical trials [10,11]. 
a b
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Meanwhile a combined CNI everolimus regimen has proven its effectiveness in a number 
of clinical trials [12,13]. This systematic review gives an oversight on current knowledge of 
clinical pharmacokinetics, pharmacodynamics and pharmacogenetics of mTOR inhibitors 
in renal transplantation. 
Literature search methods and results
An initial Pubmed search was conducted to find all available literature concerning clinical 
pharmacokinetics and pharmacodynamics of mTOR inhibitors using the following search 
criteria: {(Everolimus OR SDZ-RAD OR 40-O-(2-hydroxyethyl)-rapamycin OR “SDZ 
RAD” OR Certican OR “RAD 001” OR RAD001 OR Sirolimus) AND (pharmacokinetics 
OR pharmacokinetic* OR “Area Under Curve” OR “Biological Availability” OR “Metabolic 
Clearance Rate” OR “Therapeutic Equivalency” OR “Tissue Distribution” OR “Pharmaco-
genetics” OR “Pharmacogenetic”* OR “Pharmacodynamics” OR “Pharma codynamic*”) 
AND (renal transplantation OR kidney transplant ) NOT oncology NOT tumors}. This 
resulted in 300 articles derived from Pubmed, subsequently the same search criteria was 
used for Web of Science ( 316 articles), EMBASE ( 102 articles) and Cochrane ( 2 articles). 
Articles were limited to those written in the English language. After removing duplicates 
525 remained were reviewed for relevancy. 344 articles remained after evaluating the 
titles and abstracts. Focusing on pharmacokinetics, pharmacodynamics, therapeutic drug 
monitoring and side effects led to a total of 109 obtained full text articles which were used 




Sirolimus is rapidly absorbed after oral administration with an average maximum blood 
concentration (cmax) (SD) of 40.5 ± 22.2 µg/L when administering a dose of 2.5 mg. The 
maximum concentration is reached after 2.7 ± 2.1 hours (tmax) and is dependent on the dose 
administered (0.5 - 6.5 mg) [14]. In patients receiving an immunosuppressive regimen 
of cyclosporine and prednisone with single or multiple doses of sirolimus, sirolimus 
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was absorbed rapidly with average tmax (%CV): 1.6 (81%) and 1.4 (85%) hours after 
administration respectively [14,15]. Steady state was reached within 14 days. Its steady 
state maximum concentration and area under the blood concentration versus time after 
administration curve (AUC) were dose proportional over the dose range of 0.5 – 6.5 mg/m2 
once daily [14]. The absolute bioavailability of sirolimus in humans is unknown, however 
is has been estimated to be around 14% and highly variable (range 10.9 – 16.9%) [16]. 
Results from preclinical studies also showed a low bioavailability (10%) [17]. Food intake 
strongly affects the bioavailiability of sirolimus; a 35% increase in AUC after a fatty meal 
was observed in a clinical trial, but absorption was more slowly [18]. Therefore sirolimus 
should be administered consistently in individual patients, either with or without meals 
to assure consistent exposure. In a cohort of 150 renal transplant patients, no correlation 
was found between sirolimus concentrations and bodyweight, gender, age or dose [19]. 
Currently two formulations are available in the clinic: a tablet and a non-aqueous oral 
solution. In a comparative study, values of cmax for the solution were significantly greater 
compared to the tablet. Moreover cmax for the tablet observed on day 1 was significantly 
greater compared with days 30 and 90. Furthermore tmax was significantly greater for the 
tablet. However average sirolimus pharmacokinetic parameters were not significantly 
different when comparing both formulations, only tmax was slower for tablet administration 
but no clinically relevant differences were found [20]. Similar results were found in a 
conversion study from one formulation to the other [21]. Intestinal CYP3A metabolism 
and intestinal P-glycoprotein (P-gp) counter transport, intestinal membrane permeability 
and hepatic first-pass affect bioavailability most likely also influence sirolimus absorption 
since sirolimus is a substrate for these enzymes and transporters [22] as schematically 
shown in Figure 2. Pharmacokinetic parameters are clearly influenced by the presence 
and timing of co-administration of cyclosporine [23] since both drugs are substrate and 
inhibitors of the same metabolizing enzymes [22,24]. 
Everolimus
Everolimus is rapidly absorbed after oral administration with an average cmax (SD) of 45 
(±21) µg/L when administering a dose of 2.5 mg. The maximum concentration is reached 
after 1.3 ± 0.4 hours after dose administration and is dependent on the dose administered 
(0.25 - 25mg) [12]. In a study with patients with immunosuppressive regimen of 
cyclosporine and prednisone receiving multiple doses of everolimus, everolimus was 
absorbed rapidly (average tmax 2 hours), Steady state was reached within 7 days. Steady 
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state maximum concentration and AUC were dose proportional over the dose range of 0.5 
– 2 mg twice daily [25]. The bioavailability of everolimus in animal models is low with an 
amount of around 16% [26,27] but slightly higher than sirolimus. Absolute bioavailability 
data of everolimus is not available since no intravenous formulation exists but intra- and 
inter-individual variability is high [25]. Currently two everolimus formulations are on the 
market; a solid tablet and a dispersible tablet, the latter initially developed for pediatrics. The 
bioavailability of everolimus from the dispersible tablet was found to be 10% lower relative 
to the conventional tablet [28]. As sirolimus, the relative bioavailability of everolimus is 
affected by food since food affects the absorption [29,30]. In healthy subjects receiving a 
single 2 mg dose it was found that when combining with a high-fat meal tmax was delayed 
by a median 1.25 hours. Furthermore cmax was reduced by 60% and reduced AUC by 16%. 
In renal transplant recipients, a high-fat meal delayed tmax by a median 1.75 hours and 
reduced cmax by 53% and AUC by 21%. Everolimus trough levels showed no food effect, 
while peak-trough fluctuation was lowered by 52%. [30]. Everolimus should therefore be 
consistently administered with or without food in individual patients. Intestinal CYP3A 
metabolism and intestinal P-glycoprotein activity, Intestinal membrane permeability 
and hepatic first-pass affect bioavailability probably play a large role in the absorption of 
everolimus since everolimus is also substrate for CYP3A4, CYP3A5, CYP2C8 and P-gp 
[31] as schematically shown in Figure 2. Co-administration of cyclosporine leads to an 




Sirolimus is a hydrophobic compound, is extensively distributed to various organs with an 
steady state distribution volume (Vss) of 7-19 L/kg [15,33] and is more partitioned into 
red blood cells (up to 95%) than plasma (3%) and lymphocytes 1% [16,34]. Whole blood is 
therefore the matrix of choice for therapeutic drug monitoring. Plasma to blood ratio was 
found to be 35:1 in a group of 36 stable renal transplant recipients and considerable inter-
individual variability (CV of 52%) was reported [15]. Sirolimus was primarily associated 
with non-lipoprotein fractions in plasma [34]. In studies in rats considerable accumulation 
of sirolimus in the heart, kidney, intestine, and testes were found [35]. Whether this is the 
same in humans has not been investigated. 
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Everolimus
The less hydrophobic compound everolimus is at therapeutic concentrations for more 
than 75% partitioned into red blood cells and 75% of the plasma fraction is bound to 
plasma proteins [25]. The estimated volume of distribution for a 71 kg patient is at steady 
state 110 L and is increased with 1.14 for each kilogram increase in body weight [29]. 
In rats the highest binding potential was observed in thymus, lungs and spleen [27]. In 
monkey lung transplant recipients the highest concentrations were found in gall bladder, 
transplant lung, cerebellum, kidneys and spleen [36]. Data in humans is not available.
Figure 2: Schematic representation of oral administration of mTOR inhibitors, interaction with metabolic 
enzymes and effect on blood levels. AUC, area under the blood concentration vs time after dose administration 
curve; CYP, cytochrome P450 enzymes (CYP3A4, CYP3A5 and CYP2C8); Cmax, maximum blood concentration; 
mTORi, mTOR inhibitor; tmax, time to reach maximum blood concentration.
Clearance
Sirolimus
Sirolimus is primarily metabolized by CYP3A4, but also by CYP3A5 and CYP2C8 
[22,37,38]. The large inter-individual variability in metabolism of sirolimus is probably 
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a reflection of the wide inter-individual variability in expression of these enzymes 
[39]. Moreover sirolimus is also a substrate for P-glycoprotein [40]. In a population 
pharmacokinetic analysis of 36 renal transplant patients a wide variability in clearance was 
found, terminal half-life was 63 hours (27.5%) and apparent oral blood clearance of 8.9 
L/hr (38.2%). Elimination was not influenced by dose [15]. In another pharmacokinetic 
study with 40 stable renal transplant patients clearance was found to be 0,208 (45%) 
mL/hr/kg; terminal half-life was, 62 (±16) hours allowing a once daily regimen. 
Furthermore a loading dose of three times the maintenance dose was suggested to achieve 
therapeutic concentrations more rapidly [14]. The four main metabolites of sirolimus are 
16-O-demethyl-sirolimus, 39-O-demethyl-sirolimus, 27-39-O-di-demethyl-sirolimus and 
di-hydroxy-sirolimus [41]. The activity of these metabolites seems to be less than 10% 
of the parent compound [42]. Preliminary results showed that black renal transplant 
patients had a higher metabolism compared to non-blacks [15]. Furthermore, another 
study showed significant lower trough concentrations and higher acute rejection rates 
for black patients [43]. In a study with 18 adult subjects with mild to moderate hepatic 
impairment and 18 healthy control subjects, mean whole-blood sirolimus weight-
normalized and oral-dose clearances (CL/F) were significantly decreased in subjects with 
mild to moderate hepatic impairment by 31.8% and 36.0%, respectively, compared with 
controls after administration of a single 15 mg oral solution dose [44].
Everolimus 
Everolimus is also metabolized by CYP3A4, CYP3A5 and CYP2C8 and is a substrate for 
P-gp [22,31,45]. In a “first into human” study with single everolimus doses the elimination 
half-life and ranged from 24 to 35 h across the doses in the range of 0.25 – 25 mg. The 
average AUC (µg*h/L) ranged from 171 ± 50 µg*h/L for the 0.75 mg group to 2400 ± 
608 µg*h/L for the 25 mg group [46]. In a population pharmacokinetic analysis of 673 
patients [29] the following pharmacokinetic parameters were found: the apparent average 
clearance for a 44 years Caucasian patient old weighing 71 kg was 8.8 L/h (± 27%) with 
a central distribution volume of 110 L (± 36%). Everolimus pharmacokinetics is greatly 
affected by cyclosporine which inhibits CYP3A4 [29]. In 8 healthy volunteers, everolimus 
apparent clearance was 19.4 L/h in absence of cyclosporine [47]. Therefore renal transplant 
patients probably also have a higher clearance in cyclosporine free regimens. Everolimus 
pharmacokinetics was not affected by age, sex and weight in adults. Asian ethnicity did 
not affect everolimus clearance. Patients indicated as black had a 20% higher clearance 
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compared to non-black patients [29,48]. Since everolimus has a rapid clearance, everolimus 
requires twice-daily administration in contrast to sirolimus. The four main metabolites of 
everolimus are: hydroxyl-everolimus, dihydroxy-everolimus, dimethyl-everolimus and a 
ring opened form of everolimus [37]. In a population pharmacokinetic study the inter-
individual variability in clearance was reduced to 27% after accounting for the covariates 
[29]. The intra-individual variability and residual error was 31%. In a multicenter 
randomized double blind study of 101 renal transplant patients inter-individual variability 
in terms of AUC for everolimus was 85.4%, intra-individual, inter-occasion variability was 
40.8% [49], implicating the need for therapeutic drug monitoring. In a study investigating 
the influence of hepatic impairment on everolimus pharmacokinetics it was found that 
the apparent clearance of everolimus was significantly reduced by 53% in subjects with 
moderate hepatic impairment compared with healthy subjects. This was reflected by a 115% 
higher AUC (245 +/- 91 versus 114 +/- 45 µg*h/L) and 84% prolonged half-life (79 +/- 42 
versus 43 +/- 18 hours) [47]. Furthermore a significant positive correlation of the 
everolimus AUC with bilirubin level (r = 0.86) and a significant negative correlation with 
albumin concentration (r = 0.72) was found. Therefore dose reduction and close TDM 
may be indicated. 
Excretion
Sirolimus 
Sirolimus is metabolized trough the liver, 91% of sirolimus metabolites are excreted in the 
bile, only 1.2% is excreted trough urine [50].
Everolimus
Everolimus is also metabolized trough the liver, after metabolizing approximately 98% is 
excreted as metabolites in the bile [46]. 
Drug interactions
Sirolimus
Since sirolimus is metabolized by CYP3A4, CYP3A5 and CYP2C8 and a substrate of P-gp, 
inhibitors or inducers of these enzyme most likely show pharmacokinetics interactions. In 
vitro anti-CYP3A antibodies, as well as the specific CYP3A inhibitors troleandomycin and 
erythromycin, inhibited small intestinal metabolism of sirolimus [22]. In a renal transplant 
recipient an interaction between dronedarone and sirolimus was reported. A 3 fold 
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increase of sirolimus trough concentration (38.6 µg/L) was observed 3 days after initiation 
of dronedarone. If concurrent administration cannot be avoided, close monitoring and a 
50-75% dose reduction of sirolimus prior to dronedarone initiation was recommended 
[51]. Trimethoprim-sulphamethoxazole combination did not affect sirolimus steady state 
pharmacokinetics in 15 renal transplant recipients [52]. In two case reports rifampicin 
significantly increased sirolimus pharmacokinetics; the dosage of sirolimus had to be 
increased, in one case up to six-fold and in the second case up to five-fold, to maintain 
serum levels after starting the rifampicin [53]. Diltiazem increased sirolimus AUC by 60%, 
ketoconazole increased sirolimus AUC by 990% and rifampicin reduced sirolimus AUC by 
82% in a phase III trial [54]. In a pharmacokinetic analysis of 36 patients cyclosporine did 
not seem to affect sirolimus pharmacokinetics [15]. In contrast Cattaneo et al. reported that 
concomitant cyclosporine therapy resulted in significantly higher sirolimus trough values 
compared to concomitant tacrolimus or mycophenolate mofetil therapy [55]. Moreover in 
another study with 24 stable renal transplant recipients sirolimus AUC and trough levels 
were consistently and significantly higher when both cyclosporine and sirolimus were 
administered concomitantly, than when they were administered 4 hours apart indicating 
a inhibiting effect of cyclosporine on sirolimus pharmacokinetics [23]. Generic and brand 
name cyclosporine also seem to alter sirolimus pharmacokinetic differently as was reported 
by Kovarik et al [56]. Finally a twofold increase in cyclosporine AUC was associated with 
a 63% mean increase in sirolimus AUC in 53 stable kidney transplant recipients [57]. 
The combination of cyclosporine and sirolimus is synergistic as previously demonstrated 
in vitro and in vivo in animal transplant experiments [9]. Sirolimus not only increases 
cyclosporine concentrations in blood but also in the kidney. This interaction may lead 
to increased cyclosporine associated nephrotoxicity by a mechanism which is still not 
entirely understood [9]. In a pharmacokinetic study investigating the effect of tacrolimus 
on sirolimus pharmacokinetics neither pharmacokinetic profiles of sirolimus nor those of 
tacrolimus were altered by simultaneous administration [58]. 
Everolimus
Administration of erythromycin, azithromycin, or itraconazole in combination with 
everolimus (0.75 or 1.5 mg twice daily) resulted in a 22, 18 and 74% lower everolimus 
clearance compared to everolimus alone [29]. Calcium channel blockers, quinolones and 
trimethoprim-sulfamethoxazole had no effect on everolimus pharmacokinetics [29]. In 12 
healthy subjects, rifampicin co-administration, a CYP3A and P-gp inducer, resulted in a 
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significantly increased apparent clearance of 172% on average [59]. Co-administration of 
atorvastatine (CYP3A4 substrate) or pravastatin (P-gp substrate) has no clinically relevant 
interaction with everolimus as was found in 24 healthy volunteers [60]. Everolimus trough 
concentrations were significantly elevated in the presence of cyclosporine [61]. In a study 
with 56 de novo renal transplant recipients received basiliximab, corticosteroid and 
either immediate or delayed initiation of cyclosporine based on renal function, trough 
concentrations were significantly lower (3 fold) in absence vs in presence of cyclosporine 
[61]. In healthy volunteers is was shown that two cyclosporine formulations; neoral® 
and sandimmune® had different effects on everolimus pharmacokinetics. Neoral® co-
administration resulted significantly greater everolimus AUC compared to sandimmune® 
co-administration 168% vs 74% increase [62]. Co-administration of tacrolimus seems to 
have a much less pronounced effect than cyclosporine on everolimus pharmacokinetics. 
No clinically relevant change in everolimus exposure was found [63].
Pharmacodynamics
Mechanism of action
Sirolimus and everolimus share the same mechanism of action (Figure 3). They block Ca2+- 
dependent and Ca2+ -independent events during G1 phase of the cell cycle, including 
transduction of second signals delivered by interleukin (IL)-2, IL-3, IL-5 and IL-6. They 
also block, but to a lesser extent, the signals delivered by fibroblast growth factor, stem cell 
factor, platelet-derived growth factor, colony-stimulating factor and insulin growth factor. 
In in vitro experiments, sirolimus and everolimus inhibited a variety of mitogen- and 
antigen driven B- and T-lymphocyte proliferative responses [6,64,65]. 
Sirolimus and everolimus bind to FK506 (tacrolimus) binding protein (FKBP12) and 
subsequently it binds to a protein known as mTOR. Both have compounds have an effector 
domain forming a composite surface with FKBP that interacts with the mammalian target 
of rapamycin, mTOR, as well as a binding domain that mediates the interaction with 
FKBP [64,66]. mTOR is an atypical serine/threonine protein kinase that belongs to the 
phosphoinositide 3-kinase PI3K-related kinase family and interacts with several proteins 
to form two distinct complexes named mTORC1 and mTORC2. mTORC1 responds to 
amino acids, stress, oxygen, energy and growth factors and is directly sensitive to sirolimus 
and everolimus. Cell growth is promoted by induction an inhibition of anabolic and 
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catabolic processes. mTORC1 also drives cell-cycle progression. In contrast, mTORC2 is 
insensitive to acute exposure of rapamycin, but chronic exposure can disrupt its structure. 
Moreover mTORC2 responds to growth factors and regulates cell survival and metabolism. 
mTORC 2 also regulates the cytoskeleton [67]. The mTORi-FKBP12-mTOR interaction 
causes dephosphorylation and inactivation of p70S6 kinase and which, when activated, 
stimulates the production of ribosomal components necessary for protein synthesis and 
cell-cycle progression. Cyclin dependent kinases (CDK) and cyclins are also inhibited, 
which are necessary to keep the cell cycle progress running. Consequently, sirolimus and 
everolimus inhibit T- and B-cell proliferation and differentiation and antibody production, 
as well as non-immune cell (fibroblasts, endothelial cells, hepatocytes, and smooth 
muscle cells) proliferation [68–70]. When compared with sirolimus, the in vitro activity 
of everolimus is in general about two to three times lower; however, when administered 
orally, everolimus is at least as active in vivo as rapamycin [65].
Figure 3: Simplified schematic representation of mTOR inhibitor mechanism of action. IL-2R, interleukin-2 
receptor; IL-2, interleukin-2; mRNA, messenger ribonucleic acid; CDK, cyclin dependent kinase; FKBP12, 
FK506 (tacrolimus) binding protein; mTORi, mTOR inhibitor.
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The main and most common adverse effects attributed to sirolimus are anemia, 
thrombocytopenia and increase in triglyceride and cholesterol levels. Significant 
relationships were found between trough concentrations and the occurrence of 
thrombocytopenia (<100 x 109/L), leukopenia (<4 x 109/L) and hypertriglyceridemia 
(>750 mg/dL), but not hypercholesterolemia (>400 mg/dL). Toxic concentrations were 
established at >15 mg/L. Furthermore sirolimus has a narrow therapeutic window (≤ 5 
µg/L) [19]. Hyperlipidemia occurs in about 40% of patients on sirolimus therapy. In a 
comparative study with azathioprine, increased fasting serum cholesterol and triglyceride 
concentration were observed, on average almost twice as high as in the azathioprine 
group. It is suggested that sirolimus inhibits the clearance of circulating, low, intermediate 
and very-low-density lipoproteins as well as their remnants [71,72]. Nevertheless only 
one patient discontinued the study because of hypertriglyceridemia and countermeasure 
therapy is often adequate [19]. Increased incidence of cardiovascular complications were 
not shown at phase III trials at one year after initiation [73]. Diarrhea incidence was 
also significantly higher than in the azathioprine group. Infections incidence including 
sepsis, cytomegalovirus, Epstein-Barr virus and Herpes zoster and lung infections were 
significantly higher in the 5 mg sirolimus group compared to the 2 mg sirolimus and the 
azathioprine group. The overall incidences of malignant disease besides lymphoma and 
lymphoproliferative disorders were similar in all treatment groups.
Everolimus
In a large (503 patients) multicenter study patients on a CNI free regimen of MPA and 
everolimus showed higher mean lipid concentrations, slightly increased urinary protein 
excretion, lower hemoglobin concentrations, also thrombocytopenia (6% vs 0%), aphthous 
stomatitis (15 vs 1%) and diarrhea (21 vs 8%) was reported more often compared to 
the CNI and MPA regimen. [11] A correlation was found between thrombocytopenia 
(<100 x 109/L) with increasing everolimus AUC [49] and trends were observed for 
increased incidence of hypertriglyceridemia and hypercholesterolemia with increasing 
everolimus AUC. The incidence of leukopenia was not related to everolimus exposure. 
In a multicenter double blind, placebo controlled dose escalating phase I study, also dose 
dependent incidence of thrombocytopenia was found [74]. Notable reversible elevations 
of cholesterol were also observed at the 10 mg/day dose. Other changes in laboratory 
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evaluations, including triglycerides, were minor, reversible and did not appear to be dose 
dependent.
mTOR pneumonia
The use of mTOR inhibitors in renal transplantation is associated with many side effects as 
mentioned above: one of the potentially most severe being interstitial pneumonitis. Non-
infectious interstitial pneumonitis is characterized by non-infectious, non-malignant 
and non-specific inflammatory infiltrates in combination with negative bacterial tests 
for blood and broncho alveolar lavage (BAL) [75,76]. Non-infectious pneumonitis is a 
class-related adverse effect of mTOR inhibitors. At the onset of this complication, patients 
present themselves with cough and/or dyspnea and/or hypoxemia. Sometimes systemic 
symptoms such as fever and fatigue are present. Pathology reveals non-specific interstitial 
pneumonitis, bronchiolitis obliterans organizing pneumonia, alveolar hemorrhage, 
desquamative interstitial pneumonia and vasculitis. The precise mechanism is unknown 
but one of the suggested mechanisms is a cell mediated autoimmune response after 
exposure of cryptic antigens or T-cell-mediated delayed-type hypersensitivity. Inhibitors 
of mTOR could also exert part of their action by limiting the destructive remodeling of 
lung structure. Over the years a number of case report were published concerning mTOR 
pneumonitis in transplantation [77–79]. The Incidence of pneumonia or pneumonitis 
with the usage of sirolimus (SRL) is about 1-10% [80]. The introduction of sirolimus led 
to an increased frequency of unexplained interstitial pneumonitis in renal transplant 
patients, which was later also observed in liver and heart transplant patients [81]. Because 
of its positive effect in cancer everolimus is currently also indicated for a number of 
oncological indications. This inflammatory disorder was also reported in everolimus-
treated non-transplanted metastatic renal cell carcinoma patients at a frequency of 8% 
[82]. Another study reported a frequency of 9.9% with everolimus therapy [83]. So 
far, no clear patient-related or context-related risk factors have been identified. Many 
patients are asymptomatic despite presenting signs of the complication on radiography 
or high resolution tomography computer tomography (HRCT)[84]. The management 
of this mTOR pneumonitis depends on the grade of the side effect, Grade 1 with no 
clinical symptoms but a positive CT up to grade 4: Life threatening complications [85]. 
By identifying patients at risk for mTOR pneumonia before treatment patient could be 
excluded from mTOR therapy and switched to another immunosuppressive drug.
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Sirolimus blood levels show good correlation with clinical outcomes and drug related 
toxicity [19,55]. Trough concentration (Ctrough) AUC correlation seems reasonable [19], 
however others showed worse correlation [86]. AUC monitoring on the other hand is 
often laborious and patient unfriendly unless limited sampling formulas and models are 
used. In general Bayesian limited sampling models are less rigid than limited sampling 
formulas and are therefore more accurate. A number of these have been published [87–89] 
with sampling times 0,1 and 3 hours as the most accurate and with the least discomfort 
for the patient in a calcineurin inhibitor based regimen [89] using Bayesian estimation. 
AUC better reflects true exposure but whether AUC monitoring is superior to trough 
monitoring with respect to firm long-term endpoints has never been investigated. Whole 
blood concentration can be measured with a number of analytical techniques. Toxic 
concentrations were established at >15 µg/L [19] and a therapeutic window has been 
proposed of 5-15 µg/L or 6-12 µg/L for calcineurin inhibitor included regimens and 10-
20 µg/L for regimens without calcineur inhibitors [19,55,58]. Currently the most used 
techniques for sirolimus therapeutic drug monitoring (TDM) are liquid chromatography 
based techniques with or without mass spectrometry and immuno assay kits.
Everolimus
Since immunosuppression efficacy and occurrence and severity of side adverse effects 
are correlated with everolimus blood concentrations [25] TDM is also indicated. The 
recommended therapeutic range for everolimus evaluated as part of a calcineurin 
inhibitor regimen a number of studies is a trough of 3 to 8 µg/L in renal transplant 
patients [90–93]. Ctrough AUC correlation has not been intensively investigated in renal 
transplant patients. Everolimus target concentrations in a regimen without calcineurin 
inhibitors ranges from 6-10 µg/L [10,11]. To date no limited sampling strategies have been 
developed for everolimus especially not in a cyclosporine free regimen. Currently the 
most used techniques for everolimus TDM are liquid chromatography based techniques 
with or without mass spectrometry and immuno assay kits.
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Pharmacogenetics
A limitation of TDM is that during the critical period of the first days after transplantation 
the exposure cannot be influenced. Especially drugs with a long elimination half-life 
are at risk of under or overexposure because correcting them takes more time. For this 
reason pharmacogenetics could be of additional value to TDM, by differentiating in 
initial dose between genotype groups and subsequently decreasing the time to reach 
target concentration for all patients. However, whether this also leads to prolonged graft 
survival and lower incidence of acute rejection is not established. The mTOR inhibitors 
sirolimus and everolimus are metabolized by cytochrome P450 (CYP) enzymes CYP3A4, 
CYP3A5 and CYP2C8. Both compounds are also a substrate for the efflux pump 
P-glycoprotein (ABCB1). Genetic polymorphisms in genes encoding these enzymes could 
in theory explain a part of the variability in pharmacokinetics. Several single nucleotide 
polymorphisms (SNPs) have been identified in the genes encoding for CYP3A4, CYP3A5 
and P-glycoprotein, including CYP3A4 -392A>G (rs2740574), CYP3A5 6986A>G 
(rs776746), ABCB1 3435C>T (rs1045642), ABCB1 1236C>T (rs1128503) and ABCB1 
2677G>T/A (rs2032582) and some have been linked to pharmacokinetics of calcineurin 
inhibitors [94]. The most recognized clinically relevant single-nucleotide polymorphism 
(SNP) CYP3A5 A6986G has been linked in a number of studies to an increased tacrolimus 
clearance [95–97]. Initial dose adjustments have been proposed and are implemented in 
some transplantation centers. To date for CYP3A4 no conclusive results for candidate 
polymorphisms have been identified to optimize immunosuppressive therapy [98]. 
For mTOR inhibitors a limited number of pharmacogenetic studies have been published; 
Le meur et al. reported in a study of 47 patients that patients carrying at least one CYP3A5 
SNP had significantly lower AUC/dose, Cmax/dose, Ctrough/dose for sirolimus indicating a 
higher clearance [99]. In 22 renal transplant patients Djebli et al. found a 2 fold higher 
clearance for carriers of at least one CYP3A5*1 allele [89] compared to non-carriers. In 
another pharmacogenetic study of 149 renal transplant recipients the effect of CYP3A4 
-392A>G (rs2740574), CYP3A5 6986A>G (rs776746), ABCB1 3435C>T (rs1045642), 
ABCB1 1236C>T (rs1128503) and ABCB1 2677G>T/A (rs2032582), on sirolimus 
pharmacokinetics was evaluated. CYP3A5 (around 1.5 fold higher compared to mutants) 
and CYP3A4 (almost 2 fold higher compared to mutants) genotype correlated significantly 
with concentration/dose ratio but variability within the genotype groups was considerable. 
This genotype effect however was only found in patients without a calcineurin inhibitor 
31Clinical pharmacokinetics and pharmacodynamics 
of mTOR inhibitors in renal transplantation
2
[100]. Polymorphism in ABCB1 did not correlate to different concentration dose ratio in 
all populations. Furthermore Renders et al. found a trend (not significant) for CYP3A5 
expressors toward higher (2 fold) clearance in 20 renal transplant patients and no influence 
for ABCB1 and ABCC2 genotypes [101]. In contrast to the above mentioned findings 
Mourad et al. [102] found no association between adjusted trough concentrations and 
dose requirements and CYP3A5 genotype in 58 renal transplant recipients.
For everolimus Picard et al found no association between CYP3A5 polymorphism 
and everolimus pharmacokinetics in renal transplant patients [103]. Furthermore in 
vitro results supported this conclusion. The potential influence of polymorphisms in 
CYP2C8 and ABCB1 on everolimus pharmacokinetics is still unknown. More studies 
investigating the potential influence of polymorphisms in CYP3A4, CYP3A5, CYP2C8 on 
pharmacokinetics and pharmacodynamics are needed to establish the potential influence 
and clinical relevancy.
The pregnane X receptor (PXR; NR1I2) is a member of the nuclear receptor (NR) 
superfamily. PXR is mainly associated with the cellular response to xenobiotics, including 
induction of enzymes involved in drug oxidation and conjugation, as well as induction 
of xenobiotic and endobiotic transporters [104]. These include the phase I enzymes 
cytochrome P450 (CYP) CYP2C8 and CYP3A4 and the transporters, multidrug resistance 
protein 1 (MDR1), MDR2, multidrug resistance-associated protein 2 (MRP2) and the 
organic anion transporter polypeptide 2 (OATP2) which are relevant for mTOR inhibitor 
metabolism, [105–107]. Polymorphism in genes coding for this receptor could be of 
interest for explaining variability in pharmacokinetics and dynamics [98]. 
Little is known about polymorphism genes coding for mTOR proteins and their effect on 
mTOR inhibitors pharmacodynamics. Recently Woillard et al [108] examined candidate 
polymorphisms in mTOR, Raptor and p70S6 kinase and a number of other time-constant 
covariates and time varying covariates. They found an significant association in decrease 
of haemoglobin levels and an mTOR variant haplotype. However, critical questions were 
asked about the matching of the two study groups [109]. 
Conclusions
The macrolide immunosuppressant sirolimus and everolimus form a relatively new 
therapeutic group in renal transplantation and have shown their efficacy in recent trials. The 
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advantage of these compounds is the lack of nephrotoxicity compared to the calcineurin 
inhibitors cyclosporine and tacrolimus. In contrast to sirolimus everolimus is dosed twice 
daily because of its shorter half-life and is therefore easier to manage with therapeutic drug 
monitoring. Both drugs are metabolized by CYP3A4, CYP3A5 and CYP2C8 enzymes 
and are substrates for P-glycoprotein and share the same pharmacodynamics. The most 
important side effects of these are thrombocytopenia, leukopenia, hypercholesterolemia, 
diarrhea and although rare but potentially life threatening interstitial pneumonia. 
The narrow therapeutic window of mTOR inhibitors, together with high variability in 
pharmacokinetics, makes therapeutic drug monitoring essential for individualizing the 
dose and thereby prevent toxicity or rejection. Pharmacogenetics might play a role in 
further optimization of mTOR base immunosuppressive therapy.
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Abstract
There is a need to monitor everolimus blood concentrations in renal transplant recipients as 
a result of its high pharmacokinetic variability and narrow therapeutic window. However, 
analytical methods to determine blood concentrations often differ in performance. 
Therefore, we investigated whether two commonly used therapeutic drug monitoring 
methods for everolimus were in agreement and to what extent their differences could 
lead to differences in dosage advice. Six hundred twelve whole blood samples were 
obtained from 28 adult renal transplant recipients receiving everolimus and prednisolone 
therapy. These samples included 286 everolimus trough concentrations. The remaining 
samples were obtained up to 6 hours post everolimus intake and allowed calculation of 84 
AUCs0–12h. All samples were analyzed with fluorescence polarization immunoassay (FPIA) 
on an Abbott TDxFLx analyzer and liquid chromatography–tandem mass spectrometry 
(LC-MS/MS). Everolimus blood concentrations measured with FPIA and LC-MS/MS 
were not in agreement. Concentrations determined by FPIA were, on average, 23% higher 
than concentrations quantified by LC-MS/MS. Moreover, concentrations lower than 15 
mg/L or AUC0–12h determined with FPIA could be twofold higher than with LC-MS/
MS. This variability can lead to clinically relevant differences in dose adjustment of up 
to 1.25 mg everolimus despite using a correction factor of 23%. Finally, when trough 
concentrations were measured with FPIA, higher intra-patient variability was observed 
compared with the use of LC-MS/MS. LC-MS/MS outperforms FPIA for clinical drug 
monitoring and intervention of everolimus therapy in adult renal transplant recipients on 
dual therapy with prednisolone. Specifically, the use of FPIA can lead to clinically relevant 
differences in everolimus dosage advice and higher intra-patient variability.
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Introduction
Everolimus (Certican; Novartis, Basel, Switzerland) is an orally administered 
immunosuppressive agent targeting the mammalian target of rapamycin receptor and is 
used in the prevention of acute and chronic rejection of solid organ transplants. Its high 
pharmacokinetic variability together with a narrow therapeutic window makes therapeutic 
drug monitoring (TDM) crucial for dose individualization [1]. Everolimus concentrations 
are determined in whole blood because over 75% of the drug is partitioned into red blood 
cells [2]. Currently, immunoassays such as fluorescence polarization immunoassay (FPIA) 
and chromatographic methods such as high-pressure liquid chromatography (HPLC) or 
the more sophisticated HPLC combined with (tandem) mass spectrometry (LC-MS/MS) 
are the most commonly used analytical techniques for TDM of everolimus [3–7]. These 
methods may differ in specificity and sensitivity leading to altered accuracy and precision. 
Inaccuracy in dosage advice caused by these differences could impact on patient outcomes 
such as toxicity or increased risk for transplant rejection. In this study, two of the most 
applied analytical techniques for everolimus, FPIA on an Abbott TDxFLx analyzer and 
LC-MS/MS, were compared. A large number of blood samples were obtained from stable 
adult renal transplant patients receiving everolimus therapy. This comparison was aimed 
at identifying whether differences between the two techniques could lead to different 
everolimus dosages in clinical practice.
Materials and methods
Patients and Samples
Whole blood samples from 28 adult renal transplant recipients (18 male and 10 female) 
were obtained. Mean age was 52 years (± 10) and ranged from 35 to 69 years. Stable renal 
transplant recipients treated with immunosuppressive therapy consisting of everolimus 
(Certican; Novartis) and prednisolone [8] were studied from 6 months up to 2 years after 
transplantation. The study was approved by the Medical Ethics Committee of the Leiden 
University Medical Center and patients gave written informed consent. Everolimus therapy 
was started at an oral dose of 3 mg twice daily and was supported by routine TDM based 
on trough concentrations and AUC0–12h. Routine TDM samples were obtained throughout 
time after starting everolimus therapy and were analyzed by FPIA. The target AUC0–12h for 
FPIA was set at 150 µg*h/L [8], which roughly corresponds with an everolimus trough 
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concentration of 7 to 11 µg/L. All samples were also quantified with LC-MS/MS. Finally, 
TDM resulted in a between-patient everolimus range from 1 mg to 4.5 mg twice daily. 
A total of 612 whole blood samples were obtained. This number corresponds to 286 trough 
concentration measurements and 326 samples drawn at 1, 2, 3, 4, 5, or 6 hours after dose 
intake. The measurements obtained up to 6 hours, representing 27 full (seven or six time 
points) and 57 sparsely sampled (four time points) AUCs, allowed the calculation of 84 
AUCs0–12h. 
The performance of the assays was investigated by the quality control (QC) samples, 
which were included in each series of everolimus patient samples. Accuracy bias for FPIA 
and LC-MS/MS was determined by calculating the concentration of the control sample as 
a percentage of the nominal concentration (determined by the manufacturer) using the 
formula: [(Cc – Cn)/Cn*100%] with Cc as the concentration of the control sample and Cn as 
the nominal concentration. Assay performance, in terms of limits of quantification, was in 
agreement with the guidelines regarding bioanalytical method validation of Shah et al. [9]. 
Innofluor Certican Assay System
Quantification of everolimus blood concentrations was performed with FPIA (Seradyn 
Inc, Indianapolis, IN) on a TDxFLx instrument from Abbott Diagnostics (Abbott Park, 
IL). FPIA is a homogeneous fluorescence polarization assay using a polyclonal rabbit 
antibody directed against everolimus [10]. Routine measurements were performed 
according to manufacturer’s guidelines [10]. Everolimus calibrators (0, 2.5, 5.0, 10.0, 20.2, 
and 39.1 µg/L) and controls levels 1, 2, and 3 were obtained from Seradyn (Seradyn Inc). 
Calibrators and controls were prepared by gravimetric addition of everolimus to a human 
blood hemolysate matrix. Each calibrator was value-assigned by the manufacturer’s 
reference laboratory using a validated HPLC-MS method [11,12]. 
Blood samples as well as calibrator and control samples (600 µL) were pretreated with 
methanol (700 mL) (Merck, Darmstadt, Germany) and precipitation reagent (100 µL), 
vortexed for at least 10 seconds, and centrifuged for 5 minutes at 4000 rpm. Subsequently, 
700 µL of each supernatant was divided into two identical samples of 350 µL and 
transferred into two reaction cells. 
According to the manufacturer’s specifications, the lower limit of quantification was 2.0 
µg/L, whereas the upper limit of quantification was 40 µg/L [10]. Samples with values 
above 40 µg/L were diluted four times with calibrator A (everolimus-free). Lot-dependent 
calibrators were used. FPIA within-run accuracy and precision were determined by 
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analyzing two controls in duplicate. Between-run precision and accuracy were evaluated 
by analyzing the QC results of each determination for the duration of the study. Controls 
used for FPIA were: control level 1: 4.0 µg/L displayed an accuracy bias of 13.0% and an 
imprecision with a coefficient of variation (CV) of 19.9%; control level 2: 11.5 µg/L had an 
accuracy bias of 1.6% and an imprecision with a CV of 15.4%; and finally control level 3: 
23.0 µg/L showed an accuracy bias of 2.2% and an imprecision with a CV of 13.5% (n = 78).
Liquid Chromatography–Tandem Mass Spectrometry Assay 
Quantification of everolimus with LC-MS/MS was performed with a validated assay 
capable of analyzing everolimus, sirolimus, and tacrolimus simultaneously. The system 
consisted of an Ultimate 3000 autosampler, a thermostatted column compartment TCC 
100, and a p680 HPLC dual low-pressure gradient pump (analytical). All were purchased 
from Dionex Benelux BV (Amsterdam, The Netherlands). The MS/MS used was a Quattro 
micro API Tandem Quadrupole system from Waters Corporation, Milford, MA. Two 
hundred microliters of blood samples, controls, or calibrators were diluted with 200 µL 
0.1M ZnSO4 and 500 µL internal standard solution. Internal standard solution consisted 
of 100 µL 16 µg/L desmethyl sirolimus in methanol and 25 mL acetonitrile (LiChrosolv; 
Merck KGaA, Darmstadt Germany). A 6 + 1 multilevel calibrator set (0, 2.1, 6.0, 12.3, 18.2, 
25.3, 46.5 µg/L) was used, which was obtained from Chromsystems (Munich, Germany). 
Blood control levels 1, 2, and 3 were obtained from RECIPE (Munich, Germany). After 
diluting, vortex mixing for 2 minutes followed by 5 minutes of centrifugation at 13,000 rpm 
was conducted. After centrifugation, the supernatant was transferred into a cylindrical 
crimp neck autosampler vial.
A 50 µL aliquot of supernatant was injected into an online solid phase extraction column 
(Cartridge Hysphere 5C18 HD, 7-µm particle size 10 × 2 mm; Spark, Emmen, The 
Netherlands) for enrichment. For sample cleanup, two mobile phases were used: mobile 
phase A: 0.1% v/v formic acid + 2 mM ammonium acetate in water and mobile phase 
B: 0.1% v/v formic acid + 2 mM ammonium acetate in methanol. The elution gradient 
used on the solid phase extraction column was 50% A and 50% B for 2 minutes followed 
by 0.8 minute 100% B and 1.5 minutes 50% A and 50% B for elution of everolimus and 
internal standard for isocratic liquid chromatography on the precolumn (Hypersil 4 × 2 
mm; Phenomenex, Utrecht, The Netherlands) and analytical column (Hypersil Phenyl 
50 × 3 mm, 3-µm particle size; Thermo Scientific, Geel, Belgium). The column oven was 
set at 55°C. The elution gradient for chromatographic separation to the MS was 10% A 
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and 90% B at a flow rate of 600 µL/min. Mass spectrometric detection was in positive ion 
mode using selected reactant monitoring (everolimus m/z 975.7→908.3, internal standard, 
desmethyl sirolimus, m/z 901.7→834.3). 
The lower limit of quantification for everolimus was 0.2 µg/L determined with the following 
criteria: accuracy limits of 80% to 120% and imprecision CV less than 20%. LC-MS/MS 
within-run accuracy and precision were determined by analyzing the three controls in 
duplicate. Interassay precision and accuracy were evaluated by analyzing the QCs of each 
determination, which provided data for this study. The accuracy biases of the calibrators 
(2.1, 6.0, 12.3, 18.2, 25.3, 46.5 µg/L) were 3.3, –1.8, –1.1, –0.9, –0.4, and 0.5%, respectively 
with CVs for imprecision of 6.1%, 4.0%, 3.1%, 2.8%, 2.4%, and 1.6%, respectively (n = 105), 
QC samples used for LC-MS/MS were: control level 1 with a theoretical value of 3.3 µg/L 
had an accuracy bias of –7.3% and a CV for imprecision of 7.0%; control level 2: 10.5 µg/L 
had an accuracy bias of –2.7% and a CV for imprecision of 5.2%. Finally, control level 3: 
17.2 µg/L had an accuracy bias of –2.2% and a CV for imprecision of 5.5% (n = 115).
Statistical Analysis
Agreement between LC-MS/MS and FPIA measurements of everolimus whole blood 
concentrations was determined using Bland and Altman analysis [13–15]. Passing-Bablok 
regression analysis was used to confirm the Bland-Altman results and to check for a linear 
relationship between the two methods. Analysis was performed with Microsoft Office 
Excel (Microsoft Inc, Redmond, WA) add-in Analyse it statistics software (Analyse-it 
Software, Ltd, Leeds, UK). Areas under the curve (AUCs) were calculated using the linear 
trapezoidal rule with everolimus trough concentrations used as 12-hour values. Figures 
were made with S-Plus (Insightful Corporation, Seattle, WA).
As suggested by Altman et al [16], we introduced a clinical acceptance limit to be able to 
decide whether two methods were in agreement. We chose the clinical acceptance limit to 
be a 20% range around the average difference between the methods. This clinical acceptance 
limit was based on the lowest everolimus oral dose available of 0.25 mg and a dose change 
that would be clinically relevant. This can be explained by the fact that the same exposure in 
terms of either trough concentration or AUC could be reached for instance with 1 mg for one 
individual versus 3 mg in another. A 20% difference in dose would mean a 0.2 mg (in clinical 
practice 0.25 mg) and 0.6 mg (in clinical practice 0.5 mg) dose difference, respectively.
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Results
The everolimus concentrations ranged from 2.3 to 59.2 µg/L and 2.1 to 50.0 µg/L measured 
by FPIA and LC-MS/MS, respectively. Everolimus trough blood concentrations in 286 
samples ranged from 2.3 to 25.0 µg/L and 2.1 to 18.0 µg/L measured by LC-MS/MS and 
FPIA, respectively. The everolimus whole blood pharmacokinetic curves constructed 
from the full AUCs collected 2 weeks after conversion from patients receiving 3 mg 
everolimus are presented in Figure 1. The mean (n = 20) AUC0–12h determined with FPIA 
was 166 µg*h/L (± 57) and the mean (n = 20) AUC0–12h determined with LC-MS/MS was 
140 µg*h/L (± 41) (P ,0.001; paired Student t test).
Figure 1: Mean everolimus whole blood concentration profile (0–6 hours after administration) of 3 mg 
everolimus start dose (n = 20) determined in renal transplant recipients using fluorescence polarization 
immunoassay (FPIA) and liquid chromatography–tandem mass spectrometry (LC-MS/MS). Bars represent the 
standard deviation. AUC, area under the curve.
First of all, a Passing-Bablok analysis was performed to give insight into the relationship 
between the two methods (Fig. 2A–B). In particular, linearity between the two methods 
and deviation from the line of identity were investigated. Figure 2A shows the relationship 
between trough concentrations measured with FPIA and LC-MS/MS, whereas a similar 
figure for all measurements is presented in Figure 2B. The slope of the regression 
equation for the trough concentrations was higher than the slope of the regression 
equation describing all concentrations. Furthermore, the regression equation for trough 
concentrations demonstrated a constant bias (95% confidence interval [CI]: –1.9 to –0.5) 
for the intercept and a proportional bias (95% CI: 1.3–1.5) for the slope. In contrast, the 
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regression equation for all concentrations only showed a proportional bias for the slope 
(95% CI: –0.2 to –0.6). Finally, when the Passing-Bablok analysis for all concentrations 
was tested for linearity with the cusum test, a significant deviation from linearity was 
observed (P< 0.01), which was not the case for the trough concentrations (P > 0.10).
Figure 2: Passing-Bablok comparison plot of the everolimus trough concentrations of renal transplant 
recipients (n = 286) (A) and all measurements (n = 612) (B) obtained by liquid chromatography–tandem mass 
spectrometry (LC-MS/ MS) and fluorescence polarization immunoassay (FPIA) with the line of identity. Dashed 
lines represent the 95% confidence intervals. The solid line within the dashed lines represents the regression 
equation.
 
To test whether the two methods were in agreement, the Bland-Altman plot of the 
difference between the two methods against the mean of the two methods was constructed 
as shown in Figure 3A. This Bland-Altman plot shows that the absolute difference ranged 
from –6.0 to 16.7 µg/L with a mean difference of 2.5 µg/L. Differences between FPIA and 
LC-MS/MS increased with higher mean concentrations of both methods. As has been 
described previously [13,14,16], the influence of this trend should be taken into account 
by either a log transformation of the data or using a concentration ratio (FPIA:LC-MS/ 
MS). For interpretation purposes, we chose the second option [14]. The ratio was plotted 
against the mean concentration. The proportional trend disappeared and the range 
of the difference decreased with higher mean concentrations (Fig. 3B). The geometric 
mean and median of the concentration ratio were 1.23, but the ratio ranged from 0.65 
to 2.14. Moreover, the range of the concentration ratio FPIA:LC-MS/MS below a mean 
concentration of 15 µg/L is much larger than above a mean concentration of 15 µg/L 
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(0.65–2.14 below compared with 0.78–1.69 above). At the start of this comparison, we set 
the clinical acceptance limits at 6 20% of the mean ratio. As can be seen from Figure 3B, 
this acceptance limit falls well within the 95% CI (mean ± 1.96 standard deviation). More 
specifically, 19% (119 of 612) of the data points exceeded the clinical acceptance limits. The 
majority of these data points (80%) were below a mean concentration of 15 µg/L. Trough 
concentrations represented 73% of the data points that were lower than 15 µg/L and were 
outside the upper acceptance limit (36 of 49). This indicates that concentrations in the 
lower range such as trough concentrations vary more between the two methods. Indeed, 
this is likely to be the case because the Passing-Bablok analysis also showed a difference for 
the two methods regarding linearity and the regression equation when comparing trough 
concentrations and all concentrations. 
Figure 3: Bland-Altman plot of difference (A) and concentration ratio (B) against mean everolimus concentration 
measured by liquid chromatography–tandem mass spectrometry (LC-MS/MS) and fluorescence polarization 
immunoassay (FPIA) (n = 612) showing data range, mean (2A: 2.5 µg/L, 2B: 1.23) with 95% limits of agreement 
and clinical acceptance limits (1.48 and 0.98).
Agreement between FPIA and LC-MS/MS was also investigated using AUC0–12h values as 
presented in the AUC ratio plot (FPIA:LC-MS/MS) in Figure 4. The ratio plot showed a 
mean ratio and median of 1.24 meaning that, on average, AUC0–12h measured with FPIA 
resulted in a 24% higher AUC0–12h than with LC-MS/MS. The ratio ranged from 0.92 to 
1.94 showing a large variability. All except two data points were within the 95% CIs of 
the mean ratio, but the acceptance limit was crossed by 10% of the data points, again 
confirming that the two methods are not in agreement.
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Figure 4: Bland-Altman plot of ratio against mean area under the curve (AUC) obtained by liquid 
chromatography–tandem mass spectrometry (LC-MS/MS) and fluorescence polarization immunoassay (FPIA) 
(n = 84) showing data range, mean (1.24) with 95% limits of agreement, and clinical acceptance limits (1.48 and 
0.99).
 
Figure 5: Difference in dosage advice (fluorescence polarization immunoassay [FPIA] versus liquid 
chromatography– tandem mass spectrometry [LC-MS/MS]) given in the study period showing range and mean 
(0.04 mg). Dose difference limits –0.25, 0.25, –0.75, and 0.75 are presented as dashed lines. Target area under the 
curve (AUC) FPIA = 150 µg*h/L, target AUC LC-MS/MS = 120 µg*h/L.
 
To investigate whether this variability would have clinical implications, dose adjustments 
were calculated using the 84 AUCs0–12h from 28 patients. The target AUC0–12h for FPIA was 
150 µg*h/L and therefore target AUC0–12h for LC-MS/MS was set at 120 µg*h/L because 
we found that FPIA results were 24% higher than LC-MS/MS results. Figure 5 shows the 
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difference in individual dosage advice based on everolimus AUC0–12h as determined by 
FPIA or LC-MS/MS. The differences ranged from –1.18 mg to 0.85 mg with an average 
difference of 0.04. Differences of 0.5 mg or higher would cause clinical concern. All 
extreme outliers (greater than 0.75 mg) were from different patients. The graph shows a 
large variability in everolimus doses leading to actual differences in dose adjustments up 
to 1.25 mg when using the average ratio (FPIA:LC-MS/MS) as a correction factor.
To investigate the variability of the methods with time during clinical monitoring 
of everolimus, dose-corrected trough concentrations from six different patients as 
determined by the two methods were plotted chronologically in Figure 6. 
Figure 6: Dose-corrected trough concentrations at monitoring occasions measured by liquid chromatography– 
tandem mass spectrometry (LC-MS/MS) and fluorescence polarization immunoassay (FPIA) showing variability 
in difference between FPIA and LC-MS/MS in six patients.
This means that all concentrations were scaled to an everolimus dose of 3 mg twice daily to 
correct for dose-related concentration differences. Next to the two lines of concentrations 
measured with both methods, a third line is introduced, which indicates the differences 
between the FPIA line and LC-MS/MS line. The horizontal axis reflects the occasion 
number. The FPIA line ascends and descends, whereas the LC-MS/MS line remained more 
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stable, resulting in pronounced fluctuations of the difference line. If both methods showed 
no difference at all, the difference line would be a flat line. Overall, FPIA-determined 
everolimus trough concentrations were higher than those determined by LC-MS/MS, but 
the difference between the two methods was not constant. This is illustrated by multiple 
peaks with the FPIA methods in this figure, whereas a straight line is observed for LC-MS/
MS. For instance, this is the case for Patient B at occasion 12 or Patient C at occasion 7.
Discussion
In this study, the two widely used analytical techniques for everolimus blood concentration 
measurement, FPIA and LC-MS/MS, were compared using a large series of blood samples 
from stable adult renal transplant recipients. Overall, this study demonstrated that these 
two methods were not in agreement, because the preset acceptance limit was exceeded. 
Furthermore, this study showed that everolimus concentrations determined by FPIA are, 
on average, 23% higher than LC-MS/MS. However, the variability found between FPIA 
and LC-MS/MS could be twofold for concentrations lower than 15 µg/L or AUC0–12h. This 
suggests a relatively large effect on variability of FPIA versus LC-MS/MS when monitoring 
trough concentrations. Moreover, the large variability of the everolimus concentrations 
determined with FPIA can lead to differences in everolimus doses of 1.25 mg compared 
with LC-MS/MS when applying dose adjustments based on a preset target AUC despite 
using a correction factor of 23%. Finally, the within-patient variability for trough 
concentrations appeared to be higher using the FPIA method. 
Previous method comparisons for everolimus [3,4,17,18] were based mainly on trough 
concentration measurements and not AUCs. Differences between the methods using 
trough concentrations, other concentration time points, or the AUC were not investigated, 
and implications of the differences between the methods on dose adjustments remained 
unclear. Moreover, in previous studies, samples were obtained from patients on a 
cyclosporine A, prednisolone, and everolimus based immunosuppressive regimen. 
Because an interaction between cyclosporine A and everolimus has been described [19], 
this could affect the results.
When comparing the regression equations obtained with this study and earlier studies, 
the regression equation: FPIA = 1.21 x LC-MS/MS + 0.2 was comparable to those of Salm 
et al: FPIA =1.19 × HPLC-MS + 0.5118 and Koster et al: 1.34 × LC-MS/MS + 0.855 found 
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in patients on a everolimus with a calcineurin inhibitor regimen. Dially et al. found, with 
a smaller number of samples of renal and heart transplant patients; FPIA = 0.851 × LC-
MS/MS + 1.773 [4], a larger difference in slope but a higher intercept, possibly caused by 
use of different internal standards [4,20]. Khoschsorur et al. [17] found in their trough 
concentration comparison of FPIA versus HPLC an equation of FPIA = 1.11 × HPLC + 
0.378 [17]. The difference with Khoschsorur et al. [17] in the trough concentration equation 
could be caused by higher process efficiency of LC-MS/MS, population differences, and 
cyclosporine A use.
In the present study, different QC samples were used for determining within-day and 
between-day precision for the two methods. It would be best to use the same controls for 
both methods but this was not possible as a result of the prefabricated packages with FPIA. 
However, the controls used were similar to those used by other research groups [3,4,17,18]. 
This study used a large number of samples obtained from 28 individuals. This means that 
multiple samples from individual patients were used for the comparison. To exclude any 
bias from repeated measurements we repeated all the analyses on data sets containing 
only one measurement per individual. All conclusions remained the same when applying 
that procedure. In fact, one should not consider these as repeated measurements because 
different days with different clinical situations (alternating hematocrit, co-medication) 
and different everolimus doses within an individual were compared.
Bland-Altman analysis of all everolimus concentrations showed large variability and a lack 
of agreement between the two methods. The majority of the data points that exceeded the 
acceptance limits were below a mean concentration of 15 µg/L. The ratio between AUC0–12h 
determined with FPIA and AUC0–12h determined with LC-MS/MS had a large variability 
corresponding to large differences in dosage advice. The dosing differences between 0.25 
mg and –0.25 mg were considered not relevant because the lowest tablet dose available is 
0.25 mg. Nevertheless, a large number of data points exceeded the ± 0.25-mg line, resulting 
in clinically relevant dosing differences. However, a difference of 0.25 mg on a total of dose 
of 3 mg has less impact than a difference of 0.25 mg on a total dose of 1 mg. This clinical 
impact is taken into account by our clinical acceptance limit. A 20% difference on a dose 
of 1 mg or 3 mg leads to a maximum adjustment of the everolimus exposure of 20%. The 
large number of data points that exceeded the clinical acceptance limit indicated that the 
two methods cannot be interchanged. All data points exceeding or near the 20% clinical 
acceptance limits in Figure 4 correspond with large differences in dosing advice in Figure 
5. Therefore, it is not desirable or acceptable to use the average AUC ratio of 1.24 or the 
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average concentration ratio of 1.23 as correction factors, because this could lead to clinically 
relevant differences in everolimus dose adjustments. The differences in dosage advice that 
were found could raise the question whether the target AUC of LC-MS/MS was calculated 
correctly. We investigated this as follows; compared with a target AUC of 115 µg*h/L or 125 
µg*h/L, the chosen target AUC of 120 µg*h/L resulted in a mean difference closest to zero, 
which means that the average dosage advice of FPIA and LC-MS/MS is similar. With any 
other approach, the dose differences are higher.
The variability of the concentration ratio was higher for concentrations less than 15 
µg/L. This of course could be the result of nonspecific binding of the antibodies [10]. 
The majority of the concentrations lower than 15 µg/L were trough concentrations. 
The concentrations are normally relatively low at the trough concentration (Fig. 3) and 
metabolites are present in relatively high concentrations before the next dose. Therefore, 
crossreactivity of these metabolites would probably have a greater impact on trough 
concentrations. For cyclosporine A, which has a similar metabolism [21], Schütz et al. 
[22] demonstrated that the relative cyclosporine A metabolite concentration was higher at 
trough concentration than at 2 hours after dose intake. Johnston et al.[23] showed higher 
crossreactivity at trough concentration for cyclosporine A as compared with 2 hours 
after dose intake. Crossreactivity of the FPIA assay was investigated by Tobin Strom et 
al. [24,25]. They identified metabolite patterns of everolimus in trough blood samples 
of renal transplant patients and found metabolite concentrations of the three main 
metabolites: 46-hydroxy 44,1% (0–784%), 24 hydroxy 7.7% (0–85.6%), and 25-hydroxy 
14.4% (0– 155.4%) (25). For FPIA, they found crossreactivity of 1% or less for 46-hydroxy 
and 24-hydroxy everolimus and 6% or less for 25-hydroxy everolimus [24]. This suggests 
that at least part of the overestimation of FPIA may be caused by crossreactivity.
The variability in differences in dosage advice showed that the risk of suboptimal dosage 
advice is present and clinically relevant. With FPIA, the question raises if an elevated 
or reduced trough concentration of a patient sample result is correct or the result of 
the variability of the assay. In the first 6 months after transplantation (patients using 
cyclosporine A and everolimus), an incorrect dose adjustment of 25% (0.75 on 3 mg 
total) resulting in too low an exposure to everolimus increases the risk of rejection up 
to 10% [26]. The risk of toxicity such as trombocytopenia after a similar incorrect dose 
adjustment resulting in an everolimus exposure 25% too high could increase up to 7% 
depending on the everolimus blood concentrations reached [26]. In general, LC-MS/MS 
is a more specific, more stable, and more accurate method for everolimus TDM. LC-MS/
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MS is able to simultaneously measure several immunosuppressive drugs in a single run 
and can provide high specificity and sensitivity. The limitations are high initial capital 
investment and highly trained analysts for operation and maintenance. Because of this 
mainly financial limitation, not every clinical laboratory has a LC-MS/MS at its disposal 
[6]. Although FPIA is easy to operate, the analysis costs are relatively high.
Conclusion
The analytical methods FPIA and LC-MS/MS are not in agreement. Everolimus blood 
concentration measurement using FPIA results in higher everolimus concentrations 
compared with LC-MS/MS. Furthermore, LC-MS/MS outperforms FPIA for clinical 
monitoring and intervention of everolimus therapy in adult renal transplant recipients on 
duo therapy with prednisolone. Specifically, the use of FPIA can lead to clinically relevant 
differences in everolimus dosage advice and higher intra-patient variability.
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Abstract
Everolimus is a novel macrolide immunosuppressant used in the prevention of 
acute and chronic rejection of solid organ transplants. Everolimus is actively being 
investigated worldwide as a non-nephrotoxic alternative for calcineurin inhibitors. Its 
highly variable pharmacokinetics and narrow therapeutic window makes it difficult to 
maintain everolimus at adequate exposure to prevent serious adverse effects. The primary 
objective of this study was to improve prediction of everolimus systemic exposure in renal 
transplant patients by describing the pharmacokinetics of everolimus and identifying 
the influence of demographic factors and a selection of polymorphisms in genes coding 
for ABCB1, CYP3A5, CYP2C8 and PXR. The secondary objective of this study was 
to develop a limited sampling strategy to enable prediction of everolimus exposure in 
an efficient way and to compare it with the widely used trough concentration (Ctrough) 
monitoring. A total of 783 blood samples were obtained from 53 renal transplant patients 
who had been switched from a triple therapy of cyclosporine, mycophenolate mofetil 
and prednisolone to a calcineurin inhibitor free dual therapy of everolimus (twice daily) 
and prednisolone. Everolimus blood concentrations were analyzed in whole blood using 
liquid chromatography tandem mass spectrometry during routine therapeutic drug 
monitoring targeting an AUC12 of 120 µg*h/L. A population pharmacokinetic model 
was developed and demographic factors and genetic polymorphisms in genes coding 
for ABCB1, CYP3A5, CYP2C8, PXR were included as covariates. In addition, a limited 
sampling strategy was developed. Maintaining everolimus systemic exposure at an AUC12 
of 120 µg*h/L resulted in low rejection rates but considerable numbers of adverse events 
and toxicity. Everolimus pharmacokinetics were best described by a two-compartment 
model with lag-time (CL/F = 17.9L/H, V1/F = 148 L and ka = 7.36 h
-1). Ideal Body Weight 
was significantly related to V1/F. None of the selected polymorphisms in genes coding 
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for enzymes involved in distribution and metabolism of everolimus had a significant 
influence on everolimus pharmacokinetics. The pharmacokinetic limited sampling model 
(Ctrough and C2) resulted in a significant improved prediction of everolimus exposure 
compared to the widely used Ctrough monitoring. A two compartment pharmacokinetic 
model with lag-time describing the concentration time profile of oral everolimus in renal 
transplant patients has been developed using pharmacokinetic modeling. Ideal Body 
Weight significantly influenced V1/F of everolimus, however the selected polymorphisms 
in genes coding for ABCB1, CYP3A5, CYP2C8, PXR had no clinically relevant effect on 
everolimus pharmacokinetics. Everolimus Ctrough and C2 as limited sampling model can be 
used to accurately estimate everolimus systemic exposure, an improvement compared to 
the widely used Ctrough monitoring.
Introduction
Everolimus (Certican®), is a non-nephrotoxic alternative for calcineurin inhibitors (CNIs) 
in renal transplantation. Its narrow therapeutic window, together with high variability in 
pharmacokinetics makes Therapeutic Drug Monitoring (TDM) useful to individualize the 
dose and thereby prevent toxicity or rejection. Everolimus is often prescribed in combination 
with CNIs. Due to CNI-related nephrotoxicity CNI minimizing and CNI free strategies 
are being actively investigated worldwide [1–6]. Everolimus is metabolized by cytochrome 
P450 enzymes CYP3A4, CYP3A5 and CYP2C8. Everolimus is also a substrate for the efflux 
pump P-Glycoprotein (ABCB1)[7,8]. The nuclear pregnane X receptor (PXR) mediates 
expression of CYP3A4 and could therefore also influence everolimus pharmacokinetics 
[9]. Differences in activity of metabolizing enzymes are likely to be responsible for a main 
part of the variability in pharmacokinetics [7,8]. Genetic polymorphisms in genes encoding 
these enzymes could explain variability in everolimus pharmacokinetics but this has only 
been investigated sparsely. Two studies investigated the role of genetic variants in genes 
encoding for CYP3A5 in everolimus pharmacokinetics but no relationship was identified 
[10,11]. However, these studies had the limitation that data were derived from patients on 
cyclosporine, prednisolone and everolimus and did not use population pharmacokinetic 
analysis. This approach enables to differentiate between inter-patient and intra-patient 
variability and results in enhanced statistical power to identify covariates. Therefore we 
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chose to perform a population pharmacokinetic analysis including demographic and 
pharmacogenetic data as potential covariates. There has been one previous population 
pharmacokinetic study of everolimus in renal transplant patients [12], but data were 
derived from patients on a combined cyclosporine and mTOR based regimen. More 
importantly, it lacked inclusion of genetic polymorphisms. Since cyclosporine affects 
everolimus pharmacokinetics, the results from this population pharmacokinetic study 
cannot be extrapolated to everolimus and prednisolone dual therapy. Everolimus TDM is 
mostly performed based on trough blood concentrations (Ctrough) [13] but some clinics use 
area under the blood concentration curve (AUC) [3]. Whether everolimus therapy should 
be based on troughs or on AUC warrants further investigation. This choice has a practical 
aspect based on the fact that TDM based on trapezoidal AUC is more laborious for both 
patients and clinic since multiple concentration markers are needed to accurately calculate 
AUC. A less laborious method such as a limited sampling strategy could influence the 
choice of performing TDM based on Ctrough or AUC.
The primary aim of the current study was to describe the population pharmacokinetics of 
everolimus in renal transplant patients following oral administration of everolimus twice 
daily in absence of a CNI and to identify covariates explaining variability. The secondary 
aim was to develop a limited sampling strategy to enable prediction of everolimus exposure 
in an efficient way and to compare it with the widely used Ctrough monitoring. 
Patients and Methods
Patients
Clinical data from 53 stable renal transplant recipients treated with immunosuppressive 
dual therapy consisting of everolimus (Certican®, Novartis, Basel, Switzerland) and 
prednisolone, participating in a prospective, open, randomized, multicenter study were 
studied from 6-24 months after transplantation [3]. During the first six months, patients 
were treated with a immunosuppressive regimen including cyclosporine, prednisolone 
and mycophenolate mofetil, Thereafter a scheduled biopsy was performed. Patients whose 
biopsy showed no sign of rejection were included and randomized into three groups [3]. 
Subsequently cyclosporine and mycophenolate mofetil were discontinued [3]. From this 
moment on data was collected for this pharmacokinetic study. Everolimus therapy was 
started at an oral dose of 3 mg twice daily and was supported by routine TDM based on 
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Ctrough concentrations and AUC from time zero to 12 hours (AUC12). Dose adjustments 
were based on AUC12. TDM was aimed at a target of 120 μg*h/L. The study was approved 
by the Medical Ethics Committee of Leiden University Medical Center (Leiden, the 
Netherlands) and patients gave written informed consent.
Bioanalytics
TDM was performed on the basis of trapezoidal rule (blood concentration at t = 0,1,2,3,4,5 
and 6 hours or t = 0,1,2 and 3 hours) in kinfit menu using MW/Pharm® 3.5 (Mediware, 
Groningen, The Netherlands)[14]. TDM samples were taken at week 6, week 36, week 
62 and week 78 after conversion and determined in whole blood by a validated liquid 
chromatography-mass spectrometric (LC-MS) method in two laboratories [15,16]. 
Quantification of everolimus with liquid chromatography tandem mass spectrometry 
(LC-MS/MS) was performed with a validated assay capable of analyzing everolimus, 
sirolimus and tacrolimus simultaneously. The system consisted of an Ultimate® 3000 
autosampler, a thermostatted column compartment TCC 100 and a p680 HPLC dual 
low-pressure gradient pump (analytical). All were purchased from Dionex Benelux B.V 
(Amsterdam, The Netherlands). The MS/MS used was a Quattro micro™ API Tandem 
Quadrupole system from Waters corporation, Milford, U.S.A.
200 μL of blood samples, controls or calibrators were diluted with 200 μL 0.1 M ZnSO4 
and 500 μL internal standard solution. Internal standard solution consisted of 100 μL 16 
μg/L desmethyl sirolimus in methanol and 25 mL acetonitrile (LiChrosolv, Merck KGaA, 
Darmstadt Germany). A 6+1 multilevel calibrator set (0, 2.1, 6.0, 12.3, 18.2, 25.3, 46.5 
μg/L) was used, which was obtained from Chromsystems (Munich, Germany). Blood 
control levels 1, 2 and 3 were obtained from RECIPE (Munich, Germany). After diluting, 
vortex mixing for 2 minutes followed by 5 minutes of centrifugation at 13000 rpm was 
conducted. After centrifugation, the supernatant was transferred into a cylindrical crimp 
neck autosampler vial.
A 50 μL aliquot of supernatant was injected into an online solid phase extraction (SPE) 
column (Cartridge Hysphere 5C18 HD, 7μm particle size 10 x 2 mm, Spark, Emmen, The 
Netherlands) for enrichment. For sample clean-up two mobile phases were used: mobile 
phase A: 0.1% v/v formic acid + 2 mM ammonium acetate in water and mobile phase B: 
0.1% v/v formic acid + 2 mM ammonium acetate in methanol. The elution gradient used 
on the SPE column was 50% A and 50% B for 2 minutes, followed by 0.8 minute 100% 
B and 1.5 minutes 50% A and 50% B for elution of everolimus and IS for isocratic liquid 
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chromatography on the pre-column (Hypersil 4 x 2 mm, Phenomenex) and analytical 
column (Hypersil Phenyl 50 x 3 mm, 3 μm particle size, Thermo Scientific). The column 
oven was set at 55°C. The elution gradient for chromatographic separation to the MS 
was 10% A and 90% B at a flow rate of 600 μL/min. Mass-spectrometric detection was 
in positive ion mode using selected reactant monitoring (everolimus m/z 975.7→908.3, 
internal standard, desmethyl sirolimus, m/z 901.7→834.3). The lower limit of quantification 
for everolimus was 0.2 μg/L. Supplementary Table I shows the samples distribution.
Supplementary table I: Pharmacokinetic data distribution.
Pharmacokinetic data Mean / Number SD Median Range
Concentrations (µg/L) 12.1 6.7 12.1 2.6 - 50









Samples per occasion (official visit)
 Week 32 271
 Week 52 148
 Week 78 75
 Week 104 193
 Other 96
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DNA was isolated from EDTA blood collected from patients. ABCB1-1236C>T, ABCB1-
3435C>T, ABCB1-2677T>G, CYP2C8-467603213T>C and CYP2C8-47631494C>T were 
determined with TaqMan 7500 (Applied Biosystems, Nieuwerkerk a.d. IJssel, The Nether-
lands) with custom designed assays, according to manufacturers’ protocol. ABCB1-
129T>C, CYP3A5-6986A>G, CYP3A5-7225G>A, PXR-G-24113A, PXR-A+7635G were 
determined with Pyrosequencer 96MA (Isogen, IJsselstein, The Netherlands). PCRs 
contained 10 ng of DNA and 5 pmol of each PCR primer in a total volume of 12 mL. Cycle 
conditions were initial denaturation for 15 minutes at 95°C, 35 cycles of 95°C, 55°C, and 
72°C each for 30 seconds, ended by 10 minutes at 72°C. The pyrosequence reactions were 
performed according to manufacturers’ protocol. Primers and probes used in the TaqMan-
based genotyping assays and primers and sequences used in the pyrosequence assays for 
each SNP are listed in Supplementary Table II. The nucleotides shown in lower case are 
negative controls, which were not incorporated in the target DNA and consequently did 
not appear in the pyrogram. As quality control, 5% of samples were genotyped in duplicate. 
In addition, negative controls (water) were used. No inconsistencies were observed. All 
allele frequencies were in Hardy–Weinberg equilibrium. Haplotype analysis for ABCB1 
and CYP2C8 SNPs was performed using gPLINK with haplotypes set with a certainty 
greater than 0.97. 
Pharmacokinetic modeling
Nonlinear mixed effect modeling was used to estimate everolimus pharmacokinetic 
parameters from blood concentration-time data. NONMEM® (v7.1.2, Icon Development 
Solutions, Ellicott City, MD, USA) was used for modeling everolimus pharmacokinetics, 
using PsN toolkit [17], and Piranã version 2.3.0 [18] as modeling environment. Results 
were analyzed using statistical software package R (v2.11.0). First order conditional 
estimation method with interaction (FOCE-I) was used throughout the analysis. Model 
selection was based on statistical significance, goodness of fit and stability. Throughout 
the model building process, an altered model was chosen over a precursor model if a 
difference in the objective function values (OFVs) (-2 log likelyhood) was >6.63 (P<0.01, 
with 1 degree of freedom, assuming χ2 distribution).
Base model 
Initially, the model was developed strictly pharmacokinetic without covariates. Plots 
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of observed concentration-time data of everolimus were examined. One and two 
compartmental pharmacokinetic models with first-order elimination were compared to 
find the best fit of the concentration-time data. The use of transit compartments and a lag 
time for drug absorption were explored. 
Covariate analysis
Diagnostic plots were constructed of the random effects of apparent oral clearance (CL/F), 
apparent volume of distribution of the central compartment after oral administration (V1/F) 
and first order absorption rate constant (ka) versus the demographic (age, total body weight 
(TBW), sex, ethnicity, length, Ideal Body Weight (IBW), Body Surface Area (BSA), Body 
Mass Index (BMI), Lean Body Weight (LBW), hematocrit, albumin, underlying disease 
and co-medications (also weighted residual vs co-medications plots) and pharmacogenetic 
(ABCB1, CYP3A5, CYP2C8 and PXR polymorphisms) characteristics. Polymorphisms 
were selected based on theoretical relationship and minimal allele frequency (>0.06) 
to assure detection of clinically relevant effects on everolimus PK. Based on these plots 
further testing in the pharmacostatistical model was performed. Subsequently, selected 
covariate relationships were evaluated by forward inclusion and backward deletion 
procedure. A covariate effect was only maintained in the model if the inclusion resulted in 
a reduction in random variability and improved model fit. Evaluation of the precision of 
the pharmacokinetic parameters was performed with 1000 bootstrap replicates.
Visual predictive check with prediction-correction
Performance of candidate and final models for the everolimus pharmacokinetic model was 
evaluated using prediction corrected visual predictive checks (predVPC), by simulation 
of 500 simulated datasets [19,20]. Since observations were spread around nominal time 
points, bin separators in the VPC were set at the lowest densities of sample points over 
time, i.e. this positions the bins such that the periods with densest sampling were in 
the middle of the bins. Shrinkage in interindividual variability and residual errors was 
automatically calculated by NONMEM® v7.1.2. to assess the informativeness of the data 
for using individual predictions in the evaluation of model fit. The distribution (median, 
10th and 90th percentiles) of the simulated concentration–time courses was compared 
with the distribution of the observed values in the original dataset. Differences and overlap 
of the simulated and original distributions indicated the accuracy of the identified model.
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Limited sampling strategy
Patients and data collection 
Fifty two full AUCs from 52 different patients were used for development of a limited 
sampling strategy (1 patient had one missing sample and was therefore excluded). 
Pharmacokinetic profiles consisted out of 7 blood samples collected over 6 hours (0 
[predose] and 1,2,3,4,5 and 6 hours postdose). 
Pharmacokinetic and statistical analysis
Trapezoidal AUC12 (full AUC) was calculated from all measured concentration-time 
points using trapezoidal rule using T=0 hours as T=12 hours. Limited sampling model 
(LSM) AUC12 (predicted AUC) was calculated by selecting several concentration-time 
points and combinations of time points. Bias and imprecision were calculated to assess 
the performance of the different LSM’s according to the guidelines proposed by Sheiner 
and Beal [21]. A Pearson correlation coefficient test was performed to determine the 
correlation between trapezoidal AUC12 and LSM AUC12. The formulas of the predictive 
performance measures used are presented in Supplementary Table III.
Supplementary Table III: Formulas.
Demographic Covariate Formulas
IBW calculated as: 
 Males: 52 kg + 1.9 kg for every inch over 5 feet (33)





69Population pharmacokinetics and pharmacogenetics 
of everolimus in renal transplant patients
4
BSA (Mosteller(1987))
Limited Sampling Strategy Statistical analysis Formulas
Bias
Mean prediction error = mean (AUCpred – AUCfull)
Mean percentage prediction error (MPPE) = mean [100% * (AUCpred-AUCfull)/AUCfull]
Imprecision
Root mean squared prediction error (√mean (AUCpred-AUCfull)2)
Mean absolute percentage prediction error (MAPE) = mean [100% * |AUCpred-AUCfull|/AUCfull]
The percentage of AUCpred within a 15% radius of AUCfull is decreased by both greater bias and 
worse precision and is therefore a usefull measure and overall predictive ability.
Discordance
Discordance between AUCpred and AUCfull (The percentage of times that AUCpred failed to 
indicate a everolimus dosage adjustment of 20% when AUCfull was out of the target range, or 
indicated a dosage adjustment of 20% or higher when AUCfull was within the target range).
Results 
Patients and Pharmacokinetic data
Fifty-three adult renal transplant recipients, 35 men and 18 women were included in 
this study. The majority of patients (81%) were Caucasian, 4% of the patients were Black 
and 15% belonged to other ethnicities. Mean age was 52 ± 12 years (range: 23-71 years), 
mean TBW was 80.7 ± 16.2 kg (52-128.8 kg). The dataset consisted out of 783 samples. 
Everolimus concentrations were obtained at steady state at clinical visits which were 
planned at 32, 52, 78 and 104 weeks after transplantation. The concentration-time data 
were reviewed for completeness and consistency of sampling and dosing times. Clinical 
characteristics and details about exposure and efficacy and safety response are listed in 
Table I. Genotype distribution for CYP3A5, CYP2C8, ABCB1 and PXR are listed in Table 
II. Haplotype distribution for ABCB1 and CYP2C8 are listed in Table III.
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Table I: Clinical characteristics.
Recipient characteristics Number (%) Mean ± SD Median (Range)
 Male 35 (66%)
 Female 18 (44%)
 Age (y) a 52 ± 12 55 (23 - 71)
 Caucasian (%) 43 (81%)
 Total Body Weight (kg) a 80.7 ± 16.2 77.5 (52 - 128.8)
 Body surface Area (m2) b 1.96 ± 0.23 1.93 (1.51 - 2.52)
 Lean Body Mass (kg) b 60.5 ± 8.6 59.4 (43.2 - 79.9)
 Ideal Body Weight (kg) b 68 ± 7.5 68.3 (52 - 83.1)
 Height (m) b 174 ± 10 174 (152 – 194)
 Creatinine (μmol/L) a 116 ± 34 116 (59 – 226)
 Albumin (g/L) 42 ± 3.6 43 (25 – 49)
 Hematocrit (L/L) 0.38 ± 0.04 0.38 (0.26 - 0.48)
Underlying disease
 Polycystic kidney disease 12 (22.6%)
 Glomerulonephritis 11 (20.8%)
 Diabetes mellitus 4 (7.5%)
 Hypertension 8 (15.1%)
 Focal segmental Glomerulosclerosis 2 (3.8%)
 Unknown 2 (3.8%)




 Everolimus Dose (mg) a 2.44 ± 0.75 2.25 (0.75 - 4.50)
  Everolimus area under the curve (AUC) 
(µg*hour/L) 130 ± 39 127 (55 – 260)
 Concentrations (µg/L) 12.1 ± 6.7 12.1 (2.6 – 50)
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Renal function
 Creatinine clearance (mL/min) c 70 ± 27 58 (26-120)
  Week 32 67 ± 27 57 (28-120)
  Week 52 67± 24 58 (28-120)
  Week 78 76 ± 27 68 (37-120)
  Week 104 72 ± 27 57 (30-120)
Efficacy and safety responses
 Freedom from acute rejection 53 (100%)
 Hypercholesterolemia (> 6.5 mmol/L) 33 (62.3%)
 Hypertriglyceridemia (> 2.9 mmol/L) 27 (50.1%)
 Thrombocytopenia (< 75 *109/L) 0 (0.0%)
 Leukopenia (< 4 *109/L) 5 (9.4%)
 Diarrhea 6 (11.3%)
 Dyspnea 4 (7.6%)
 BK nephropathy 1 (1.9%)
 PCP infection 2 (3.8%)
 Pneumonia 3 (5.7%)
 Edema 4 (7.6%)
  Infections  
(airway, gastro-intestinal, urinary tract) 6 (11.3%)
 Cardiovascular events 2 (3.8%)
 Patients who did not complete the entire study 16 (30.2%)
a, During trial; b, At first TDM moment; c, Modification of Diet in Renal Disease (MDRD) when <60ml/min and 
Cockcroft-Gault when > 60 ml/min (cut-off 120 ml/min); AUC, area under the blood concentration vs time 
curve.
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Table II: Genotype frequencies in studied population (n = 53).
Gene SNP(s) Nucleotide position and alleles Genotype Frequency [N (%)]
ABCB1
rs1128503 1236C>T C/C 20 (38)
C/T 25 (47)
T/T 8 (15)
rs2032582 2677T>G T/T 22 (42)
G/T 25 (47)
G/G 6 (11)
rs1045642 3435C>T C/C 16 (30)
C/T 30 (57)
T/T 7 (13)




rs10509681 47603213T>C T/T 47 (89)
C/T 6 (11)
rs11572080 47631494C>T C/C 47 (89)
C/T 6 (11)
CYP3A5
rs776746 6986A>G A/A 2 (4)
G/A 4 (7)
G/G 47 (89)




rs2276706 -24113G>A G/G 23 (43.4)
G/A 23 (43.4)
A/A 7 (13.4)
rs6785049 7635A>G G/G 7 (13)
A/G 20 (38)
A/A 26 (49)
CYP, cytochrome p450; PXR, pregnane X receptor; SNP, single nucleotide polymorphism.
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Table III: ABCB1 and CYP2C8 haplotype table. This table shows the frequencies of the haplotype combinations 
on the left, and the frequency of the individual triplets/duplets on the total amount of 60 triplets/duplets on the 














rs1128503 CCG CCG 13 (24) CCG 55 (52)
rs2032582 CCG CTG 2 (4) TTT 35 (33)
rs1045642 CCG TTT 19 (36) TCG 9 (8)
CCT TTT 1 (2) CTG 4 (4)
CTG TTT 2 (4) CTT 2 (2)
CTT CCG 1 (2) CCT 1 (1)
TCG CCG 7 (13)
TTT CTT 1 (2)
TTT TCG 2 (4)
TTT TTT 5 (10)
CYP2C8
rs10509681 CT CT 47 (89) CT 100 (94)
rs11572080 TC CT 6 (11) TC 6 (6)
 
CYP, cytochrome P450; SNP, single nucleotide polymorphism.
Structural model development 
The pharmacokinetic data of everolimus was best described by a two-compartmental 
model with first order absorption with lag time and first order elimination from the central 
compartment. Random effect parameters for inter-individual variability in clearance 
(CL), distribution volume of central compartment (V1) and rate of absorption (ka) were 
identified. Variability between occasions was best described with a random effect on ka 
and (fixed) bioavailability (F). Thereafter the random effects were tested for structural 
relationship with dose and time to create a model with unbiased and randomly distributed 
random effects for covariate analysis. The structural pharmacokinetic model indicated a 
CL/F of 18 L/h, an V1/F of 153 L and an apparent peripheral distribution volume (V2/F) 
of 495 L (Table IV). The absorption rate constant was 7.36 h-1. Inter-compartmental 
clearance was 56.1 L/h and lag time was 0.714 h. Inter-occasion variability was estimated 
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for the fixed bioavailability term and not for clearance because of a better model fit. The 
pharmacokinetic data showed inter-individual variability in CL/F of 26.4% and inter-
occasion variability (25.9%) with a range of 6-37 L/h. A dose clearance relationship was 
observed showing an increase in apparent clearance with increasing dose according to 
TVCL={[dose/2.25]**0.5}. This relationship improved the model fit in terms of objective 
function. After testing the dose clearance relation according to Jae Eun Ahn et al. [22] the 
effect appeared to be caused by strict TDM. Patients with a high everolimus clearance 
will change over time to a higher daily dosage and vice versa. As a results; an apparent 
concentration-clearance relationship emerges.
The base model was used in the search for demographic and genetic covariates. Diagnostic 
plots of random effect from CL, V1 and ka in the initial model against age, TBW, sex, 
hematocrit, albumin, Length, IBW, BSA, BMI, LBW, co-medication, underlying disease 
and ethnicity were constructed. Plots of weighted residuals versus co-medications were 
made in case co-medications were not constantly administered. The co-medications 
that were evaluated are found in Supplementary Table IV. Criteria for evaluation were 
probability of interaction based on literature and high enough frequency of administration. 
 The plots of random effects of distribution volume against sex, length and IBW indicated 
a relationship between V1/F and these covariates. The addition of IBW centered on the 
population median as exponential function on V1/F improved the model (ΔOFV = -15.3, 
P<0.001), explaining 21% of the random variability between individuals in V1/F. In the 
backward elimination step, removal of the covariate resulted in an increase of the OFV 
of 15.3. Sex, length, and IBW were also related to V1/F but IBW had the highest objective 
function decrease and showed a better prediction corrected Visual Predictive Check. 
TBW, age, LBW, BSA, BMI, albumin, hematocrit, co-medication and underlying disease 
were not significant covariates on CL/F, V1/F or ka.
Diagnostic plots of random effects of CL/F, V1/F and ka against genetic polymorphisms in 
CYP3A5, CYP2C8, ABCB1 or PXR were created. The inclusion of a genetic polymorphism 
in CYP3A5, CYP2C8, ABCB1 or PXR as covariate on CL/F, V1/F or ka of the base model did 
not result in a significant OFV drop (P>0.05 or P>0.01). The population pharmacokinetic 
parameters obtained with the base and final model are presented in Table V. 
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Supplementary Table IV: Comedications of interest for covariate analysis an number of patients using them. 
Immunosuppression






 Sulfamethoxazole / Trimethoprim (n=11)
Hypertension
 Nifedipine (n=39)




* In some cases statins were switched for another statin.
Evaluation of the precision of the pharmacokinetic parameters was performed with 1000 
bootstrap replicates. The mean values for all fixed effect parameters were within 15% of those 
obtained by the final model, indicating good reliability (Table V). Since different dosages were 
used during the study the performance of the model was evaluated with a predictive corrected 
visual predictive check (19)(Figure 1). Predicted and observed intervals (median, 10th and, 
90th percentiles) are almost identical showing good predictive performance of the final model. 
Figure 2a shows the variable pharmacokinetics of everolimus two weeks after conversion 
(3 mg twice daily). The median trapezoidal everolimus AUC12 was 155 µg*h/L (range: 
81-178 µg*h/L) while the target AUC12 was 120 µg*h/L [3,15]. Figure 2b shows trough 
and trapezoidal AUC12 correlation with the trough and corresponding trapezoidal AUC12 
target range. Although a good correlation is found between Ctrough and AUC12, some outliers 
remain at risk. The trough target range (6-8 µg/L) used in this study [3,15] corresponds 
with a relatively wide or at least twofold AUC12 range. When aiming at a target AUC12 of 
120 µg*h/L using this trough range the actual exposure will be in 13% of the patients more 
than 20% lower or higher than intended. This could result in incorrect dose adjustments 
leading to increased risk of toxicity or rejection [15,23,24]. However, using a full AUC 
based on trapezoidal rule remains an invasive and intensive way of performing TDM since 
a large number of samples are required. A limiting sampling model (LSM) with good 
predictive performance could help solve this problem.
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Figure 1: Prediction corrected visual predictive check with median, 10th and 90th prediction and observed 
percentile. The observed everolimus blood concentrations are shown as open circles. The dashed lines with 
square symbols represent the observed median and 10th and 90th percentile. The solid lines represent the 
prediction median and 10th and 90th percentile. The shaded areas around the prediction intervals represent the 







































































































































































































Figure 2: (a) Full concentration-time profiles of everolimus in 37 renal transplant patients exactly 2 weeks 
after conversion receiving everolimus 3 mg twice daily. (b) Trough blood concentration and trapezoidal AUC12 
correlation of 52 different patients (based on full AUC12 curves) 32–104 weeks after transplantation (dose range 
1 – 4.5 mg twice daily). Dotted lines crossing the x-axis represent the trough blood concentration target area 
used in this trial. Dotted lines crossing the y-axis represent the 20% deviation area from the target AUC12 of 
120µg*h/L. AUC12, area under the blood concentration-time curve from time zero to 12 hours.
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With the development of a LSM we calculated the predictive performance of different 
LSMs and since trough concentrations are widely used in TDM also a limited sampling 
formula (LSF) of Ctrough to show the difference between the two methods. Using NONMEM
® 
post hoc estimation on the final model, LSMs were calculated using 52 curves based on one 
or a combination of measured blood concentrations at different time points. For the LSF 
the linear regression equation was calculated. Results of the development of a LSM and 
LSF of Ctrough are shown in Figure 3 and Supplementary Table V. Predictive performance 
measurements are; the percentage of predicted AUCs within a 15% range of the AUC 
calculated with the “trapezoidal rule”; discordance (%) [meaning a predicted AUC leading 
to incorrect dose change] and different ways of describing bias and imprecision: mean 
prediction error (MPE), mean percentage prediction error (MPPE), mean absolute 
percentage error (MAPE), Root Mean Square prediction Error (RMSE)) and correlation. 
Figure 3 shows results of four LSMs, with both regression lines with 95% CI as measurements 
of predictive performance; The limited sampling formula of Ctrough (11.605 × Ctrough+45.774) 
for everolimus in predicting systemic exposure had a reasonable correlation with full 
trapezoidal AUC12 (Discordance=5.77%, MAPE=10.66% and R
2=0.87). The best single 
point marker was Ctrough (Discordance=3.85%,MAPE=8.48%; R
2=0.87). The best two 
points marker was Ctrough and C2 (Discordance=1.92%; MAPE=7.10%; R
2=0.90). The best 
3 points marker was Ctrough, C1 and C3 (Discordance=1.92%, MAPE=5.31% and R
2=0.92). 
The widely used Ctrough showed poorer performance with LSF and LSM compared to the 
two point marker Ctrough and C2. When taking predictive performance, intensity of the 
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R2 pearson AUCpred within 15% AUCfull (%)
Figure 3: Regression line (dotted lines) plots comparing the different limited sampling methods with 95% 
confidence intervals (solid lines) and predictive performance data. The full trapezoidal AUC12 (using eight 
timepoints) is presented on the y-axis. The predicted AUC12 of the different limited sampling models (b, c and d) 
and a linear regression limited sampling formula (a) are shown on the x-axis. (a) Shows the predictive performance 
of Ctrough used in a limited sampling formula without the use of the pharmacokinetic model (linear regression = 
11.605 × Ctrough + 45.774); (b) shows the predictive performance of Ctrough as limited sampling pharmacokinetic 
model; (c) shows the predictive performance of Ctrough and C2 as limited sampling pharmacokinetic model; (d) 
shows the predictive performance of Ctrough, C1 and C3 as limited sampling pharmacokinetic model. The table 
shows the corresponding measurements of predicting performance of each of the graphs. AUC12 = area under 
the blood concentration-time curve from time zero to 12 hours; AUCfull, trapezoidal AUC12; AUCpred, limited 
sampling model AUC12; Cx, blood drug concentration at x hour(s) postdose; Ctrough, trough blood concentration; 
LSM, limited sampling model.
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Discussion
The pharmacokinetics of everolimus in renal transplant patients using everolimus and 
prednisolone was best described by a two-compartmental model with first order absorption 
and lag time. This study shows for the first time that everolimus pharmacokinetics is not 
significantly influenced by genetic polymorphisms in coding genes for the metabolizing 
enzymes CYP3A5, CYP2C8, ABCB1 and PXR or drug transporter ABCB1. In addition, 
demographic covariates TBW, age, sex, hematocrit, albumin, length, BMI, BSA, LBW, 
underlying disease, co-medication and ethnicity did not significantly influence everolimus 
pharmacokinetics. In contrast, IBW did significantly correlate with the variability in V1/F. 
The development of a LSM resulted in identification of a two point concentration marker 
for accurately predicting everolimus systemic exposure and can be used to optimize 
therapy in renal transplant patients. In this study, the mean CL/F and V1/F was 17.9 L/h 
and 148L respectively. The pharmacokinetic parameter estimates were in agreement with 
those (CL/F = 8.8 L/h) found by Kovarik et al. when taking the effect of cyclosporine 
on everolimus pharmacokinetics, differences in patient population, and differences in 
modeling into account. Cyclosporine is known to influence everolimus pharmacokinetics 
leading to an increase of everolimus Cmax and AUC by 82% and 168% respectively [25].
In this analysis we report for the first time that IBW significantly correlates with V1/F. Since 
everolimus is for more than 75% partitioned into red blood cells and 75% of the plasma 
fraction is bound to plasma proteins this relationship can be physiologically explained 
since length and sex are incorporated in the IBW formula [26,27]. In contrast, Kovarik et 
al. [12] found a significant influence of TBW on clearance. The small influence of TBW 
could be explained by the presence of cyclosporine in the immunosuppressive regimen in 
this study. TBW has been reported earlier to be a covariate on cyclosporine clearance [28]. 
The relationship between ethnicity and clearance as was found by Kovarik et al. could not 
be identified in our study [12]. This difference can be explained by the small amount of 
black patients in our cohort. The fact that we found no effect for concomitant medications 
is probably caused by the fact that none of the medications that were previously found to 
be of influence on everolimus clearance were administered to our patient population for 
safety reasons [12]. Although theoretically plausible, we neither found an effect for drugs 
such as statins, nifedipine and sulfamethoxazole/trimethoprim, This is in accordance with 
the results of Kovarik et al [12]. Noncompliance, diarrhea and fatty food intake could 
not be quantified in this study, although these factors could contribute to the observed 
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variability as previously published studies reported [29,23].
This is the first comprehensive study investigating the influence of pharmacogenetics 
on everolimus pharmacokinetics. More specifically, polymorphisms in genes encoding 
CYP3A5, CYP2C8 and PXR, and the multidrug-resistance transporter ABCB1 were 
investigated for possible relationship with everolimus pharmacokinetics. At the time 
the study was conducted CYP3A4 lacked a reliable genetic marker for prediction of 
CYP3A4 expression [30–32], therefore SNPs in CYP3A4 were not included. However 
recent data suggests that CYP3A4*22 may influence CNI pharmacokinetics [33]. These 
polymorphisms were studied before in relation to pharmacokinetics of sirolimus, 
tacrolimus and cyclosporine [34–37]. For sirolimus and tacrolimus clearance a relationship 
to CYP3A5 genotype was found [38,39,40]. Since everolimus is primarily eliminated by 
CYP3A enzymes [7,8] and PXR is related to CYP3A4 expression [31], CYP3A5, CYP2C8 
and ABCB1 and PXR genotypes were evaluated. Allele frequencies found in our dataset 
corresponded with those published previously [41]. We found subjects with CYP3A5 
*3/*3, *1/*3 and *1/*1 genotype. However, CYP3A5 as covariate on apparent clearance 
did not explain variability in pharmacokinetics [12]. Previously, no relationship was 
found between dose requirement, Ctrough, Cmax or AUC12 and CYP3A5 polymorphisms 
[10,11]. Although it is known from in vitro and in vivo studies that CYP3A5, CYP2C8 
enzymes and ABCB1 are involved in everolimus pharmacokinetics [7], no relationship 
was found between the genetic polymorphisms in ABCB1, CYP3A5, CYP2C8 and PXR 
and everolimus pharmacokinetics in our study. In contrast to nonpopulation- based 
approaches a population model has greater statistical power to identify a covariate effect on 
PK parameters, since analyzing multiple observations per subject one is able to compensate 
for the small number of individuals. We performed a posterior power calculation to 
determine the power (95% convidence) of our study to find a minimum clinically relevant 
genotype effect (i.e. 20%) on everolimus PK [42,43]. With the most unfavorable genotype 
distribution (Table II and III) we found a power of 79% in detecting a clinically relevant 
genotype effect. Therefore it is unlikely that our analysis missed a clinically relevant effect of 
genotypes. However for CYP3A5*6 which is only found in individuals who are genetically 
sub-Saharan African, only one subgroup was identified, therefore a comparison could not 
be made. The remaining variability of our final being model was 26.2% and could reflect 
the wide inter-individual variability in CYP3A4 expression [44]. The novel CYP3A4*22 
polymorphism [33] is suggested to predict CYP3A4 activity. Analysis of this SNP and 
everolimus pharmacokinetics warrants investigation. Furthermore, phenotyping CYP3A4 
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by use of a midazolam probe could help to explain the remaining variability in everolimus 
pharmacokinetics [45,46]. 
Our study has some limitations. This study was performed with patients on a cyclosporine 
free regimen; therefore the model cannot be used for patients using normal dose 
cyclosporine and everolimus simultaneously, since cyclosporine has a significant effect on 
everolimus pharmacokinetics [25]. However, although contradictory results were found 
[47], the majority of research suggests that tacrolimus does not influence everolimus 
pharmacokinetics. As a consequence, the applicability of the presented model on tacrolimus 
+ everolimus regimens warrants to be investigated. Since CNI minimizing and CNI free 
strategies are being actively investigated worldwide [1–6] there could be an increasing 
demand for implementing the developed model in clinical practice. Mostly everolimus 
trough concentrations are monitored. Besides the higher impact of assay variability [15] 
when using one marker to predict everolimus systemic exposure, the correlation between 
Ctrough and AUC is not optimal and could theoretically lead to therapy failure when 
exposure is 20% higher or lower as intended. Maintaining everolimus exposure above the 
target range in a regimen of everolimus with reduced-dose cyclosporine increases the rate 
of thrombocytopenia by 6% and hypertriglyceridemia by 16% [24,26]. Exposure below 
the target range increases the rate of acute rejection with 49% [24,26]. Worse predictive 
performance of a TDM marker can lead to incorrect dose adjustments resulting in 
exposure outside the target range. Maintaining a target AUC12 of 120 μg*h/L in the current 
study resulted in low acute rejection rates and renal function was preserved. Moreover 
low rates of thrombocytopenia and leukopenia were reported. On the other hand higher 
rates of hypercholesterolemia and adverse events were found. Adverse events and side 
effects were the main reasons of stopping everolimus therapy before the trial ended. In 
our study Ctrough monitoring had a worse performance in estimating AUC12 when using 
LSF and LSM compared with Ctrough and C2 in LSM, especially the LSF which resulted in a 
15.5% higher percentage of patients outside of the 15% range of the full trapezoidal AUC 
and a 3.8% increase in discordance. The presented pharmacokinetic model and limited 
sampling method is a clear improvement in terms of inconvenience for patient and clinic 
and predictive performance. Ctrough and C2 monitoring based on the presented PK model 
results in an improved predictive performance compared to Ctrough monitoring. Clinicians 
should decide whether this improved performance as shown in figure 3 is worth the 
effort. Whether TDM based on trough or AUC12 does lead to differences the occurrence 
of hazardous side effects in clinical in side effects warrants to be investigated more 
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thoroughly. The limited sampling models were developed using the most densely sampled 
AUC12 from the same dataset used for population pharmacokinetic model development. 
Therefore we recommend external validation to evaluate the limited sampling models.
Conclusion
A wide range of factors possibly contributing to variability of everolimus pharmacokinetics 
were investigated in this study. The population pharmacokinetics of everolimus in 
renal transplant patients is described by a two compartment pharmacokinetic model 
with lag-time. IBW significantly contributes to the pharmacokinetics of everolimus, 
by explaining variability in apparent volume of distribution. Polymorphisms in genes 
coding for ABCB1, CYP3A5, CYP2C8 and PXR with an allele frequency >6% do not 
clinically relevant influence everolimus pharmacokinetics and are therefore not suitable to 
improve prediction of everolimus exposure. However using the pharmacokinetic model 
and limited sampling model as presented here can be further tested in clinical practice to 
predict systemic exposure in an efficient and less invasive way for both patient and clinic. 
Everolimus Ctrough and C2 can be used to accurately estimate everolimus systemic exposure, 
an improvement compared to the widely used Ctrough monitoring.
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Abstract
The use of inhibitors of the mammalian target of rapamycin (mTORi) in renal 
transplantation is associated with many side effects, the potentially most severe being 
interstitial pneumonitis. Several papers have reported on sirolimus-induced pneumonitis, 
but less is published on everolimus-induced pneumonitis (EIP). Data on risk factors for 
contracting EIP are even more scarce. In the present casecohort study in renal transplant 
recipients (RTR), we aimed to assess the incidence and risk factors of EIP after renal 
transplantation. This study is a retrospective substudy of a multi-center randomized 
controlled trial. All patients included in the original trial and treated with prednisolone/
everolimus were included in this substudy. RTR who developed EIP, were identified as 
cases. RTR without pulmonary symptoms served as controls. Thirteen out of 102 patients 
(12.7%) developed EIP. We did not find any predisposing factors, especially no correlation 
with everolimus concentration. On pulmonary CT scan, EIP presented with an organizing 
pneumonia-like pattern, a non-specific interstitial pneumonitis-like pattern or both 
Median time (range) to the development of EIP after start of everolimus was 162 (38-407) 
days. In conclusion, EIP is common in RTR, presenting with an organizing pneumonia, a 
non-specific interstitial pneumonitis-like pattern or both. No predisposing factors could 
be identified.
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Introduction
Inhibitors of the mammalian target of rapamycin (mTORi), sirolimus and everolimus, 
are potent immunosuppressive drugs widely used after organ transplantation. They have 
been introduced in renal transplantation because of their supposed lack of nephrotoxicity 
and potential anti-oncogenic and anti-atherosclerotic effects [1-5]. Unfortunately, the 
use of mTORi is associated with many side effects like edema, impaired wound healing, 
mouth ulcers, anemia, proteinuria, development of lymphoceles, hyperlipidemia and 
hypertriglyceridemia [6]. Also interstitial pneumonitis may complicate treatment with 
an mTOR inhibitor. There are many reports of sirolimus-induced pneumonitis (SIP) 
[7]. Estimates of the incidence of SIP vary between 5 and 15% in solid organ transplant 
recipients. Clinical presentation ranges from asymptomatic to respiratory failure, 
but published reports suggest that SIP generally has a mild course and resolution of 
symptoms usually occurs after dose reduction or discontinuation of sirolimus. Far less 
is known on everolimus-induced pneumonitis (EIP), case reports of EIP do exist in solid 
organ transplantation and oncology, but systematic case-control studies have not been 
performed in renal transplant recipients (RTR).
The mechanism responsible for pulmonary toxicity by mTORi is not completely 
understood. Some suggest a dose-dependent risk [8-10], but there are also reports of cases 
with low mTORi trough levels [11,12]. Apart from the dose of mTORi, other possible 
risk factors have been identified in patients with non-small cell lung cancer, like smoking 
and pre-existing pulmonary disease [13]. Other studies found plasma creatinine and 
glomerular filtration rate (GFR) to be risk factors for development of EIP [14], indicating 
that the tolerance to mTORi may be altered in the presence of severe renal insufficiency. 
The presence of lymphocytes and eosinophils in broncho-alveolar lavage fluid suggests 
an immune mediated reaction [7,10,15]. It has been hypothesized that sirolimus binds 
to plasma proteins and that this complex is processed by antigen presenting cells in the 
lungs with consecutive T-cell recognition and recruitment of inflammatory cells like 
macrophages [7]. Others suggested that sirolimus exposes cryptic alveolar antigens 
evoking an ongoing cellular immune response [10]. Both mTOR inhibitors, despite 
inhibiting the adaptive immune response, enhance innate immunity [16,17], thereby 
possibly contributing to the development of pulmonary inflammation. Histopathological 
patterns include bronchiolitis obliterans organizing pneumonia, lymphocytic interstitial 
pneumonia, non-necrotizing granulomatous inflammation and vasculitis that support 
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the immune mediated hypothesis [7,8,10,18,19]. The mechanisms involved in EIP are 
speculative due to the lack of detailed studies. However, a recent study suggests a similar 
immunological mechanism for EIP [12], although there are also reports of resolution of 
SIP after conversion to everolimus [20-22]. In conclusion, ongoing exposure to mTORi 
may lead to a persistent inflammatory response in the lungs presenting clinically as 
pneumonitis. With the present case-cohort study we aimed to describe the incidence, 
clinical presentation, radiologic findings and predisposing factors of EIP in RTR.
Patients and Methods
Patients
This study was conducted as part of a larger prospective, multicenter randomized trial 
studying the effects of withdrawal of cyclosporin A (CsA) from an immunosuppressive 
regimen containing an IL-2 antagonist (basiliximab), CsA, prednisolone (P) and 
mycophenolate sodium (MPS) early after transplantation. Three university hospitals in 
the Netherlands participated in this trial from January 2005 until December 2009: the 
Academic Medical Center in Amsterdam (AMC), the Leiden University Medical Center 
(LUMC) and the University Medical Center in Groningen (UMCG). Institutional review 
board approval has been obtained. The study was conducted in accordance with the 2000 
Declaration of Helsinki and the Declaration of Istanbul 2008. Informed consent was 
obtained from every patient. The details and results of an interim analysis of this trial 
have previously been published (trial registration number: NTR567 (Dutch trial registry), 
ISRCTN69188731, www.trialregister.nl) [23]. 
In short, RTR, receiving their first or second renal transplant, were treated with quadruple 
immunosuppressive therapy consisting of P, CsA, MPS and basiliximab. After 6 months, 
RTR were (in the absence of rejection, proven by renal biopsy) randomized to one of 
three immunosuppressive regimens: P/CsA, P/MPS and P/everolimus. Drug exposure of 
CsA and everolimus was monitored by AUCs at fixed moments. The target value of the 
AUC for CsA was 5400 μg*h/L in the first 6 weeks and 3250 μg*h/L thereafter. The target 
AUC for everolimus was 150 μg*h/L for Fluorescence Polarization Immunoassay (FPIA) 
and 120 μg*h/L for Liquid Chromatography tandem Mass Spectrometry (LC-MS/MS), 
corresponding to the average 23% overestimation of FPIA [24]. The primary outcome 
was interstitial graft fibrosis and hyalinosis. Secondary outcome was, among others, 
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graft rejection. Patients who received a third or fourth transplant were excluded, as were 
patients with >50% panel reactive antibodies.
Case definition
For this retrospective sub-study, all RTR who were randomized to treatment with P/
everolimus and/or effectively switched to treatment with P/everolimus during the study 
were included. Pulmonary problems in patients using everolimus were detected by the trial 
reports of (serious) adverse events and review of the charts of all included patients. Charts 
were analyzed for clinical signs (for example dypnea, cough or fever) and radiological 
signs of pulmonary involvement (abnormal chest X-ray and pulmonary CT scans). RTR, 
who developed symptoms of an EIP, were identified as cases. We used the following 
criteria for EIP [10]: (1) exposure to everolimus before the onset of pulmonary symptoms, 
(2) exclusion of other pulmonary disease, especially infection, (3) radiographic findings 
on CT of the chest not compatible with other diagnoses and (4) resolution of pulmonary 
symptoms after discontinuation of everolimus. When available, histopathological 
diagnosis consistent with drug-induced lung-toxicity was considered gold standard.
RTR who were treated with P/everolimus, but did not develop pulmonary symptoms, served 
as control patients. Patients in whom everolimus was discontinued because of pulmonary 
symptoms, but in whom no CT imaging was performed were excluded from the analysis. 
These patients were classified as possible EIP. The following data were retrospectively 
collected from medical records: sex, age, race, original renal disease, organ origin (living 
related or deceased), data on rejection episodes and CMV infection, analysis of BAL fluid, 
dialysis mode, history of pulmonary disease, smoking, everolimus AUCs and trough 
levels. Chest X-rays and (HR)CT of the chest from possible cases were re-analyzed by two 
independent reviewers (radiologist (IB) and pulmonologist (RJ)), who were blinded to the 
clinical information of patients. New abnormalities (compared to a pre-transplantation 
chest X-ray) were scored. Pulmonary function tests (when performed) were also recorded. 
The course of the EIP was analyzed and time to clinical recovery was noted.
Radiologic classification
Imaging findings on chest CT scan were classified into three distinct patterns (a simplified 
version of the approach by Endo et al. [25]): 1) multifocal areas of airspace consolidation 
with a predominantly peribronchial and/or sub-pleural distribution and bronchial wall 
thickening, compatible with OP, 2) extensive bilateral ground-glass attenuation or airspace 
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consolidation with traction bronchiectasis, compatible with a NSIP, or 3) a combination 
of OP and NSIP.
Measurements
Plasma creatinine was measured with an enzymatic PAP+ (phenol /4-aminoantipyrine) 
assay on a Roche Modular analyser (Roche, Almere, the Netherlands). Estimated GFR 
was calculated using the abbreviated MDRD formula: GFR = 175 x (Pcr ÷ 88.4)-1.154 
x age-0.203 (female: multiply result by 0.742, black: multiply result by 1.210). Cytology, 
Ziehl-Neelsen staining, bacterial, viral and fungal cultures were routinely performed on 
all BAL fluid specimens. AUCs0-12h for everolimus were calculated from blood samples 
drawn at T=0, 1, 2, 3, 4, 5 and 6 hours after administration. The everolimus AUCs0-12h 
consisted of full AUCs (seven or six time points) and sparsely sampled AUCs (four time 
points), calculated using linear trapezoidal rule. Everolimus levels were determined 
by immunoassay (Innofluor® Certican® Assay System) according to manufacturers’ 
instructions (Seradyn Inc, IN, USA) or by a validated LC-MS/MS method [24]. Since 
there is an average overestimation of 23 % by FPIA [24], the average AUC0-12h measured 
with LC-MS/MS was corrected by this 23 % to eliminate the differences between both 
methods. Pulmonary function (VC and DCLO) was measured using standard testing 
procedures.
Statistical analysis
All statistical analyses were performed using SPSS statistical software, version 16.0 (SPSS 
Inc., Chicago, Illinois, USA). Univariate analysis was performed to identify risk factors 
associated with EIP. Associations of discrete variables with EIP are expressed in terms 
of exact odds-ratios with their 95% confidence interval and analyzed with a chi-square 
test. Associations of continuous variables were analyzed with a Mann-Whitney U test. A 
p-value < 0.05 was considered statistically significant. Areas under the curve (AUCs0-12h) 
were calculated using the linear trapezoidal rule with everolimus trough concentrations 
used as 12-hour values. AUCs were grouped into three different time periods (range): 1 
month (0.2-3.5), six months (4.0-8.1) and 12 (9.4-14.5) months after start of everolimus. 
If one patient had multiple AUC measurements within one time period, the average AUC 
was calculated and used in the analysis.
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Results
Figure 1: Kaplan Meyer curve demonstrating the time to development of everolimus induced inter stitial 
pneumonitis (EIP) in 13/102 (12.7%) renal transplant recipients treated with everolimus.
Presentation of EIP
102 RTR were treated with prednisolone (P) and everolimus during the study period. At 6 
months, 96 patients were randomized to P/everolimus [Bemelman et al, Transplantation 
2009]. Six additional patients who switched to P/everolimus for various reasons outside 
the study protocol, were also included in this case-cohort study. We identified 13 cases, 
corresponding with an incidence of 12.7% (i.e. 13/102). Seven cases were classified as ‘possible 
cases’ and were excluded from the definite analysis. A detailed description of these patients 
can be found as supplementary data (supplementary table S1). Eighty-two RTR who did not 
develop pulmonary symptoms, served as control patients. Table 1 shows the demographic 
data of cases and control patients. The characteristics of the 13 patients who developed an 
EIP are listed in table 2. The median (range) time on everolimus of all patients was 752 
(32-1502) days. In the cases, the median time (range) on P/everolimus until confirmation 
of EIP by computed tomography (CT) was 162 (38-407) days. Beyond 407 days, no more 
EIP occurred (figure 1). The most common presenting symptoms were dyspnea and cough 
(10/13 cases). Fever was present in 8/13 cases. One patient was asymptomatic, however 
2-deoxy-2-(18F) fluoro-D-glucose (FDG) positive pulmonary infiltrates were discovered 
on a PET scan performed because of multiple unexplained bone fractures. A consecutive 
HRCT scan showed an image compatible with drug induced pneumonitis.
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Odds ratio (CI) P-value
Male gender n (%) 9 (69.2) 50 (61.0) 0.694 (0.20-2.45) 0.57
Recipient age, median 
(range) 
50.0 (32-71) 53.5 (22-70) - 0.37
Caucasian n (%) 11 (84.6) 70 (85.4) 1.061 (0.21-5.39) 0.94
Underlying renal disease 0.25
 vascular 3 (23.1%) 15 (18.3%) 1.00
 immunological 4 (30.8%) 22 (26.8%) 0.91 (0.2-4.7)
 urological - 10 (12.2%) 0.00
 other 3 (23.1%) 28 (34.1%) 0.54 (0.1-3.0)
 eci 3 (23.1%) 7 (8.5%) 2.14 (0.3-13.4)
Renal transplant type 
(living) n (%)
6 (46.2) 43 (52.4) 1.286 (0.40-4.16) 0.67
Smoking 0.52
 yes 1 (7.7) 17 (22.1) 0.2 (0.04-2.6)
 stopped prior to Tx 4 (30.8) 19 (24.7) 1.1 (1.3-4.0)
 no 8 (61.5) 41 (53.2) 1.0 
Pulmonary history n (%) 4 (30.8) 14 (17.1) 0.463 (0.13-1.72) 0.25
Rejection episode n (%) 1 (7.7) 16 (19.5) 2.909 (0.35-24.04) 0.32
Time on RRT (months) 48.1 (0-277) 28.8 (0-344) - 0.23
Dialysis mode n (%) 0.34
 pre-emptive 1 (7.7) 13 (15.9) 1.0
 HD 7 (53.8) 23 (28.0) 4.0 (0.4-35.8)
 PD 3 (23.1) 31 (37.8) 1.3 (0.1-13.2)
 HD & PD 2 (15.4) 15 (18.3) 1.7 (0.1-21.4)
GFR* (ml/min) 
 6 months after Tx 59.1 (30.8-87.8) 52.4 (17.4-110.2) - 0.10
 9 months after Tx 54.5 (35.8-79.5) 52.8 (20.6-102.8) - 0.53
 12 months after Tx 50.4 (35.5-75.4) 51.2 (11.7-96.8) - 0.65
 18 months after Tx 54.2 (37.0-93.3) 50.1 (14.3-101.6) - 0.84
 24 months after Tx 58.8 (22.6-97.8) 47.0 (10.1-104.6) - 0.45
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Time on EVL (days) 157.5 (32-485) 864.5 (69-1502) - <0.001
AUC EVL 1 month  
after start (μg*h/L)
173 (65-447) 169.5 (77-439) - 0.972
AUC EVL 6 months  
after start (μg*h/L)
172 (164-238) 171 (98-356) - 0.403
AUC EVL 12 months after 
start (μg*h/L)
237 169 (89-261) - NA
Trough level EVL 1 month 
after start (μg/L)
9.2 (3.8-25.4) 9.1 (4.0-28.1) - 0.982
Trough level EVL 6 months 
after start (μg/L) 
10.8 (8.0-14.0) 9.4 (2.9-22.0) - 0.438
Trough level EVL 12 months 
after start (μg/L)












AUC, Area Under the Curve; CI, confidence interval; CMV, cytomegalovirus; EVL, everolimus; HD, 
haemodialysis; NA, not available; PD, peritoneal dialysis; RRT, renal replacement therapy; Tx, transplantation. 
*GFR estimated by the abbreviated MDRD. Associations of discrete variables with everolimus-associated 
pneumonitis are expressed in terms of exact odds-ratios with their 95% confidence interval and analyzed with a 
chi-square test. Associations of continuous variables are analyzed with Mann-Whitney U test.
 
In all identified cases, the pulmonary CT scan revealed consolidations matching an 
organizing pneumonia (OP), a non-specific interstitial pneumonitis (NSIP)-like pattern 
or a combination of the two (figure 2). In one patient, no CT scan could be retrieved, 
but EIP was confirmed with pulmonary biopsy. Eight cases underwent a bronchoalveolar 
lavage (BAL). No pathogenic micro-organisms could be detected. In all cases everolimus 
was discontinued. In 6/13 cases everolimus was only discontinued when antibiotic 
therapy did not result in improvement. The absence of any microorganisms in the 
BAL fluid and the failure of empirical antibiotic treatment ruled out infection in these 
patients. Corticosteroids were administered in three cases. Pulmonary function tests 
were performed just after the onset of symptoms in 6/13 cases, showing normal to mildly 
lowered VC 90.2% (range 68-112), normal Forced Expiratory Volume in 1 second (FEV1) 
84.8% (70-100) with a decreased single-breath diffusion capacity for carbon monoxide 
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AB, antibiotics; OP, organizing pneumonia; CT, computed tomography; EVL, everolimus; NA, not available; 
NSIP, non-specific interstitial pneumonia; VATS, video assisted thoracoscopy; BAL, Bronco-alveolar lavage.
4 First AB (ceftriaxone) was given, which did not improve the pulmonary symptoms. Hereafter ceftriaxone was 
stopped and everolimus was discontinued.
9 First AB (amoxicilline/clavulanic acid) was given which did not improve the pulmonary symptoms and AB 
was discontinued. After histopathologic prove of organizing pneumonia, everolimus was discontinued and 60 
mg prednisolone was started.
10 Everolimus was discontinued and AB (ciprofloxacine and co-trimoxazole) together with 40 mg prednisolone 
were given. Sputum cultures revealed no bacteria, some candida species. After one day oseltamivir was added 
and three days later voriconazol. 
11 First AB (doxycycline) was given which did not improve the pulmonary symptoms and AB was discontinued. 
Then everolimus was discontinued, 30 mg of prednisolone was administered and pulmonary symptoms resolved.
12 AB (cefuroxime) was given due to 10-100 colonies of Escherichia coli in sputum, because of lack of improvement, 
everolimus was discontinued and pulmonary symptoms resolved.
13 One month before pulmonary CT, patient was admitted with suspected pneumonia. AB were given. BAL 
cultures remained negative, everolimus was discontinued. Because of continuing pulmonary symptoms, patient 
was readmitted one month later (while on prednisolone and tacrolimus). CT revealed OP and pulmonary 
embolism, anticoagulation was started. 
 
Figure 2: (a) Organizing pneumonia: sharply demarcated consolidation, with a peribronchial and subpleural 
localization in the right-sided dorsal pleural sinus. Both lungs reveal a mosaic pattern. (b) Nonspecific 
interstitial pneumonitis: subpleural and peribronchovascular ground-glass opacities (white arrow head). 
Bronchodilation (black arrow) and thickened interlobular septa (black arrow head) within these ground-glass 




All patients had a full clinical recovery within one year. In nine cases this was a subjective 
recovery because of the absence of follow-up with CT-scan or pulmonary function tests. 
Only in one case pulmonary function tests were performed after discontinuation of 
everolimus, showing an improvement of pulmonary function (data not shown). In three 
cases follow-up CT-scans were made after the diagnosis of EIP, which showed complete 
resolution of pulmonary abnormalities compatible with pneumonitis seen on earlier CT-
scans. None of the patients were re-challenged with everolimus. 
Follow-up data on renal outcome were available for 12/13 patients. Of those 12 patients, 
7/12 switched to P/CsA, 2/12 switched to P/tacrolimus, 2/12 switched to P/CsA/MPS 
(of those one continued later on P/MPS) and 1/12 switched to P/MPS. None of these 
patients developed a rejection after conversion. The median time from the switch from 
everolimus to another immunosuppressive regimen and last follow-up was 658 (0 – 1217) 
days. In that period, eGFR declined with a median (range) of 4.5 (-14.1 to 24.2) ml/min, 
corresponding with a median decline of 2.8 (range -5.1 to 18.3) ml/year. Kidney function 
in the patients on everolimus who did not develop an EIP, remained stable after switch 
from P/CsA/MMF at 6 months until 2 years after transplantation (median (range) GFR 
change + 1.3 ( – 24.2 to 13.4) ml/min/year).
Risk analysis for EIP development
We could not identify any predisposing factors to EIP, for example a known prior 
pulmonary history or smoking, nor was there a difference in renal function between cases 
and controls. Exposition to everolimus, expressed as Area Under the Curve (AUC) or 
trough levels, was similar in cases and control patients (table 1). According to the study 
protocol, everolimus exposure was monitored by AUCs one month, six months, 12 months 
and 18 months after the initiation of everolimus. Additional everolimus AUC or trough 
level measurements were only performed when asked for by the treating nephrologist. In 
cases, median time between confirmation of EIP by CT scan and most recent AUC was 69 
(6-318) days. In case of patient compliance the AUC is expected to be stable. The (median) 
AUC of everolimus was 207 (108 -266) μg*h/L, corresponding with trough levels of 10.7 
(6.6 -15.2) μg/L. During follow-up, 68.4% and 50% of the AUCs measured in the cases 
were > 150 and > 200 μg*h/L, respectively, versus 69.0% and 32.2% in the control patients 
(NS). 73.7% and 38.9% of the trough levels measured in cases versus 69.4% and 23.1% in 
control patients, respectively, were > 8 and > 12 μg/L.
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Figure 3: Algorithm for the diagnosis everolimus-induced pneumonitis in patients using everolimus. OP, 
organizing pneumonia; NSIP, nonspecific interstitial pneumonitis; BAL, broncho-alveolar lavage; PFT, 
pulmonary function test; EIP, everolimus-induced pneumonitis; EVL, everolimus; HRCT, high resolution CT. a 
If abnormal in previous test.
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Discussion
Our study is the largest case series of everolimus induced pulmonary disease in solid organ 
transplantation. Pneumonitis appears a common adverse event complicating the use of 
everolimus after renal transplantation, with an incidence of 12.7%. No clear predisposing 
factors are identified in our case-cohort study. Pulmonary CT scans reveal an OP or NSIP-
like pattern. The course seems benign with disappearance of symptoms within one year 
after discontinuation of the drug. The incidence of EIP (12.7%) reported in our study is 
higher than previously reported in RTR on mTORi, varying between 4 and 6.8% [26-
28]. The true incidence of EIP in our cohort might even be higher because possible cases 
in which pulmonary imaging with CT scan was lacking, were excluded from analysis 
(table A, supplementary data). Furthermore, the reported incidence in our study is an 
underestimation of the true incidence of EIP, since EIP can be present on pulmonary CT 
scan without causing symptoms as demonstrated by White et al, who routinely performed 
pulmonary CT scans in patients with advanced non-small cell lung cancer treated with 
everolimus [13]. We identified one asymptomatic case in our cohort. 
In patients treated with everolimus for renal cell carcinoma the incidence of EIP has been 
reported to be around 25% [13,29,30]. This high incidence of EIP has been attributed to 
higher dosage of everolimus in these patients in combination with a higher detection level 
of EIP due to routinely performed pulmonary CT scans. In our study, drug exposure was 
relatively high with an AUC around 170 μg*h/L and trough levels around 10 μg/ml since 
everolimus was prescribed as part of a double immunosuppressive regimen. However, 
everolimus exposure was not higher in the cases compared to controls. Remarkably, all 
patients developed EIP within 407 days; hereafter no EIP occurred. When reviewing the 
literature, we found only two cases of EIP occurring beyond 407 days’. Much debate exists 
on the etiology of mTOR-induced pneumonitis. White et al. [13] showed that patients 
with interstitial lung disease on baseline CT scans, whether focal or diffuse, had a higher 
incidence of all types of pneumonitis. This may reflect the tendency of patients with 
underlying lung disease to develop more serious toxicity. Therefore, we hypothesized that 
previous pulmonary disorders (reported in the medical charts) could be a predisposing 
factor to the development of EIP in our patient cohort. The incidence of an underlying 
pulmonary disease was 30.8 and 17.1% in cases and controls, respectively. This difference 
was not significant (p=0.25), nor was the difference in smoking. Furthermore, we found no 
difference in GFR which has also been suggested as a potential risk factor [14]. Therapeutic 
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drug monitoring (TDM) of everolimus is essential due to the narrow therapeutic window 
in combination with highly variable pharmacokinetics. Moreover, direct toxicity of 
everolimus in the etiology of EIP is suggested [8]. Since systematic everolimus AUCs and 
trough levels were determined in our study, we were able to accurately assess the exposure 
to everolimus in the cases and controls. Comparable exposure to everolimus in cases and 
controls makes toxicity simply based on higher exposure unlikely. We were not able to 
confirm the immune mediated hypothesis, due to lack of flowcytometric analysis of BAL 
fluid.
Our study confirms the previous findings of EIP presenting radiographically with an OP-
like pattern, NSIP-like pattern, or a combination of both, making CT imaging a valuable 
tool to discriminate infection from a direct everolimus effect. Limitations of this study are 
its retrospective design and the lack of a standardized follow-up of the patients. Although 
this is a large cohort of patients and we found an incidence of EIP of 12.7%, the absolute 
number of cases is still limited, which might have masked significant risk factors. Another 
limitation is that in some patients a BAL to rule out pathogenic micro-organisms, was not 
performed and that previous use of antibiotics could have masked underlying infection 
in those patients who underwent a BAL. However, antibiotic treatment did not result in 
clinical improvement and recovery only occurred when treatment with everolimus was 
stopped. Three patients received additional corticosteroids. The effect of corticosteroids, 
administered at the same time as withdrawal of everolimus, on the disappearance of 
symptoms is unclear. Some found that inhibition of mTOR blocks the anti-inflammatory 
effects of glucocorticoids in myeloid immune cells [31], suggesting that corticosteroids 
might not be beneficial in mTOR-induced pneumonitis. All patients subjectively recovered 
within one year. The long-term outcome after EIP is unclear since NSIP is known to 
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Conclusion
EIP is a common side-effect of everolimus in RTR presenting radiographically with 
consolidations matching an organizing pneumonia, a non-specific interstitial pneumonitis 
like pattern or a combination of both. No clear predisposing factors could be identified. 
Since the presentation of EIP can be insidious or even asymptomatic, we recommend to 
perform radiographic imaging of the lungs when patients present with dyspnea, cough 
or fever while on treatment with this drug according to the algorithm shown in figure 3. 
Moreover, since we did not find a correlation with exposure to everolimus between cases 
and controls, we advise to halt everolimus instead of reducing the dosage following EIP.
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Abstract
The mTOR inhibitor everolimus is an emergent non-nephrotoxic alternative for calcineurin 
inhibitors (CNIs) with substantial potential non-renal benefits in renal transplantation 
which slowly finds its way into new immunosuppressive regimens. Despite its proven 
efficacy and close therapeutic drug monitoring everolimus is also known for relative 
high discontinuation rates and some serious side effects. The aim of this study was to 
find risk factors for discontinuation and serious side effect to further optimize everolimus 
immunosuppressive therapy and to improve patient outcome. An extensive dataset 
consisting out of demographic, transplant related and pharmacogenetic data of 99 stable 
adult renal transplant recipients was used for a systematic analysis using a parametric 
survival model to describe the time to discontinuation and the most hazardous side 
effects including pneumonitis, (opportunistic) infection and new onset diabetes mellitus 
by means of nonlinear mixed-effects modelling. The baseline hazard of discontinuation, 
pneumonitis and infection data was best described by a Gompertz function and an 
exponential hazard function was used to the baseline hazard new onset diabetes mellitus. 
Risk factors for everolimus discontinuation of renal transplant recipients on a regimen of 
everolimus and prednisone duo therapy were constant too high everolimus (> 120 µg*h/L) 
exposure and increasing age. Furthermore, risk factors for the hazardous side-effect non-
infectious interstitial pneumonitis were constant too high everolimus exposure and PXR 
(NR1|2)( -24113G>A): AA genotype. For infection and new onset diabetes mellitus no 
significant covariates could be detected. The current findings indicate that discontinuation 
rates and non-infectious pneumonitis in renal transplant recipients on everolimus can 
be prevented by avoiding excess initial and/or prolonged excess maintenance everolimus 
exposure.
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Introduction
Improving long term survival remains currently the key challenge in renal transplantation. 
Although calcineurin inhibitors (CNIs) have lowered the incidence of acute rejection 
dramatically, especially in the higher dosing ranges and vulnerable kidney grafts they are 
associated with allograft nephropathy and calcineurin toxicity [1,2]. The mTOR inhibitor 
everolimus is an emerging in essence non-nephrotoxic alternative for either mycophenolate 
or CNIs in renal transplantation which slowly finds its way into new immunosuppressive 
regimens. Everolimus is registered for maintenance immunosuppressive combination 
therapy with CNIs. Due to CNI-related nephrotoxicity and possible synergism between 
mTOR inhibitors and CNIs, CNI-minimizing and CNI free strategies combined with 
mTOR inhibitors are being actively investigated worldwide [3–7]. The narrow therapeutic 
window and high variable pharmacokinetics of everolimus, makes therapeutic drug 
monitoring (TDM) essential for prevention of toxicity or rejection [8]. Despite its proven 
efficacy and close TDM, everolimus is also known for high discontinuation rates and some 
serious side effects. Discontinuation is often directly side effect related [9,10]. Leukopenia, 
thrombocytopenia, hypertriglyceridemia and hypercholesterolemia are the most common 
side effects of mTOR inhibitors [5] and can often be managed with counteracting medication 
and/or dose reduction [9,11]. A potentially life threatening side effect of everolimus is 
non-infectious interstitial pneumonitis. This pneumonitis is characterized by the non-
infectious, non-malignant infiltration of the lungs that presents as ground-glass opacities 
and focal consolidations on CT-scan [12]. It typically presents itself within 2 to 6 months 
after initiation of mTOR inhibitor therapy [13]. The exact mechanism of mTOR inhibitor-
induced pneumonitis is still unknown. Direct damage to alveolar structures, formation of 
immunogenic molecules that react with specific antibodies, and direct immunologic drug 
responses have been suggested as possible mechanisms [14]. A dose relationship may be 
present and a higher incidence was found in males versus females on sirolimus therapy 
[15]. Infectious diseases are an important cause of death in transplant recipients [16,17] 
and strongly related to excessive and/or long-term clinical immunosuppression [18]. 
Everolimus is associated with a relatively low incidence of viral infections as compared 
to other immunosuppressive groups [19–21]. Everolimus is also associated with a higher 
incidence of new onset diabetes mellitus (NODM) which subsequently is associated with 
increased graft failure and mortality due to cardiovascular events [22]. Patients with diabetes 
mellitus or NODM have lower long term survival compared with non-diabetic patients [23]. 
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NODM is therefore a serious complication of immunosuppressive therapy in transplant 
recipients. It occurs in around 4-5 % of renal transplant patients treated with everolimus 
and low dose cyclosporine [24,25]. In a non-CNI based regimen study it was 1% [26]. 
Tacrolimus based regimens are currently associated with the highest incidence of NODM 
[17,27]. Finding risk factors for discontinuation and the most severe side effects could help 
improve immunosuppressive therapy with mTOR inhibitors by monitoring them more 
closely or excluding patients with excessive risk from everolimus therapy. The cytochrome 
P450 (CYP) enzymes CYP3A4, CYP3A5 and CYP2C8 are involved in the metabolism of 
everolimus and everolimus is also a substrate for the efflux pump P-glycoprotein (ABCB1) 
[28,29]. The nuclear pregnane X receptor (PXR) mediates expression of CYP3A4 and 
multi drug resistance proteins (MDR1 and MDR2) and could therefore also influence 
everolimus pharmacokinetics [30–32]. Although polymorphisms in genes coding for these 
metabolizing enzymes do not seem to affect pharmacokinetics [33,34], tissue and immune 
cell concentrations and metabolite patterns might be affected resulting in differences in 
susceptibility for certain side effects. In the present study we performed a systematic analysis 
using a parametric survival model to describe the time to everolimus discontinuation and 
the most hazardous side effects data in renal transplant recipients by to explore potential risk 
factors for everolimus discontinuation and the most common and severe side effects. Such 
an approach has advantages compared to non-parametric and semi parametric analyses, 
because it enables inclusion of time-varying covariates and allows simulation based on the 
final model. A wide range of demographic, transplantation related, drug exposure as well as 
pharmacogenetic parameters were available for the analysis. The primary aim of this study 
was to develop time-to-event models for the time to drug discontinuation and the key side 
effect (i.e pneumonitis, infection and new onset diabetes mellitus) to identify risk factors 
that may determine therapy outcome.
Methods
Patients 
Clinical data from 99 stable renal transplant recipients treated with immunosuppressive 
dual therapy consisting of everolimus (Certican®, Novartis, Basel, Switzerland) and 
prednisolone, who participated in a prospective, open, randomized, multicenter study 
were studied from 6 to 24 months after transplantation. During the first 6 months 
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after transplantation, patients received induction therapy with basiliximab (20 mg days 
0 and 4; Simulect Novartis, Basel, Switzerland), prednisolone dose (50 mg twice daily 
intravenously), rapidly tapered to daily 10 mg oral at day 4. Additional maintenance 
immunosuppressive therapy consisted of cyclosporine, prednisolone and mycophenolate 
mofetil. At 6 months after transplantation a scheduled biopsy was performed. Patients 
without inflammation were included and randomized in three groups [4] and cyclosporine 
and mycophenolate mofetil were subsequently discontinued [4]. From this point onwards 
data of the everolimus group were collected for the present study. The study was approved 
by the Medical Ethics Committee of Leiden University Medical Center (Leiden, the 
Netherlands) and patients gave written informed consent.
Bioanalytics 
Everolimus therapy was started at an oral dose of 3 mg twice daily and was supported by 
routine TDM. TDM was aimed at a target AUC0-12h of 120 µ*h/L for LC-MS/MS and 150 
µg*h/L for FPIA. During the trial AUC0-12h were calculated using the trapezoidal rule using 
blood concentrations drawn at t = 0, 1, 2, 3, 4, 5, and 6 h after transplantation using the 
KinFit tool of MW/Pharm 3.5 (Mediware, Groningen, The Netherlands). Determined in 
whole blood by a validated liquid chromatography tandem mass spectrometric (LC-MS/
MS) and previously published method [35,36] or fluorescent polarization assay FPIA [37] in 
three laboratories. Individual pharmacokinetic data for the current study such as AUC, Cmax 
and Cmin were derived using the previously published population pharmacokinetic model 
by Moes et al. [34] which accounts for the differences between the analytical methods and 
inter-occasion variability. For patients (n=3) without blood samples, the population mode 
prediction based on dose and demographic properties was used to estimate exposure.
Genotyping Assays
DNA was isolated from EDTA blood collected from patients. ABCB1-1236C>T, ABCB1-
3435C>T, ABCB1-2677T>G and CYP3A4-15389C>T were determined with TaqMan 
7500 (Applied Biosystems, Nieuwerkerk a.d. IJssel, the Netherlands) with predesigned or 
custom designed assays, according to manufacturers’ protocol. ABCB1-129T>C, CYP3A5-
6986A>G, CYP3A5-7225G>A, PXR-G-24113A and PXR-A+ 7635G were determined with 
Pyrosequencer 96MA (Isogen, IJsselstein, the Netherlands). Polymerase chain reactions 
(PCRs) contained 10 ng of DNA and 5 pmol of each PCR primer in a total volume of 12mL. 
Cycle conditions were initial denaturation for 15 minutes at 95°C, 35 cycles of 95°C, 55°C 
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and 72°C each for 30 seconds, ended by 10 minutes at 72°C. The pyrosequence reactions 
were performed according to manufacturers’ protocol. Primers and probes used in the 
TaqMan based genotyping assays and primers and sequences used in the pyrosequence 
assays for each single-nucleotide polymorphism (SNP) are listed Supplementary Table I. 
The nucleotides shown in lower case are negative controls, which were not incorporated 
in the target DNA and consequently did not appear in the pyrogram. As quality control, 
5% of samples were genotyped in duplicate. In addition, negative controls (water) were 
used. No inconsistencies were observed. All allele frequencies were in Hardy-Weinberg 
equilibrium. Haplotype analysis for ABCB1 was performed using gPLINK with haplotypes 
set with a certainty greater than 0.97. To investigate the combined effect of CYP3A5*3 
and CYP3A4*22, genotype clusters were made as follows: Slow metabolizers (C1): No 
CYP3A5 activity (CYP3A5*3/*3) and at least one decreased activity allele in CYP3A4 
(CYP3A4*22/*22 or CYP3A4*1/*22), Intermediate metabolizers group 1 (C2): No CYP3A5 
activity (CYP3A5*3/*3) and no decreased activity allele in CYP3A4 (CYP3A4*1/*1), 
Intermediate metabolizers group 2 (C3): Carriers of at least one increased activity allele 
in CYP3A5 (CYP3A5*1/*1 or CYP3A5*1/*3) and at least one decreased activity allele in 
CYP3A4 (CYP3A4*22/*22 or CYP3A4*1/*22) and extensive metabolizers (C4): Carriers 
of at least one increased activity allele in CYP3A5 (CYP3A5*1/*1 or CYP3A5*1/*3) and no 
decreased activity allele in CYP3A4 (CYP3A4*1/*1).
Discontinuation
Discontinuation was recorded on the exact date therefore the exact time to discontinuation 
could be calculated. Patients who did not discontinue therapy were censored at study end 
(550 days).
Side effects
For side effects the exact date of the start of symptoms were recorded, as well as the date 
that symptoms disappeared. For the analysis the date of the start was used to calculate the 
time to side effect. Patients who did not have a side effect during everolimus therapy were 
censored at discontinuation or at study end (550 days).
Non-infectious Interstitial Pneumonitis
Pulmonary problems in patients using everolimus were detected by the trial reports of 
serious adverse events and adverse events and review of the patient charts of all included 
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patients [38]. Charts were analyzed for clinical signs (for example dyspnea, cough or fever) 
and radiological signs of pulmonary involvement (abnormal chest X-ray and pulmonary 
CT scans). Patients, who developed symptoms of a non-infectious pneumonitis, were 
identified as cases. For the time to pneumonitis the date of the first symptoms were marked 
as the start date. The following criteria for pneumonitis were used [39]: (1) exposure to 
everolimus before the onset of pulmonary symptoms, (2) exclusion of other pulmonary 
disease, especially infection, (3) radiographic findings on CT of the chest not compatible 
with other diagnoses and (4) resolution of pulmonary symptoms after discontinuation 
of everolimus. Whenever available, a histopathological diagnosis consistent with drug-
induced lung-toxicity was considered gold standard [38]. Patients classified with non-
infectious pneumonitis were identified as cases. For the time-to-pneumonitis the date of 
the first symptoms were marked as the start date. Any infection (viral, fungal or bacterial) 
reported as (serious) adverse event requiring treatment was used for the time-event-
analysis to identify risk factors for infection. New onset diabetes mellitus was diagnosed 
according to world health organization the (WHO) guidelines: – fasting plasma glucose ≥ 
7.0 mmol/l (126 mg/dl) or 2–h plasma glucose ≥ 11.1 mmol/l (200 mg/dl) after everolimus 
initiation with the oral glucose tolerance test (OGTT) as the diagnostic test.
Model Development 
The development of the different time-to-event models was a two steps approach: first a 
base model without any explanatory factors was constructed; thereafter the base model 
was used to explore potential covariates. In order to describe the time-to-first event a 
parametric survival function was used as presented below:
The hazard is h(t), and the ‘survival’ S(t) is a function of the cumulative hazard within the 
time interval between start of the study (time zero) and the time t of the event describing 
the probability of not experiencing an event within this interval. Since time to first event 
only happens once per individual, random effect of the baseline hazard could not be 
estimated, therefor the same baseline hazard was assumed for all subjects. The base models 
were developed by exploring different function for the hazard h(t): Weibull, exponential, 
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Development of covariate model
Of the available potential covariates different covariates were selected for each endpoint 
based on theoretical probability. The selected covariates for each endpoint are reported in 
the results. All preselected covariates were included in the stepwise covariate modelling 
(SCM). Relationships of the selected continuous covariates were also explored using 
KMMC plots [41]. Available covariates were:
 
Continuous: Age, Weight, AUC, Cmin, Cmax, AUCmin, Leukocytes, Thrombocytes, Choles-
terol, Triglycerides. AUCmin is the minimal everolimus exposure during the trial of each 
individual. If this value was above the preset target value exposure has been too high 
during the entire study. 
 
Dichotomous: Race (Caucasian vs non Caucasian); diabetes mellitus at start (yes vs no); 
Sex (male vs female); donor Type (deceased vs living); mean daily cyclosporine AUC until 
week 6 after transplantation (above target vs on/below target); mean daily cyclosporine 
AUC from week 6 until conversion to everolimus (above target vs on/below target). 
CYP3ACOMBINED (C1 vs C2,C3 and C4); PXR (NR1|2) -24113G>A (AA vs AG and 
GG); PXR (NR1|2) 7635A>G (GG vs AG and AA); ABCB1 3435C>T (CC vs TC and TT); 
ABCB1 1236C>T (TT vs CT and CC); ABCB1 2677T>G (GG vs GT and TT); ABCB1 
-129T>C (TT vs TC); ABCB1 haplo CCG (2 copies vs 0 or 1 copy); ABCB1 haplo TTT (2 
copies vs 0 or 1 copy); ABCB1 haplo TCG (2 copies vs 0 or 1 copy)
The hazard (h), including covariates was modeled over time (t) as: 
where h0(t) is the base hazard without covariates included. βi is the coefficient describing 
the effect of covariate Xi. The covariate coefficient (βi) was modeled for dichotomous 
covariates as βi·Xi and for continuous covariates as a change from the median covariate: 
βi·(Xi-Xi median). 
 
Dichotomous covariates were coded as 0, where for the most frequent category, otherwise 
1, so that the covariate parameter is estimated for the less frequent category. All continuous 
covariates were tested for both linear and bi-linear relationship. All preselected covariate 
relationships were used for a systematic stepwise covariate modelling (SCM), with 
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stepwise forward inclusion and backward deletion [42]. Forward inclusion and backward 
deletion the level of statistical significance was set to P < 0.05 and P < 0.01, respectively, 
corresponding to differences in the NONMEM objective function value (OFV) of 3.84 
and 6.64, respectively (1 degree of freedom). 
Software: NONMEM (v7.3.0, Icon Development Solutions, Ellicott City, MD) was used 
for modeling, using PsN toolkit 3.4.2 [44]and Pirana version 2.8.0 [45] as modeling 
environment. Results were analyzed using statistical software package R (v2.15.2) and 
RStudio (v0.97.248; Boston, MA). 
Model evaluation: Selection between hierarchical models was based on the likelihood ratio 
test using OFV. The OFV is proportional to -2 log likelihood and the difference in OFV 
for the two hierarchical models is approximately χ2 distributed. Models were also selected 
based on scientific plausibility and precision in parameter estimates. In addition, the TTE 
models were evaluated by means of visual predictive check (VPC), which is the Kaplan-
Meier (KM) curve of the observed data together with a 95% prediction interval based on 
data simulated from the TTE model (200 replicates). 
Results
Clinical details
A total of 99 adult stable renal transplant recipients were included in this study with 
patients followed up to 18 months after conversion to everolimus and prednisolone dual 
therapy. Mean age was 52 ±13 years (range: 22-71 years). Mean weight was 79 ±15 kg 
(range: 50 -129 kg). Rejection rate after conversion was very low (3%), however finally 
only 58 patients remained on therapy the entire study due to discontinuation, which 
was primarily caused by side effects. The majority of the patients (85%) were Caucasian. 
Further demographic, transplant related and exposure details and as well as efficacy and 
safety response data, are summarized in Table 1. 
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Table 1: Demographic and transplantation characteristics





Age (years) 52 (13) 54 (22-71)
Weight (kg) 79 (15) 78 (50 -129)
Ideal Body Weight (kg) 67 (8) 67 (49-83)
Height (cm) 174 (10) 174 (152 -194)
Creatinine (µmol/L) 118 (34) 113 (61 - 251)
Diabetes Mellitus at start 11 (11)
Hematocrit (L/L) 0.38 (0.04) 0.37 (0.29-0.5)
Underlying disease (%):
 polycystic kidney disease 23 (23.2)
 glomerulonephritis 17 (17.2)
 diabetic nephropathy 4 (4.0)
 hypertension 15 (15.2)
 focal glomerulosclerosis  4 (4.0)
 etiology uncertain (e.c.i.) 5 (5.1)
 interstitial disease 3 (3.0)
 urological origin 10 (10.1)
 other 18 (18.2)
Transplantation related
Rank of kidney transplantation
1 93 (94)
2 6 (6)
Delayed graft function 15 (15.2)
Cold Ischemic Time (h) 9.4 (7.8) 8.5 (2 -28)








Everolimus dose (mg) 2.5 (0.8) 3 (0.75 -5.25)
Everolimus AUC (µg*h/L) 156 (60) 148 (54 - 488)
Everolimus Cmax (µg/L) 24 (9.5) 23.5 (6.2 - 66.6)
Everolimus Cmin (µg/L) 9.5 (4.3) 8.5 (3.3 - 32.2 )
Everolimus AUCmin (µg*h/L) 122 (37) 118 (54 -228)
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Efficacy and safety responses
Freedom from acute rejection 96 (97)
Completion of study 58 (59)
Hypercholesterolemia 55 (56)
 mild (>6.5 mmol/L) 37 (37)
 severe (>8 mmol/L) 18 (18)
Hypertriglyceridemia (>2.9 mmol/L) 45 (45)
 mild (>2.9 mmol/L) 43 (43)
 severe (>11.3 mmol/L) 2 (2)
Thrombocytopenia (<75 · 109/L) 2 (2)
Leukopenia (<4 · 109/L) 12 (12)
Diarrhea 7 (7)
Dyspnea 6 (6)
Serious infections (airway, 
gastrointestinal, urinary tract) 
35 (35)
Interstitial Pneumonia 11 (11)
Edema 1 (1)
Cardiovascular events 10 (10)
New onset Diabetes Mellitus 14 (14)
Malignancy 4 (4)
Renal Function 
Week 32 (ml/min) 70 (25) 71 (23 - 120)
Week 52 (ml/min) 71 (24) 70 (23-120)
Week 104 (ml/min) 71 (25) 76 (23 -120)
Discontinuation reasons
Pneumonia 11







BK virus nephropathy 1




* 6 out of 9 patients withdrew consent because of side effects and comorbidities.
Discontinuation data
Of the 99 patients, 58 patients complete the study, discontinuation reasons are presented 
Table 1. The majority of the discontinuations were related to side effects. The median 
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time to discontinuation in the group of patients who discontinued therapy was 130 days. 
Patients who did not discontinue therapy were censored at study end (550 days).
Side effects data
For the current analysis only the most severe side effects, being interstitial pneumonitis, 
infection and new onset diabetes mellitus, were analyzed separately for risk factors. Patients 
who did not have a side effect during everolimus therapy were censored at discontinuation 
or at study end (550 days).
Non-infectious interstitial pneumonitis 
Of the 99 patients in this dataset, 11 patients experienced non-infectious interstitial 
pneumonitis and everolimus therapy had to be stopped to assure recovery. The median 
time to pneumonitis was 106 days.
Infection
In the period from everolimus initiation to end of study (550 days) 35 patients of the 99 
total patients had an infection requiring treatment. The median time to first infection was 
76 days. 
New onset Diabetes Mellitus
For the new onset diabetes mellitus time to event analysis 11 patients were excluded 
because they were already diagnosed with diabetes mellitus. Of the 88 included patients 
14 developed new onset diabetes mellitus during the study. The median time to new onset 
diabetes mellitus diagnosis was 254 days.
Genotyping
The distributions of all single-nucleotide polymorphisms were in Hardy–Weinberg 
equilibrium (P>0.05). The distributions of the investigated CYP3A4, CYP3A5, the 
combined CYP3A4 and CYP3A5 genotype and P-gp polymorphisms are listed in Table 2. 
Allele frequencies found in our data set corresponded with those published previously. 
Haplotype distributions are listed in table 3. The combined CYP3A4 and CYP3A5 
genotype (CYP3ACOMBINED), in theory reflecting the largest differences in metabolite 
patterns [33] and was therefore chosen as the only CYP3A genotype covariate for the 
current analysis.
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Genotype Frequency [n (%)]

















ABCB1  rs1128503 1236C>T  C/C 36  [36]
C/T 46  [47]
T/T 16 [16]
N.G. 1 [1]
















rs6785049 7635A>G G/G 13 [13]
A/G 47 [47.5]
A/A 38 [38.5]
      N.G. 1 [1]
CYP, cytochrome p450; PXR, pregnane X receptor; SNP, single nucleotide polymorphism.
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Frequency [N (%)] Haplotype Frequency [N (%)]
ABCB1 rs1128503 TTT CCG 29 29.3 CCG 87 44
rs2032582 CCG CCG 20 20.2 TTT 72 36.4
rs1045642 TTT TTT 14 14.1 TCG 27 13.6
CCG TCG 13 13.1 CTG 6 3
TTT TCG 10 10.1 CTT 2 1
CCG CTG 3 3.0 CCT 1 0.5
CCG CTT 1 1.0 TCT 1 0.5
TTT CTG 2 2.0
TCG TCG 2 2.0
TTT CCT 1 1.0
TTT CTT 1 1.0
CCG TCT 1 1.0
TCG CTG 1 1.0
Base model
The time to everolimus-discontinuation, non-infectious interstitial pneumonitis and 
infection was best described using the Gompertz function with regard to objective 
function value (OFV) and Kaplan-Meier plots: 
The formula contains two parameters: λ describing the scale and γ describing the shape 
of the survival curve. New onset diabetes mellitus was equally well described by an 
exponential, Weibull and Gompertz hazard function. The exponential was chosen over 
the Weibull and Gompertz because the exponential function contains only 1 parameter: 
λ describing the scale of the survival curve.
126 Chapter 6
Table 4 shows the OFV of the different explored survival distributions for each endpoint. 
Figure 1 presents the VPCs of the different endpoints from 200 simulations showing that 
the model adequately describes the data for the different endpoints discontinuation, non-
infectious interstitial pneumonitis, infection and new onset diabetes mellitus. 
Covariate Model
Covariates were selected based on theoretical plausibility. All selected covariates were 
included in the SCM. Results of the univariate testing of the selected covariate relationships 
(the first step in the SCM) are presented in Table 5. Results of the full SCM analysis are 
presented in Table 6.
Table 4: Objective function value and number of parameters of different tested survival distribution functions.
Survival function Number of parameters OFV
Discontinuation
 Weibull 2 632.9
 Exponential 1 642.0
 Gompertz 2 623.3
 Log logistic 2 630.2
 Log normal 2 627.2
Pneumonia
 Weibull 2 197.6
 Exponential 1 200.7
 Gompertz 2 194.0
 Log logistic 2 198.0
 Log normal 2 196.0
Infection 
 Weibull 2 545.7
 Exponential 1 555.0
 Gompertz 2 540.3
 Log logistic 2 543.5
 Log normal 2 540.3
New onset DM
 Weibull 2 243.9
 Exponential 1 244.0
 Gompertz 2 244.0
 Log logistic 2 245.0
 Log normal 2 244.0
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Figure 1: Kaplan-Meier Plots of the percentage of patients without an event (Discontinuation, 
Pneumonitis, Infection, NODM) vs Time after everolimus initiation. The shaded area represents the 
95% prediction intervals for the simulated data. The continuous line represents the real data, the 
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For discontinuation the following covariates were selected: Age, Weight, AUC, Cmin, Cmax, 
and AUCmin as continuous covariates and Race, Diabetes Mellitus at start, Sex and a number 
of pharmacogenetic covariates: CYP3A combined (CYP3A5*1 and CYP3A4*22) genotype, 
PXR (NR1|2) -24113G>A, PXR (NR1|2) 7635A>G, ABCB1 3435C>T, ABCB1 1236C>T, 
ABCB1 2677T>G, ABCB1 -129T>C, ABCB1 haplo CCG, ABCB1 haplo TTT and ABCB1 
haplo TCG. For discontinuation significant relationships were found in the univariate 
analysis for Age, Weight, AUCmin, PXR (NR1|2) -24113G>A (AA vs GA and GG), ABCB1 
3435C>T (CC versus CT and TT) and ABCB1 haplo CCG (2 copies vs 1 or zero copies). 
Patients with a constant excess exposure (high AUCmin) had a higher hazard of drug-
discontinuation as graphically shown in Figure 2. Higher age also increased the risk of 
discontinuation as shown in Figure 3.
Figure 2: Kaplan-Meier VPC of final time to event model stratified by AUCmin groups. The shaded area represents 
the 95% prediction intervals for the simulated data. The continuous line represents the real data, the dashed red 
lines represent the 90% confidence interval of the real data.
Figure 3: Kaplan-Meier VPC of final time to event model stratified by age group. The shaded area represents the 
95% prediction intervals for the simulated data. The continuous line represents the real data, the dashed red lines 
represent the 90% confidence interval of the real data.
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Table 6: Results of the multivariate covariate analysis for each endpoint.




 Step 1: AND effect AUCmin 603.844 -19.432 0.00001
 Step 2: AND effect Age 595.580 -8.264 0.00404
 Step 3: AND effect Race 589.757 -5.823 0.01581
 Step 4: AND effect PXR (NR1|2) -24113G>A 584.079 -5.678 0.01718
backward deletion
FULL-model 584.079
 Step 1: MINUS effect PXR (NR1|2) -24113G>A 589.757 5.678 0.01718
 Step 2: MINUS effect Race 595.580 5.823 0.01581
 Step 3: MINUS effect Age 603.844 8.264 0.00404




 Step 1: AND effect AUCmin non-linear 173.901 -20.127 0.00001
 Step 2: AND effect PXR (NR1|2) -24113G>A 165.396 -8.505 0.00354
backward deletion
FULL-model 165.396
 Step 1: MINUS effect P227 173.901 7.406 0.00650




 Step 1: AND effect Leukocytes 517.793 -4.143 0.04181
backward deletion
FULL-model 517.793
 Step 1: MINUS effect Leukocytes 521.936 4.143 0.04181
New Onset Diabetes Mellitus
forward inclusion
BASE-model 244.012
 Step 1: AND effect Age 237.468 -6.54369 0.01053
backward deletion
FULL-model 237.468
 Step 1: MINUS effect Age 244.012 6.54369 0.01053
∆OFV >3.84 (P<0.05) forward inclusion and >6.64 (P<0.01) for backward deletion.* left out of the final model. 
∆OFV difference of objective function value.
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ABCB1 3435C>T: CC genotype and ABCB1 CCG haplotype were associated with lower 
risk of discontinuation compared to the other variants. However, only AUCmin and Age 
remained significant after the forward inclusion and backward deletion step as showed in 
Table 6. These two covariates were included in the final time-to-event model.
Non-infectious interstitial pneumonitis
The selected covariates to investigate for non-infectious interstitial pneumonitis were: Age, 
Weight, AUC, Cmin, Cmax, and AUCmin as continuous covariates and Race, Diabetes Mellitus 
at start, Sex and the following pharmacogenetic covariates: CYP3A combined (CYP3A5*1 
and CYP3A4*22) genotype, PXR (NR1|2) -24113G>A, PXR (NR1|2) 7635A>G, ABCB1 
3435C>T, ABCB1 1236C>T, ABCB1 2677T>G, ABCB1 -129T>C, ABCB1 haplo CCG, 
ABCB1 haplo TTT and ABCB1 haplo TCG. For non-infectious interstitial pneumonitis, 
AUCmin and PXR (NR1|2) -24113G>A (AA vs GA and GG) were significant covariates 
on the hazard for pneumonitis. Both covariates remained significant in the multivariate 
analysis. Figure 4 shows graphically that having an AUCmin above 150 µg*hr/L clearly 
increased the risk of experiencing non-infectious interstitial pneumonitis. Figure 5 shows 
that patients with a PXR (NR1|2) (-24113G>A) AA genotype had a slight increase of the 
risk of experiencing pneumonitis.
 
Figure 4: Kaplan-Meier VPC of final time to event model stratified by AUCmin groups. The shaded area represents 
the 95% prediction intervals for the simulated data. The continuous line represents the real data, the dashed red 
lines represent the 90% confidence interval of the real data.
Infection
The selected covariates to investigate for Infection were: Age, Weight, AUC, Cmin, Cmax, and 
AUCmin, Leukocyte count, Cholesterol and Triglycerides levels as continuous covariates 
and Race, Diabetes Mellitus at start, Sex and a number of pharmacogenetic covariates: 
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PXR (NR1|2) -24113G>A, PXR (NR1|2) 7635A>G, ABCB1 3435C>T, ABCB1 1236C>T, 
ABCB1 2677T>G, ABCB1 -129T>C, ABCB1 haplo CCG, ABCB1 haplo TTT and ABCB1 
haplo TCG. For infection only leukocyte count had a significant effect in the univariate 
analysis, but was dropped after backward elimination. No significant risk factors were 
determined for the occurrence of infection and were not included in the final model.
Figure 5: Kaplan-Meier VPC of final time to event model stratified by PXR (NR1|2) -24113G>A groups. The 
shaded area represents the 95% prediction intervals for the simulated data. The continuous line represents the 
real data, the dashed red lines represent the 90% confidence interval of the real data.
New Onset Diabetes Mellitus
The selected covariates to investigate for New Onset Diabetes Mellitus: Age, Weight, AUC, 
Cmin, Cmax, and AUCmin, as continuous covariates and Race, Sex, Donor Type, Average daily 
Cyclosporine AUC till week 5 after Tx (Target value was 5400 (µg*hr/L)), Average daily 
Cyclosporine AUC from week 6 till conversion to Everolimus (Target value was 3250 
(µg*hr/L) ) and a number of pharmacogenetic covariates: PXR (NR1|2) -24113G>A, 
PXR (NR1|2) 7635A>G, ABCB1 3435C>T, ABCB1 1236C>T, ABCB1 2677T>G, ABCB1 
-129T>C, ABCB1 haplo CCG, ABCB1 haplo TTT and ABCB1 haplo TCG. For new onset 
diabetes mellitus, Age, PXR (NR1|2) -24113G>A and Donor type had a significant effect on 
the hazard in the univariate analysis. Higher age, PXR (NR1|2) -24113G>A (AA) genotype 
and having a kidney of a deceased donor were associated with higher risk of developing 
NODM. However, after the forward inclusion step only Age remained significant but was 
left out of the final model after the backward elimination step and therefore no covariate 
relationships were included in the final time-to-event model.
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Discussion
In the current analysis the time from everolimus initiation to discontinuation, time to non-
infectious interstitial pneumonitis and time to first infection were adequately described 
in a time-to-event model with the Gompertz distribution function. Time to new onset 
diabetes mellitus was best described by a time-to-event model with the exponential 
distribution function. This study shows for the first time that excess exposure during 
the study period and older age were risk factors for everolimus-discontinuation. The 
risk of experiencing non-infectious pneumonitis was also increased by prolonged excess 
exposure. Renal transplant recipients with a PXR (NR1|2)( -24113G>A): AA genotype 
had a higher risk of developing pneumonitis compared to those carrying the AG or GG 
genotype. In addition no significant covariates were included in the final time to event 
model for infection and new onset diabetes mellitus. 
To our knowledge this is the first study exploring risk factors for discontinuation and 
severe side effects in renal transplant recipients on an everolimus and prednisolone 
regimen using a sophisticated time-to-event analysis with inclusion of demographic, 
transplant related and pharmacogenetic covariates. The effect of continuous high 
exposure (high AUCmin) on the risk of discontinuation everolimus can be explained by 
the fact that, in the majority of discontinuation was side effect related and certain side 
effects have previously shown to be dependent on exposure [46,47]. Furthermore patients 
experiencing non-infectious pneumonitis always discontinued everolimus therapy. As can 
be concluded from our results, clinicians should prevent renal transplant recipients from 
reaching excess everolimus exposure (i.e. AUC12> 120 -150 µg*h/L), therefore close TDM 
remains warranted. Looking at the high discontinuation rates and low rejection risk we 
can extrapolate an initial target trough level between 6 µg/L and 8 µg/L from this study 
and an initial dose of 2 mg b.i.d. The lower exposure threshold cannot be established 
from this study since only 3 patients experienced an acute rejection episode. Moreover 
only a prospective trial should establish the lower exposure threshold for everolimus and 
prednisolone dual therapy. 
The effect of age on discontinuation, meaning a higher age results in a higher risk of 
discontinuation can be explained be fact that often patients with higher age have more 
comorbidities and have a weaker immune system such as changes in T-cell function[48] 
where the effect of the same immunosuppression exposure might be higher. Furthermore 
older patients with more comorbidities are less able to cope with side effects compared 
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to young patients with no comorbidities. In addition the other investigated covariates 
for discontinuation that were significant in the univariate analysis were Weight, ABCB1 
3435C>T and ABCB1 haplo CCG. Higher weight increased the risk of discontinuation, 
presumably because high weight is correlated with more comorbities and worse outcome 
[49]. ABCB1 3435C>T (CC vs CT and TT) and ABCB1 haplo CCG (2 copies vs 0 and 
1 copy) decreased the risk of discontinuation and these genotypes are both associated 
with higher P-gp activity [50,51]. Since everolimus is also a substrate for the efflux pump 
P-glycoprotein (ABCB1) [28,29] this higher P-gp activity for patients with CC genotype 
and CCG haplotype could reflect lower intracellular everolimus concentrations in T-cells. 
P-gp is highly polymorphic and for this study four most relevant SNP’s were selected. These 
ABCB1 polymorphism have previously also been linked to altered drug transporter activity 
leading to differences in peripheral blood mononuclear cell tacrolimus concentrations 
[52]. Concluding, the discovered effect of the ABCB1 polymorphism disappeared in the 
multivariate analysis, most likely by the fact that the AUCmin covariate effect neutralizes 
the effect of the polymorphisms. The polymorphism however could become more relevant 
when maintaining a lower target AUC than was used in the current study. 
The incidence of non-infectious interstitial pneumonitis was relatively high 11% in this 
study. In other studies the incidence of pneumonia or pneumonitis with the usage of 
sirolimus (SRL) was about 1-10% [53], for everolimus 0-7% [11] and in oncology where 
higher daily dosage (10 mg) are used even higher (14%) incidence has been reported [13].
The precise mechanism is still unclear but a cell mediated autoimmune response after 
exposure of cryptic antigens or T-cell-mediated delayed-type hypersensitivity is one of the 
suggested mechanisms. Over the years a number of case report were published concerning 
mTOR pneumonitis in transplantation [39,54,55]. So far, no clear patient-related or 
context-related risk factors had been identified. In the current analysis we found a bi-
linear relation for AUCmin, with increasing risk of pneumonitis starting to increase above 
an AUCmin above 120 µg*h/ L. In an earlier analysis the average AUC was not significantly 
related to the incidence of non-infectious pneumonitis, however in contrast to the 
current analysis time to event was not taken into account and this type of relationship 
was not investigated [38]. One could argue that AUCmin is not a very accurate measure 
for exposure during the trial, however at worst it is underestimation of the true exposure 
and according to the found relationship an exposure above the target value increases even 
further with an rising exposure. While the time varying AUC as a continuous covariate 
was not significant when tested linear or as a bi-linear relation, AUC was significant when 
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tested categorically: patients with an exposure of > 180 µg*h/L had a significant higher risk 
of developing pneumonitis. The measure AUCmin which represent the lowest measured 
AUC of the patient however, had a larger impact on the objective function drop and was 
therefore chosen over the other for inclusion in the SCM. Since all pneumonitis cases also 
discontinued everolimus therapy a large part of the effect of AUCmin on discontinuation 
is caused by the pneumonitis cases. The increase in risk of patient with that was found for 
patients with PXR (NR1|2) (-24113G>A) AA genotype might be related to an increased 
accumulation of everolimus in the lungs. In animal experiment high affinity for lungs and 
kidney were found for everolimus [56] and could this could also take place in humans. 
PXR is a nuclear receptor whose primary function is to sense the presence of foreign 
toxic substances and in response up regulate the expression of proteins involved in the 
detoxification and clearance of these substances from the body. PXR polymorphism could 
therefore also have an effect on drug transporter activity since PXR is able to influence 
enzyme activity and multi drug transporter proteins [30–32]. The effect seems to be 
limited as shown in figure but warrants further investigation in another dataset.
Infections continue to be an important feature in the first year following both renal and 
heart transplant and occur in around 50% of patients [16]. The incidence has previously 
been related to the intensity and type of immunosuppression [17]. For example, in a 
year-long comparison of everolimus versus traditional immunosuppressant treatment, 
viral infections occurred in 31 % of subjects receiving azathioprine versus 15% and 17% 
for everolimus 1.5 mg/day and 3.0 mg/day groups, respectively. The use of everolimus 
reduced the risk of CMV infection by almost one-third as compared with azathioprine-
based therapy [18]. In the current analysis no significant factors were found of infections 
presumably because all patients received the same immunosuppressive regimen and 
exposure was aimed at a preset target value. In another study comparing two dose 
regimens 1,5 mg vs 3 mg everolimus (daily dose with CsA) no differences were found in 
the occurrence of infection [57]. 
New onset diabetes mellitus is a serious side effect which decreases long term survival 
of renal transplant recipients [23]. Although known from literature, important risk 
factor for the development of NODM include African ethnicity, increased age, obesity, 
increased number of transplants, donor type, a family history of diabetes and the use of 
prednisolone [27] none of these relationships remained significant in our multivariate 
analysis. Increased age, PXR (NR1|2) -24113G>A (AA genotype) and a having a donor 
kidney from a deceased donor increased the risk of NODM. The effect however appeared 
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to be too small to be included in the final model. The analysis for NODM has some specific 
limitations; the dataset lacked a significant number of patients from African ethnicity, 
Family history of diabetes was not available in the dataset en could therefore not be 
included in the covariate analysis. The number of renal transplants could not be tested 
since only 5 patients in the dataset had a second kidney transplant, all other patients 
received a first transplant. Furthermore none of the patients who had a second transplant 
was diagnosed with NODM during everolimus therapy. Exposure did not seem to affect 
the occurrence of NODM. This is in accordance with a study by Shihab et al. who also 
found no clear correlation between everolimus exposure and NODM, and the differences 
in exposure between patients in that particular study were even much larger [47].
Our study had some limitations, the dataset was relatively small and therefore not all side 
effects could be explored. However, the current study is relatively small, it is currently the 
largest dataset available with this specific immunosuppressive regimen and the extensive 
dataset is comprehensive which has advantages for identifying possible risk factors for 
the investigated endpoints. Data on exposure, demographic, transplant related factors as 
well as pharmacogenetic factor were available for analysis. Since all included patients were 
included in the same clinical trial and the majority of patients were of Caucasian origin 
the dataset was very homogeneous. The previously published pharmacokinetic model 
[33] was developed on the same data set, which included rich pharmacokinetic sampling 
thereby enabling precise estimation of the everolimus exposure.
In conclusion, risk factors of everolimus discontinuation of renal transplant recipients on 
a regimen of everolimus and prednisone duo therapy were constant too high everolimus 
exposure and increasing age. This study shows that the initial dose of 3 mg b.i.d might be 
too high given the high discontinuation rate and low acute rejection rate. Furthermore, 
risk factor for the hazardous side-effect non-infectious interstitial pneumonitis were 
constant too high everolimus exposure and PXR (NR1|2)( -24113G>A): AA genotype. For 
infection and new onset diabetes mellitus no significant covariates could be detected. The 
current findings can be used to further optimize everolimus based immunosuppressive 
therapy by preventing too high exposure by strict therapeutic drug monitoring.
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Abstract
Cyclosporine, everolimus and tacrolimus are the cornerstone of immunosuppressive 
therapy in renal transplantation. These drugs are characterized by narrow therapeutic 
windows, highly variable pharmacokinetics and metabolism by CYP3A enzymes. Recently 
the decreased activity allele CYP3A4*22, was described as a potential predictive marker for 
CYP3A4 activity. This study investigated the effect of CYP3A4*22, CYP3A5*3 and CYP3A 
combined genotypes on cyclosporine, everolimus and tacrolimus pharmacokinetics in 
renal transplant patients. CYP3A4*22 carriers showed a significant lower clearance for 
cyclosporine (-15%) and a trend was observed for everolimus (-7%) and tacrolimus 
(-16%). Patients carrying at least one CYP3A5*1 allele had 1.5 fold higher tacrolimus 
clearance compared to non-carriers, however CYP3A5*3 appeared not predictive for 
everolimus and cyclosporine. CYP3A combined genotype did not significantly improve 
prediction of clearance compared to CYP3A5*3 or CYP3A4*22 alone. These data suggest 
that dose individualization of cyclosporine, everolimus or tacrolimus therapy based on 
CYP3A4*22 is not indicated.
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Introduction
Cyclosporine, everolimus and tacrolimus are the cornerstone of maintenance 
immunosuppressive therapy in renal transplantation. These drugs are characterized by 
a small therapeutic window and highly variable pharmacokinetics (PK) which makes 
therapeutic drug monitoring (TDM) essential for maintaining adequate exposure and 
preventing serious drug-related toxicities [1–4].
Cyclosporine, everolimus and tacrolimus are primarily metabolized by cytochrome 
P450 enzymes CYP3A4 and CYP3A5 [5–8]. Differences in activity of these metabolizing 
enzymes are likely to be responsible for a significant part of the inter-individual variability 
in pharmacokinetics [9,10]. Genetic polymorphisms in genes encoding these metabolizing 
enzymes have previously been found to explain a part of the variability in pharmacokinetics 
of these immunosuppressive drugs [1,11–15]. Recently the decreased activity allele 
CYP3A4*22 was identified as a novel predictive marker for tacrolimus pharmacokinetics 
[16,17], however these findings have not been successfully reproduced [12]. CYP3A4*22 
has also been investigated to a less extend in cyclosporine pharmacokinetics but its effect 
on everolimus pharmacokinetics is still unknown [16–18]. CYP3A5*3 was studied before 
in relation to pharmacokinetics of everolimus, tacrolimus and cyclosporine [11,19–21] 
but the CYP3A combined genotype (CYP3A4 and CYP3A5), which most likely better 
reflect CYP3A activity, has only been evaluated for tacrolimus [16]. 
The studies investigating the effect of CYP3A4*22 on tacrolimus pharmacokinetics were 
limited by the use of trough concentrations, lack of data on co-medications and did not use 
population pharmacokinetic analysis. Such an approach enables to differentiate between 
inter-patient and intra-patient variability which results in enhanced statistical power to 
identify factors influencing pharmacokinetics. Therefore we investigated the effect of 
CYP3A4*22, CYP3A5*3 and CYP3A combined genotype on cyclosporine, everolimus and 




Clinical data from 298 renal transplant recipients treated with a immunosuppressive 
regimen cyclosporine (Neoral®, Novartis, Basel, Switserland), prednisolone and 
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mycophenolate sodium participating in a run in phase of a prospective, open, 
randomized, multicenter study were studied up to 6 months after transplantation [22]. 
Induction therapy consisted of 2 doses of 20 mg Basiliximab (Simulect®, Novartis, Basel, 
Switzerland) before transplantation and on day 4, rapidly tapered prednisolone dose (50 
mg b.i.d intravenously tapered to daily 10 mg oral prednisolone). Cyclosporine therapy 
was started at an oral dose of 4 mg/kg twice daily and was supported by routine TDM 
based on AUC0-12h. TDM was aimed at a target of 5400 μg*h/L the first 6 weeks and 3250 
μg*h/L thereafter. Cyclosporine concentrations were obtained at steady state at clinical 
visits which were scheduled at 1, 5, 12 and 24 weeks post transplantation.
Everolimus
Clinical data from 97 stable renal transplant recipients treated with immunosuppressive 
duotherapy consisting of everolimus (Certican®, Novartis, Basel, Switzerland) and 
prednisolone, participating in a prospective, open, randomized, multicenter study were 
studied from 6 to 24 months after transplantation [22]. During the first six months, 
patients were treated with an immunosuppressive regimen cyclosporine, prednisolone 
and mycophenolate, Thereafter a scheduled biopsy was performed. Patients whose biopsy 
showed no sign of rejection were included. Subsequently cyclosporine and mycophenolate 
were discontinued. Everolimus therapy was started at an oral dose of 3 mg twice daily and 
was supported by routine TDM based on AUC0-12h. TDM was aimed at a target of 120 
μg*h/L. Everolimus concentrations were obtained at steady state at regular clinical visits 
scheduled at 32, 52, 78 and 104 weeks after transplantation.
Tacrolimus
Clinical data from 101 renal transplant patients on an immunosuppressive regimen of 
tacrolimus (Prograft®, Astellas, Leiden, The Netherlands), prednisolone and mycophenolate 
mofetil studied for first two TDM moments after transplantation. Induction therapy 
consisted of 2 doses of 20 mg Basiliximab (Simulect®) before transplantation and on day 
4, rapidly tapered prednisolone dose (50 mg b.i.d intravenously tapered to daily 10 mg 
oral prednisolone). Tacrolimus therapy was started at a fixed oral dose of 5 mg twice daily 
and was supported by routine TDM based on AUC0-12h. TDM was aimed at a target of 
160 μg*h/L the first 6 weeks and 120 μg*h/L thereafter. Tacrolimus concentrations were 
obtained at steady state at ranging from 1 week to 66 weeks after transplantation with a 
median of 2 weeks. 
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The study was approved by the Medical Ethics Committee of Leiden University Medical 
Center and patients gave written informed consent.
Bioanalytics
TDM was performed on the basis Bayesian estimation (cyclosporine [23] and tacrolimus 
[24]) or trapezoidal rule (everolimus) (blood concentration at t = 0,1,2,3,4,5 and 6 
(everolimus and tacrolimus) up to 12 h for some patients (cyclosporine) or t = 0,1,2,3,4 
hours in a small number of visits in the everolimus dataset) using MW/Pharm 3.5 
(Mediware, Groningen, The Netherlands)[25]. TDM samples were determined in whole 
blood by a validated liquid chromatography-mass spectrometric method in two labo-
ratories [26,27] or by Fluorescent Polarization Immunoassay (FPIA; Abbott Laboratories, 
Abbott Park, IL, USA). Tacrolimus blood concentrations were all determined with 
LC-MS/MS, Everolimus with LC-MS/MS and FPIA and cyclosporine with FPIA alone. 
Table 1 shows the samples distribution of the blood concentrations used in this study.
Genotyping Assays
DNA was isolated from EDTA blood collected from patients. CYP3A4*22 was determined 
with TaqMan 7500 (Applied Biosystems, Nieuwerkerk a.d. IJssel, The Netherlands) with 
predesigned assays, according to manufacturers’ protocol. CYP3A5*3 was determined with 
Pyrosequencer 96MA (Isogen, IJsselstein, The Netherlands). Further Details with regard 
to the genotyping protocol are provided in Supplementary Table I. No inconsistencies 
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Pharmacokinetic modeling
Nonlinear mixed effect modeling was used to estimate pharmacokinetic parameters 
from blood concentration-time data. NONMEM (v7.2.1, Icon Development Solutions, 
Ellicott City, MD) was used for modeling, using PsN toolkit 3.4.2, and Piranã version 
2.8.0 [28] as modeling environment. Results were analyzed using statistical software 
package R (v2.15.2) and RStudio (v0.97.248). First order conditional estimation method 
with interaction (FOCE-I) was used throughout the analysis. Model selection was based 
on statistical significance, goodness of fit and stability. Throughout the model building 
process, an altered model was chosen over a precursor model if a difference in the objective 
functions (-2 log likelihood) was >6.63 (P<0.01, with 1 degree of freedom, assuming X2 
distribution).
Base model 
The model was initially developed strictly pharmacokinetic without covariates. Since only 
data after oral and not after intravenous administration was available the absolute oral 
bioavailability could not be determined. Therefore the value for bioavailability was fixed. 
Plots of observed concentration-time data were examined. One and two compartmental 
pharmacokinetic models with first-order elimination were compared to find the best 
fit of the concentration-time data. The use of transit compartments and a lag time for 
drug absorption were explored. After building the base model, demographic and genetic 
covariates were explored. 
Covariate analysis
Diagnostic plots were constructed of the random effects of Clearance, Volume, Ka and F 
versus the demographic (age, bodyweight, sex, ethnicity, length, LBW, IBW, BSA, BMI 
(Formulas in supplementary table II), hematocrit, underlying disease, co-medications 
(also weighted residuals vs co-medication plots) and pharmacogenetic (CYP3A4*22 
and CYP3A5*3) characteristics. Polymorphisms were selected based on theoretical 
relationship and minimal allele frequency (>6%) to assure detection of clinically relevant 
effect on pharmacokinetics. Based on these diagnostic plots further testing in the 
pharmacostatistical model was performed. Subsequently, selected covariate relationships 
were evaluated by forward inclusion and backward deletion procedure. A covariate effect 
was only maintained in the model if the inclusion resulted in a reduction in random 
variability and improved model fit.
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Supplementary Table II: Formulas.
Demographic Covariate Formulas
IBW calculated as: 
Males: 52 kg + 1.9 kg for every inch over 5 feet 





BSA ( Mosteller (1987) )
 
Visual predictive check with prediction-correction
Performance of candidate and final models for cyclosporine, everolimus and tacrolimus 
pharmacokinetic models was evaluated using prediction corrected visual predictive 
checks (predVPC), by simulation of 500 simulated datasets. A prediction corrected VPC 
differ from a traditional VPC in that both observations and the model predictions are 




The cyclosporine dataset consisted of 298 adult renal transplant recipients, 187 men and 
111 women. The majority of patients (88%) were of Caucasian origin. Mean age was 51 
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± 13 years (range 18-73), mean weight was 77±15 kg (41-141 kg). A total of 6,800 blood 
samples were collected. 
Everolimus
97 adult renal transplant recipients, 62 men and 35 women were included. The majority of 
patients (86%) were of Caucasian origin. Mean age was 51±13 years (range 22-71), mean 
weight was 79 ± 15 kg (50-129 kg). The dataset consisted out of 1,807 blood samples. 
Tacrolimus
101 adult renal transplant recipients, 56 men and 45 women were included in this analysis. 
The majority of patients (77%) were of Caucasian origin. Mean age was 51±14 years (range 
15-77), mean weight was 76±9 kg (40-114 kg). The dataset consisted out of 921 blood samples. 
The concentration-time data were reviewed for completeness and consistency of sampling 
and dosing times. All measured concentrations were above the lower limit of quantification. 
Baseline characteristics of the included patients are presented in Table 1. 
Genotyping
The distributions of all SNPs were in Hardy-Weinberg equilibrium. The distribution of the 
investigated CYP3A5 and CYP3A4 polymorphisms are listed in Table 2. Allele frequencies 
found in our dataset corresponded with those published previously [16,30–32]. To 
investigate the combined effect of CYP3A4*22 and CYP3A5*3, genotype clusters were 
made: 
Slow metabolizers (C1): No CYP3A5 activity (CYP3A5*3/*3) and at least one decreased 
activity allele in CYP3A4 (CYP3A4*22/*22 or CYP3A4*1/*22), Intermediate metabolizers 
group 1 (C2): No CYP3A5 activity (CYP3A5*3/*3) and no decreased activity allele in 
CYP3A4 (CYP3A4*1/*1), Intermediate metabolizers group 2 (C3): Carriers of at least 
one increased activity allele in CYP3A5 (CYP3A5*1/*1 or CYP3A5*1/*3) and at least one 
decreased activity allele in CYP3A4 (CYP3A4*22/*22 or CYP3A4*1/*22) and extensive 
metabolizers (C4): Carriers of at least one increased activity allele in CYP3A5 (CYP3A5*1/*1 
or CYP3A5*1/*3) and no decreased activity allele in CYP3A4 (CYP3A4*1/*1).
152 Chapter 7
Table 1: Baseline characteristics of the patients included in the population PK/PG analyses.
  Ciclosporine Everolimus Tacrolimus
Male 187 62 56
Female 111 35 45
Age (yrs) 51 ± 13 51 ± 13 50 ± 14
Weight (kg) 77 ± 15 79 ± 15 76 ± 14 
Body surface Area (m2) 1.93 ± 0.22 1.94 ± 0.22 1.90 ± 0.22 
Lean Body Mass (kg) 57 ± 10 58 ± 10 55 ± 10
Ideal BW (kg) 67 ± 9 67 ± 8 65 ± 9
Height (cm) 174 ± 10 174 ± 10  172 ± 11
Creatinine clearance  
(ml/min) 46 ± 30  70 ± 25 56 ± 35 
Exposure      
 Dose (mg) 177 ± 78 (50-500) 2.49 ± 0.79 (0.75-5.25) 4.2 ± 1.7 (0.5-12)
 AUC0-12 (µg*hr/L) 5648 ± 2574  
(702-16499)
150 ± 42 (56-336) 170 ± 81 (49-462)
 Trough concentration 219 ± 131 (25-1209) 9.3 ± 4.2 (2.6-32) 10.8 ± 5.5 (3.3-33.6)
Ethicity (%)      
 Caucasion 88 86 77
 Mediterranean 3 5 13
 Asian 6 7 9
 Black 2 2 1
 Other 1    
Hematocit (l/l) 0.36 ± 0.05 0.38 ± 0.04 0.34 ± 0.04
Underlying disease (n)      
 Polycystic kidney disease 63 22 16
 Glomerulonephritis 50 15 7
 Diabetes mellitus 12 4 22
 Hypertension 50 15 15
  Focal segmental 
glomerulosclerosis
13 4 8
 E.c.i. 13 5 5
 Interstitial nephritis 11 3 3
 Urological 23 10 3
 Other 63 19 23
PK data      
 Concentrations (µg/l) 591 ± 434 (25-2615) 15.8 ± 8.1 (2.6-59) 16.8 ± 10 (3.3-96)
 Samples per patient 23 ± 6 (3-37) 19 ± 8 (7-36) 9 ± 2 (3-14)
 Total Samples 6800 1807 921
AUC, area under the curve; BW, body weight; E.c.i., e causa ignota (cause unknown); PG, pharmacogenetic; PK, 
pharmacokinetic.
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Table 2: Genotype distribution in study population.
SNP Frequency and Genotype
Cyclosporine (n=298)
CYP3A4*22 (rs35599367) 264 *1/*1 32 *1/*22 2 *22/*22 0 NG
CYP3A5*3 (rs776746) 239 *3/*3 48 *1/*3 9 *1/*1 2 NG
CYP3A4/CYP3A5 cluster 29 C1 210  C2 5  C3 52 C4 2 NG
Everolimus (n=97)
CYP3A4*22 (rs35599367) 87 *1/*1 8 *1/*22 1 *22/*22 1 NG
CYP3A5*3 (rs776746) 81 *3/*3 12 *1/*3 3 *1/*1 1 NG
CYP3A4/CYP3A5 cluster 9 C1 72  C2 0  C3 15 C4 1 NG
Tacrolimus (n=101)
CYP3A4*22 (rs35599367) 92 *1/*1 7 *1/*22 2 *22/*22 0 NG
CYP3A5*3 (rs776746) 79 *3/*3 18 *1/*3 4 *1/*1 0 NG
CYP3A4/CYP3A5 cluster 7 C1 72  C2 2  C3 20 C4 0 NG
C1, CYP3A5*1 noncarriers and CYP3A4*22 carriers; C2, CYP3A5*1 noncarriers and CYP3A4*22 non-carriers; 
C3, CYP3A5*1 carriers and CYP3A4*22 carriers; C4, CYP3A5*1 carriers and CYP3A4*22 noncarriers; NG, not 
genotyped.
Concomitant medication
An overview of concomitant immunosuppressive and non-immunosuppressive 
medication with possible interaction of pharmacokinetics in the different groups is 
presented in Supplementary Table III.
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Supplementary Table III: Comedications of interest for covariate analysis and number of patients using them.






Atorvastatin 47 2 28
Pravastatin 26 5 20
Simvastatin 25 3 7
Rosuvastatin 0 0 1
Antibiotics
Sulfamethoxazole / 
Trimethoprim 35 80 17
Hypertension
Calciumantagonist 134 40 45
Proton Pump inhibitors 
Pantoprazole 28 9 7
Omeprazole 33 6 16
Esomeprazole 22 1 23
Antifungants
Fluconazole 0 1 0
* In some cases statins were switched for another statins.
Population pharmacokinetic modeling
The pharmacokinetic data of cyclosporine, everolimus and tacrolimus was best described 
by a two-compartmental model with first order absorption and first order elimination 
from the central compartment. The delayed absorption of everolimus and tacrolimus 
was best described with a lag time and the delayed absorption of cyclosporine was best 
described with a transit compartment, using a first order rate constant describing the 
transfer from the dose compartment into the transit compartment and subsequently into 
the central compartment (Figure 1). 
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Figure 1: Schematic representation of the linear two-compartment model with first-order absorption and 
elimination of cyclosporine, including the transit compartment to describe the absorption phase.
Random effect parameters for inter-individual variability in clearance (CL), volume 
of central compartment (Vc) and were identified for all three drugs. Random effect 
parameters for inter-individual variability in the rate of absorption (Ka) were identified for 
cyclosporine and everolimus. For tacrolimus a random effect parameter for inter-individual 
variability was identified for bioavailability. Variability between occasions (IOV) was best 
described with a random effect on (fixed) bioavailability (F) for cyclosporine, everolimus 
and tacrolimus. For everolimus also IOV on Ka was identified. The random effects were 
tested for structural relationship with dose and time to create a model with unbiased and 
randomly distributed random effects for covariate analysis. 
The structural pharmacokinetic model of cyclosporine indicated an apparent clearance 
(CL/F) of 15.9 L/h, with the bioavailability term fixed to 0.5, an apparent central 
distribution volume (Vc/F) of 59.6 L and an apparent peripheral distribution volume of 
99.7 L. The absorption rate constant of was 2.1 h-1. Inter-compartmental clearance was 
13.1 L/h. Inter-occasion variability was estimated for the fixed bioavailability term and not 
for clearance because of a better model fit. 
The structural pharmacokinetic model of everolimus indicated an apparent clearance 
(CL/F) of 16.7 L/h, with the bioavailability term fixed to 1, an apparent central distribution 
volume (Vc/F) of 144 L and an apparent peripheral distribution volume of 348 L. The 
absorption rate constant was 7.36 h-1. Inter-compartmental clearance was 42.7 L/h and lag 
time was 0.71 h. Inter-occasion variability was estimated for the fixed bioavailability term 
and not for clearance because of a better model fit. 
A dose clearance relationship was observed showing an increase in apparent clearance 
with increasing dose according to TVCL = {[dose/2.5]*0.34}. This relationship improved 
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the model fit in terms of objective function. The effect appeared to be caused by strict 
TDM. Patients with high everolimus blood levels (i.e. with a lower clearance) were titrated 
to receive lower doses and vice versa to reach the stable target AUC0-12h of 120 μg*h/L. 
Subsequently an apparent dose clearance relationship emerges. Additional test described 
by Ahn et al [33] were performed and confirmed that this effect was caused by strict 
TDM. Since two different assays were used for the determination of everolimus blood 
concentrations (LC-MS/MS and FPIA) a residual error for each assay was incorporated 
in the model. The model improved by adding an additive error to the FPIA data. This 
overestimation of FPIA was expected as investigated previously [27].
The structural pharmacokinetic model of tacrolimus indicated an apparent clearance 
(CL/F) of 5.7 L/h, with the bioavailability term fixed to 0.23, an apparent central 
distribution volume (Vc/F) of 20.5 L and an apparent peripheral distribution volume of 
which was fixed to 500 L. The absorption rate constant was 0.55 h-1. Inter-compartmental 
clearance was 17.2 L/h and lag time was 0.809 h. Inter-occasion variability was estimated 
for the fixed bioavailability term. The pharmacokinetic data of cyclosporine showed inter-
individual variability in CL/F of 23.5% and inter-occasion variability (22.7%). Everolimus 
data revealed an inter-individual variability in CL/F of 28.8% and inter-occasion variability 
(26.4%). Tacrolimus showed considerably higher inter-individual variability in CL/F of 
42.2% and inter-occasion variability (35.5%). 
Covariate analysis
Pharmacogenetics 
In table 3 the summary of the univariate pharmacogenetic covariate analysis is presented. 
CYP3A4*22 was significantly associated with cyclosporine CL/F and patients who carried 
at least one decreased activity allele in CYP3A4*22 had a 15% lower clearance compared 
to non-carriers. CYP3A combination showed a significant effect; C1, C2 and C3 showed 
lower clearance compared to C4 (-16%, -2% and -12% respectively. 
Everolimus pharmacokinetics did not reveal a significant relation with CYP3A5*3, 
CYP3A4*22 nor the CYP3A genotype combination. For tacrolimus CYP3A5*3 was 
significantly associated with tacrolimus CL/F. Carriers of at least one CYP3A5*1 allele 
had 53% higher clearance compared to non-carriers. In contrast, CYP3A4*22 as covariate 
on CL/F did not result in a significant objective function drop (P=0.218). Although not 
significant a trend of 16% lower tacrolimus clearance was observed for CYP3A4*22 allele 
carriers. CYP3A combination showed a significant effect on tacrolimus clearance.
157Effect of CYP3A4*22, CYP3A5*3 and CYP3A combined genotypes on cyclosporine, 












































































































































































































































































































































































































































































































































































































































































































































































Figure 2: Box plots representing the average cyclosporine, everolimus, and tacrolimus apparent clearance (l/h) 
of the different genotype groups with error bars and the number of patients in each group. CYP3A4 (*1/*1 = 
CYP3A4*22 noncarriers, *1/*22 or *22/*22 = CYP3A4*22 carriers, NG = not genotyped), CYP3A5 (*1/*3 or 
*1/*1 = CYP3A5*1 carriers, *3/*3 = CYP3A5*1 noncarriers, NG = not genotyped), and CYP3A cluster: (C1: 
CYP3A5*3/*3 and CYP3A4*22/*22 or CYP3A4*1/*22, C2: CYP3A5*3/*3 and CYP3A4*1/*1, C3: CYP3A5*1/*1 
or CYP3A5*1/*3 and CYP3A4*22/*22 or CYP3A4*1/*22, and C4: CYP3A5*1/*1 or CYP3A5*1/*3 and 
CYP3A4*1/*1, NG = not genotyped). *P < 0.01. Apparent clearance was calculated using the base model.
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C1 showed C2 and C3 showed lower clearance compared to C4 (-47%, -33% and -3% 
respectively). Although significant, the genetic covariates explained variability in 
clearance to a limited degree. In figure 2 boxplots of clearance vs genotype are presented 
for cyclosporine, everolimus and tacrolimus and also show the significant variability 
within the genotype groups. 
Demographics
The demographic covariates that showed a possible relation with the pharmacokinetics 
of the drugs in the diagnostic plots were evaluated in the covariate analysis. Univariate 
analysis (P<0.05) on cyclosporine showed significant associations for the following 
demographic covariates: Bodyweight (BW) on CL/F and Vc/F, prednisolon dose ≥ 20 mg 
on Ka and F for cyclosporine, ideal body weight (IBW) on Vc/F and hematocrit on Cl/F 
for everolimus. Significant demographic covariates for tacrolimus were prednisolone dose 
≥ 25 mg on F and hematocrit on CL/F. The remaining demographic covariates such as 
ethnicity and other co-medication that were evaluated in this study were not significant 
on CL/F, Vc/F nor Ka.
After the forward inclusion and backward elimination step the following covariates 
remained significant (P < 0.01): Cyclosporine: BW on CL/F and Vc/F, prednisolon dose ≥ 
20 mg on Ka and F (better model fit and objective function drop compared to prednisolon 
dose on CL/F) and CYP3A4*22 on CL/F. Inter-individual variability of CL/F decreased 
from 23.5% to 22.6%. In Supplementary Table IV, all significant covariates improving 
model fit together with their effects on observed variability are presented for cyclosporine, 
everolimus and tacrolimus. Everolimus: IBW centered on the population median as 
exponential function on Vc/F improved the model reduced the random variability 
between individuals in Vc/F by 12%. Hematocrit was lost in de forward elimination step 
(P>0.01) and was therefore not incorporated in the final model. Significant covariates for 
tacrolimus were found in prednisolone dose ≥ 25 on F (higher objective function drop 
compared to prednisolon dose on CL/F), CYP3A5*3 and hematocrit on tacrolimus CL/F. 
Incorporation of these covariates decreased the inter-individual variability of CL/F from 
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IBW, Ideal Body Weight ; HTC, hematocrit; CYP, cytochrome P450; DDPR, daily dose prednisolone; IIV, inter-
individual variability; IOV, inter-occasion variability; Ka, Absorption rate constant; F1, Bioavailability; CL, 
clearance; Vc, distribution volume of the central compartment; Q, intercompartmental clearance; Lagtime, 
lagtime of absorption. Shr. (%), shrinkage (%). Expl Var (%); Percentage explained of total variability.
The population pharmacokinetic parameters obtained with the base and final models are 
presented in Table 4. Evaluation of the precision of the pharmacokinetic parameters of all 
three models was performed with 1000 bootstrap replications. The percentage of successful 
runs was 99% for cyclosporine, 82% for everolimus and 96% for tacrolimus. Moreover, the 
parameter estimates of the non-successful runs were analysed and did not deviate from the 
parameter estimates of the successful runs. The mean values for all fixed effect parameters 
were within 15% of those obtained by the final model, indicating good reliability. Since 
different dosages were used during the study the performance of the model was evaluated 
with a predictive corrected visual predictive check [34]. Predictive and observed intervals 
(10%, 90% and median) are almost identical showing good predictive performance of the 
final models (Figure 3).
Figure 3: Prediction-corrected visual predictive checks with 80% prediction interval of cyclosporine, everolimus, 
and tacrolimus. The observed concentrations are shown as solid circles. The solid lines with open circles represent 
the observation intervals. The solid lines represent the prediction interval. The shaded areas around the 
prediction intervals represent the 95% confidence interval around each of the prediction interval.
Discussion
This is the first comprehensive study investigating the influence of CYP3A4*22, CYP3A5*3 
variant alleles and its combined clusters on the pharmacokinetics of the three main kidney 
transplant immunosuppressive drugs cyclosporine, everolimus and tacrolimus. This study 
demonstrates that carriership of the CYP3A4*22 allele is significantly associated with 
a decreased cyclosporine clearance. Carriers of the CYP3A4*22 allele showed 15% lower 
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cyclosporine clearance as compared to non-carriers. Moreover CYP3A genotype clusters 
were significantly associated with cyclosporine and tacrolimus clearance but not with 
everolimus clearance. Finally this study also demonstrates that patients carrying at least one 
CYP3A5*1 allele have on average 53% higher tacrolimus clearance compared to noncarriers. 
Cyclosporine, everolimus and tacrolimus are primarily eliminated by CYP3A enzymes 
[5–7,35] and as shown before in in-vitro and in-vivo studies, CYP3A4 is involved in their 
pharmacokinetics [6,36,37]. CYP3A4 is most likely predominant in cyclosporine and 
everolimus metabolic clearance and CYP3A5 contributes more significantly to tacrolimus 
metabolic clearance compared with CYP3A4 [6,7]. In contrast to CYP3A5, CYP3A4 lacked 
a reliable genetic marker for prediction of CYP3A4 expression which was suitable for dosing 
adjustments [38,39], however CYP3A4*22 was recently marked as a potential reliable 
marker [16,17]. In contrast, as part of our analysis only a significant influence of CYP3A4*22 
on cyclosporine pharmacokinetics was found, but a trend was also seen in tacrolimus 
(16% lower clearance (95%CI: -47 to 14%)) and everolimus pharmacokinetics (7% lower 
clearance (95%CI: -23 to 9%)). This effect is not high enough to justify dose modification 
based on CYP3A4*22. In clinical practice only an effect of at least 20% on clearance will lead 
to dose adjustments, since these drugs also possess a considerable degree of intra-individual 
variability. Since the clinical studies from which all data was derived were not primarily 
designed to identify a genotype effect and the fact that we found no clinically relevant 
genotype effect for CYP3A4*22 we had to confirm afterwards that our study had enough 
power. Therefore we performed a posterior power calculation using the stochastic simulation 
and estimation tool of the PsN toolkit to determine the power (95% and 99% confidence) 
of our study to find a clinically relevant genotype effect (at least 20%) on cyclosporine, 
everolimus and tacrolimus pharmacokinetics [40,41]. With the most unfavorable genotype 
distribution (CYP3A4*22) and the least amount of data (tacrolimus) we found a power of 
95% (α=0.05) and 91% (α=0.01) in detecting a clinically relevant genotype (at least 20%) 
effect. It is therefore highly unlikely that our analysis was underpowered and missed a 
clinically relevant effect of the investigated genotypes due to limited sample size. 
In contrast to our findings the studies of Elens et al. and Gijsen et al. [16,17,42] showed 
that CYP4A4*22 allele carriers required up to 30% lower tacrolimus doses compared to 
CYP3A4*1/*1 to reach target trough concentration. However these exploratory findings 
have not been confirmed by another research group. Moreover, more recently, Santoro et 
al. [12] presented a study in 140 renal transplant patients showing that independent effects 
of CYP3A4*22 on tacrolimus dose requirements could not be verified. The studies of Elens 
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et al. [16,42] had some limitations: the data were not corrected for corticosteroid use or 
hematocrit levels. Corticosteroid and hematocrit levels are known to influence tacrolimus 
exposure [13,43] and could therefore have influenced their results. The study of Gijsen et 
al. [17] performed on a small dataset has the limitation that they could not correct their 
results for co-medication. Both studies [16,17] only used trough levels in their analysis, 
which do not give a full insight in pharmacokinetics. The more recent study of Elens et 
al. [42] in contrast used an additional 59 whole PK curves to support their conclusion, 
however since they were collected only on one occasion, intra-individual variability could 
not be assessed. To investigate whether shrinkage could have been the cause of the lack 
of significance of the CYP3A4*22 effect in this study, we also performed the univariate 
genetic covariate analysis with only the first PK profiles to be able to compare the results 
in more details with Elens et al. (Supplementary Table V). 
The results were the same as with the complete dataset, so therefore the results found in the 
study of Elens et al. [42] could not be replicated in our study. In another study by Elens et al. 
[18] no significant effect was found for cyclosporine trough concentrations and CYP3A4*22 
carriership. Our analysis was based on an extensive amount of data consisting of area-under-
the-curves (AUCs). Moreover a wide range of factors possibly influencing pharmacokinetics 
including demographic factors and co-medication was also investigated. 
The difference in tacrolimus clearance between CYP3A5*1 carriers and non-carriers found 
in the current analysis was similar to what was published previously [11,13]. We confirmed 
with our study that dosing adjustments based on CYP3A5*3 could be indicated to quickly 
reach target exposure, however the variability explained by CYP3A5*3 is limited and the 
variability within the CYP3A5 genotype groups remains significant and therefore close 
TDM remains essential. The absence of a clinically relevant influence of CYP3A5*3 on 
cyclosporine and everolimus pharmacokinetics is in line with previous studies [39,44,45].
Using CYP3A combined genotype of CYP3A4 and CYP3A5 as a predictor for cyclosporine, 
everolimus or tacrolimus clearance does not seem to be an improvement compared to 
the individual polymorphisms. As shown in the results, the combined analysis did not 
further improve identification groups of slow metabolizers, intermediate metabolizers 
and extensive metabolizers. For cyclosporine the differences in average clearance between 
the groups remain less than 16%. For tacrolimus a difference of 14% is introduced for 
non-carriers of the CYP3A5*1 allele by the effect of CYP3A4*22 carriership which makes 
a further differentiation unnecessary.
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Supplementary Table V: Model parameter estimates and genetic covariate testing using only the first PK profiles.









Value 95% CI ΔOF P value
CL/F 6.08 5          
 CYP3A5*3 on CL/F       56% 19 to 93% -14.847 <0.01
 CYP3A4*22 on CL/F       -13% -53 to 27% -0.611 0.43
 CYP3ACOMBI on CL/F           -16.059 <0.01
C1       -46% -77 to -15%    
C2       -34% -51 to -18%    
C3       7% -42 to 56%    
C4       0% -19 to 14 %    
F (fixed) 0.23            
Vc/F (L) 28.5            
Q/F (L/h) 19.6 9          
Vp/F (L) (fixed) 500 25          
ka (h-1) 0.621 15          
Lagtime              
Interindividual variability              
 IIV CL/F (CV%) 49 7 1        
 IIV Vc/F (CV%) 142.8 11 18        
Random residual variability              
 σ1 (proportional error) 0.0301 7 13        
CYP, cytochrome P450; IIV, inter-individual variability; IOV, inter-occasion variability; Ka, Absorption 
rate constant; F1, Bioavailability; CL, clearance; Vc, distribution volume of the central compartment; 
Q, intercompartmental clearance; Lagtime, lagtime of absorption, Shr. (%), shrinkage (%),95% CI; 95% 
Confidence Interval. 
Up to now the only suggested clinically relevant polymorphism in CYP3A enzymes 
relevant for kidney transplantation are CYP3A5*3 and CYP3A5*6 for tacrolimus which 
are primarily found in Africans and have low allelic frequencies in the Caucasian 
population. CYP3A5*6 was left out of this analysis because of too low allele frequency 
(<6%). CYP3A4*22 is able to predict CYP3A4 activity however the clinical relevancy 
seems to be limited. The search for a reliable and clinically relevant predictive biomarker 
for CYP3A4 is still open although CYP3A4 phenotyping shows more promising results as 
recently published by de Jonge et al. [15]. 
The demographic covariates that were identified in this study have been reported in 
previous studies [11,20,46,47]. The clinical relevancy of the different identified covariates 
is limited since the explained variability by the individual covariates did not exceed 12%. 
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The effect of prednisolone dose on cyclosporine and tacrolimus bioavailability (high dose, 
lower bioavailability) can be explained by CYP3A induction in the intestine and has been 
reported before [11,47,48]. The cut off values were chosen based on literature [11,47,48] 
and highest objective function drop. The pharmacokinetic parameter estimates of the 
three models were in agreement with those found in previous studies [20,46,49] when 
taking the effect of differences in fixed bioavailability terms, patient population and TDM 
assays into account. In contrast to a number of other studies we fixed the bioavailability 
term to 0.5 for cyclosporine and 0.23 for tacrolimus instead of 1, which leads to an 
apparent clearance twice lower for cyclosporine and 4.3 times lower for tacrolimus. The 
variability in pharmacokinetics was high in tacrolimus, although as known from literature 
[1] around 20% of this could be explained by the fact that the majority of the data used in 
the current analysis was collected within two weeks after transplantation. Unstable renal 
transplant patient show much higher variability in pharmacokinetics [1]. 
Cyclosporine absorption was best described with a transit compartment as we previously 
described [47]. As found in our smaller study Ideal Body Weight significantly correlates 
with Vc/F of everolimus [20]. Since everolimus is primarily partitioned into red blood 
cells and 75% of the plasma fraction is bound to plasma proteins this relationship can 
be physiologically explained since length and sex are incorporated in the ideal weight 
formula [3,50]. The significant effect of hematocrit on everolimus clearance in the 
univariate covariate analysis could also be explained by same mechanism. Ethnicity 
could not be identified as a covariate on clearance of everolimus or cyclosporine as was 
found previously by Kovarik et al. [51] and Hesselink et al. [46]. This difference could be 
explained by the lack of black patients in our cohort. Although theoretically plausible 
we did not find an effect of concomitant medication such as statins, calcium antagonists, 
sulfamethoxazole/trimethoprim or proton pump inhibitors on CL/F. This is in accordance 
with what has been previously been described in literature [9,51]. Co-medications known 
to have an potent effect on the pharmacokinetics of the drugs were avoided for safety 
reasons [22]. The remaining variability in clearance between patients of our final model 
was 22.6% for cyclosporine, 28.8% for everolimus and 38.9% for tacrolimus which could 
reflect the wide inter-individual variability in CYP3A4 expression [52].
Our study has some limitations: Fatty food intake, non-adherence or diarrhea could not 
be quantified, although these factors could contribute to the observed variability since 
previously published studies reported food interactions with the investigated drugs 
[9,10,53]. Furthermore, Ka of everolimus was difficult to estimate since the dataset had low 
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number blood samples collected between 0 and 1 hour after dose intake, but is unlikely 
this would have influenced the genotype covariate analysis on clearance.
In conclusion, CYP3A4*22 does not influence cyclosporine, everolimus or tacrolimus 
pharmacokinetics to a clinically relevant extend. This study confirmed that CYP3A5*3 is 
only suitable as a predictive marker for tacrolimus clearance but close TDM remains essential 
due to the remaining variability between patients with the same genotype. The CYP3A4 
and CYP3A5 combined genotypes do not further improve the predictive performance 
compared to the predictive performance of the polymorphisms alone. Therefore the newly 
discovered CYP3A4*22 or CYP3A combined genotypes are not indicative to be used for 
dose adjustments in clinical practice to further improve immunosuppressive therapy of 
cyclosporine, tacrolimus or everolimus in the investigated patient population.
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The effect of POR*28, CYP3A5*3 
and their combined genotypes 
on everolimus pharmacokinetics 
in renal transplant recipients
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176 Chapter 8
In our recent article “Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined 
Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal 
Transplantation” published in this journal [1] we reported that there is no clinically relevant 
effect of CYP3A5*3, and CYP3A combined genotypes on everolimus pharmacokinetics. 
Recently, relationships between POR polymorphisms and tacrolimus pharmacokinetics 
in renal transplantation have been reported [2,3]. These publications showed that the 
POR*28 allele was associated with increased in vivo CYP3A5 activity for tacrolimus 
metabolism in CYP3A5*1 allele carriers. To investigate whether the effect of POR*28 
and the combined effect of POR*28 and CYP3A5*3 had a clinically relevant effect on 
everolimus pharmacokinetics we genotyped all patients for POR*28. Hepatic microsomal 
P450 enzymes require P450 oxidoreductase (POR). Polymorphisms in the gene encoding 
POR have been linked to altered CYP activity and they appear to be substrate specific 
[4], however this relationship was absent for sirolimus pharmacokinetics [5]. Our stable 
renal transplant recipient cohort were genotyped for CYP3A5*3 (rs776746) and POR*28 
(rs1057868) with Pyrosequencer 96MA (Isogen, IJsselstein, The Netherlands). All allele 
frequencies were in Hardy–Weinberg equilibrium and distribution corresponded with 
previous findings [2,3,5]. Univariate covariate analysis using population pharmacokinetic 
methodology showed no significant association between apparent everolimus clearance 
and POR*28, CYP3A5*3 nor POR*28 & CYP3A5*3 combined. Clinically irrelevant 
trends were observed for POR*28 (-4% for *28 allele carriers vs non-carriers), CYP3A5*3 
(+12% for *1 allele carriers vs non-carriers) and their combination (+11% for *1 allele 
carriers of CYP3A5*3 with at least one *28 allele of POR vs non-carriers). Moreover 
,high variability was seen within the genotype groups as shown in Figure 1. In contrast 
to what was found for tacrolimus by Elens et al. and de Jonge et al. [2,3] CYP3A5*1 allele 
carriers that were carriers of at least 1 POR*28 allele showed no clinically relevant effect on 
everolimus pharmacokinetics. Our results are similar to what was found for sirolimus by 
Woillard et al. [5]. In summary these data show that in contrast to tacrolimus but just like 
sirolimus, POR*28, or the combination of combination of POR*28 & CYP3A5*3 appears 
not to be suitable as a biomarker to improve prediction of everolimus exposure in renal 
transplantation recipients on everolimus and prednisolone duo therapy. 
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Figure 1: Box plots representing the average everolimus apparent clearance (L/hour) of the different genotype 
groups with error bars and the number of patients in each group. POR (*1/*1 = POR*28 non-carriers, *1/*28 
or *28/*28 = POR*28 carriers, NG = not genotyped), CYP3A5 (*1/*3 or *1/*1 = CYP3A5*1 carriers, *3/*3 = 
CYP3A5*1 non-carriers, NG = not genotyped), and POR & CYP3A5 combined: (C1: CYP3A5*3/*3 and POR*1/*1 
or POR*1/*28, C2: CYP3A5*3/*3 and POR*28/*28, C3: CYP3A5*1/*1 or CYP3A5*1/*3 and POR*1/1, and C4: 
CYP3A5*1/*1 or CYP3A5*1/*3 and POR*1/*28 or POR*28/*28, NG = not genotyped). Apparent clearance was 
calculated using the base model.
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Abstract
Besides traditional immunological risk factors, pharmacological factors such as 
pharmacogenetics and drug exposure may serve as predictive biomarkers for delayed graft 
function (DGF), acute rejection (AR) and/or subclinical rejection (SCR) in renal transplant 
recipients on calcineurin-inhibitor based immunosuppression. Adult renal transplant 
recipients (n=361), receiving basiliximab prophylaxis and triple therapy including 
concentration controlled cyclosporine A (CsA), mycophenolate and prednisolone were 
followed until the first 6 months after transplantation. During this period the incidence of 
DGF and AR episodes were documented as well as the prevalence of SCR in and at 6 months 
in surveillance biopsies. Demographic, transplant related factors, and pharmacological 
factors, including systemic drug exposure and pharmacogenetic data (ABCB1, CYP3A5, 
CYP2C8, NR1I2, PPP3CA and PPP3CB polymorphisms) were analyzed in relation to the 
occurrence of DGF, time to first AR and prevalence of SCR at month 6. Fourteen percent 
of the patients experienced at least one clinical rejection episode and only DGF showed 
an significant effect on the time to AR. As expected the incidence of DGF correlated with 
a deceased donor kidney transplant (27% vs 0.6% of living donors). 6 month protocol 
biopsies biopsies were obtained for 275 transplant recipients and 50 (18%) showed 
SCR. A deceased donor kidney and an acute rejection history were the most important 
determinants for SCR, resulting in a 52% risk of SCR at 6 months (versus 11% on average). 
Along with female sex and carrying ABCB1 TTT-haplotype, these two factors were also 
related to a higher drop-out (i.e. no protocol biopsy) frequency with an overall drop-out 
of 24%. In a subanalysis of the patients with AR, those treated with rejection treatment 
including antithymocyte globulin (ATG) significantly less frequent SCR was found in 
the 6-month biopsy (13% vs 50%). Transplant related factors were the most important 
determinants of DGF, AR and SCR within this AUC-controlled population on CsA-based 
therapy and rejection treatment with depleting antibodies effectively prevented SCR in 6 
month surveillance biopsies.
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Introduction 
Over the past decades acute rejection (AR) rates have decreased dramatically, mainly due 
to calcineurin inhibitor (CNI) based immunosuppressive regimens. One of the dominant 
risk factors , previously identified for AR is delayed graft function (DGF) which is highly 
related to transplant related factors such as vulnerability of the allograft and/or prolonged 
preservation times [1]. Clinical episodes of AR have previously been identified as a risk 
factor for subclinical rejection (SCR) [2]. SCR is by definition histologically defined acute 
rejection and has been associated with interstitial fibrosis and tubular atrophy and with 
time progressive deterioration of renal function and inferior graft survival. Despite the 
current standard relative low acute rejection rates in the first year after transplantation 
with current standards for immunosuppressive therapy, long-term outcome after renal 
transplantation has not improved accordingly [3]. Protocol biopsies two years after 
transplantation have shown high prevalence of chronic allograft nephropathy (CAN), 
defined by renal interstitial fibrosis and tubular atrophy (IF/TA), in CNI treated patients 
[4]. The causes of IF/TA are multi-factorial and determined by transplantation related 
factors including donor organ quality, ischemic/reperfusion injury, acute rejection and/or 
CNI toxicity. Subclinical rejection has been associated with IF/TA in subsequent biopsies 
and inadequate immune suppression and/or tapering may turn out to be a key factor 
in persistent or recurrent (chronic) cellular rejection and/or humoral rejection, finally 
leading to IF/TA and progressive loss of renal function [5–7]. 
SCR is defined by (cortical) tubulo-interstitial mononuclear cell infiltration without 
detectable functional renal deterioration. If graded according to Banff, approximately 
two-third can be graded as borderline and the remainder as grade-I rejection and vascular 
rejection is seen in only a few cases. The prevalence of SCR decreases over time after 
transplantation [6] largely depending on the intensity of clinical immunosuppression 
[8–11] and the use and type of induction therapy [12,13]. This is illustrated by a decrease 
in SCR at 3 months post-transplantation from 63% in the era of cyclosporine A (CsA)/
azathioprine, towards only 5% with tacrolimus/mycophenolate in otherwise comparable 
groups of transplant recipients [7]. 
Besides the choice in immunosuppressive therapy, a prior acute rejection episode, 
histoincompatibility, degree of sensitization and donor age have been reported as risk 
factors for SCR [8,9,14,15]. The role of pharmacological factors, such as drug exposure 
and pharmacogenetic parameters for the occurrence of SCR is still unclear. It has 
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previously been suggested that optimal CNI-exposure may prevent SCR and progressive 
renal dysfunction [11]. In this context variability in the genes coding for the metabolic 
cytochrome enzymes (i.e. CYP3A5 and CYP3A4), transporter proteins (i.e. ABCB1), and 
the nuclear factor pregnane-X-receptor (NR1I2) may be of interest. While there are no 
clear relationships between single nucleotide polymorphisms (SNPs) in ABCB1 and CsA 
exposure [16], associations between genetic variants in ABCB1 and graft function and 
graft survival have been described [17–20]. Transplant recipients on CsA therapy carrying 
T-allelic variants in ABCB1 C3435T or G2677T had a 3-fold higher risk for delayed graft 
function and a lower glomerular filtration rate at study end [18], while ABCB1 2677T allele 
carriers had a 3-fold higher odds of developing acute rejection [19]. Furthermore, graft 
survival was not altered in renal transplant recipients on CsA therapy, when either these 
recipients or their donors were carriers of the CYP3A5*1 allele [21], but these recipients 
were found to have a survival benefit [22]. A metabolic enzyme of potential relevance 
to CsA therapy could be CYP2C8. The CYP2C8*3 allele was related to a higher risk of 
developing renal toxicity in liver transplant recipients on CNIs, predominantly tacrolimus 
[23]. But, to the best of our knowledge no pharmacogenetic risk factors for SCR have been 
reported for renal transplant recipients on CsA therapy.
Genetic variability in genes coding for calcineurin, the target enzyme of CsA, in theory 
could alter the susceptibility for CsA. Polymorphisms in these genes could potentially be 
related to AR and/or SCR [16]. Two different calcineurin isoforms exist; with the alpha-
subtype predominantly expressed in the kidney and the beta-subtype by immune cells 
(lymphocytes). These calcineurin isoforms are encoded by two different genes, PPP3CA 
and PPP3CB respectively. Therefore, we hypothesize that variability in PPP3CB gene of the 
recipient, may be related to AR and/or SCR. 
For the current evaluation we selected a cohort of 361 transplant recipients, who entered 
the run-in phase of a multicenter, prospective study. These patients received quadruple 
immunosuppressive therapy with basiliximab induction and concentration-controlled 
CsA, mycophenolic acid and prednisolone maintenance therapy. A scheduled biopsy was 
performed at six months after transplantation to exclude SCR before patients were allowed 
to enter their assigned treatment arm during the second phase of the study. To identify 
risk factors for DGF, AR and SCR generally accepted risk factors were combined with 
demographic factors and pharmacological parameters. The principal aim was to identify the 
contribution of CsA exposure and/or genetic variability in the genes coding for PPP3CA, 
PPP3CB, ABCB1, CYP3A5, CYP2C8 and NR1I2 to the risk for DGF, AR and ultimately SCR. 
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Patients & Methods
Study design and patient population
Renal transplant recipients (n=361) participating in the run-in phase for a multicenter, 
randomized prospective trial aiming to minimize immunosuppression starting 6 
months after transplantation [24]. Patients were treated in the Academic Medical Center 
Amsterdam (n=137), the University Medical Center Groningen (n=126) and the Leiden 
University Medical Center (n=98). Patients were aged between 18 and 70 years receiving 
a first or second kidney graft from either a deceased or living kidney donor. The following 
exclusion criteria were applied: HLA-identical sibling donor, third or fourth transplant, 
current or historical panel reactive antibodies (> 50%), female patients unwilling to use 
adequate contraception during the study and a cholesterol level higher than 8.5 mmol/L 
despite the use of lipid lowering drugs. Medical ethics approval was provided by the review 
boards of all participating centers and written informed consent was obtained from each 
patient before study entry. 
The immunosuppressive regimen up to 6 months after transplantation consisted of 
induction therapy with 2 doses of 20 mg basiliximab (Simulect®) intravenously before 
transplantation and on day 4, rapidly tapered prednisolone dose (50 mg b.i.d. intravenous 
tapered to 10 mg once daily oral prednisolone at day 4), twice daily 720 mg mycophenolate 
sodium (Myfortic®) and twice daily CsA (Neoral®). CsA was initially dosed 4 mg/kg b.i.d 
and subsequently adjusted to reach a predefined whole blood target Area Under the 
blood-concentration versus time Curve (AUC0-12h) of 5400 µg*h/L the first 6 weeks and 
3250 µg*h/L thereafter.
Therapeutic drug monitoring was performed on four time points, the first visit one week 
after transplantation, followed by 6 weeks, 3 months and 6 months at the time of the 
protocol biopsy, just prior to entering the second phase of the study. Patients were seen in 
the outpatient clinic in between these study visits. 
To guide safe reduction of immunosuppressive drugs a protocol biopsy was performed 
at 6 months after transplantation and examined for histological signs of acute rejection 
according to the Banff 2005 grading system. The biopsy scores used in this study were not 
divided into borderline changes or at least grade IA rejection. We considered this justified 
by the fact that these criteria are based on for-cause biopsies and not protocol biopsies. In 
addition, especially for borderline changes, there may be issues related to sampling error 
and inter-observer variability [25–27]. Furthermore serum creatinine is not only a poor 
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marker for changes in renal function [28], also the definition for stable renal function in 
different studies was not strict and ranged from 10 to 25% difference in creatinine relative 
to baseline. 
Patient characteristics (Table 1) considered relevant for this study were: demographics 
(age, body weight, length, sex and age category (only for time to event analysis (1:<46 
year, 2: 46 – 64 years and 3:>64 years) underlying disease, transplantation characteristics 
(donor type, deceased donation type, donor age, HLA-matching (class I-A,-B, class II-
DR), cold-ischemic time, end of study reason, acute rejection episode and the time of 
this event after transplantation, information of the scheduled biopsy at 6 months after 
transplantation, serum creatinin concentration, CsA exposure and pharmacokinetic 
parameters and finally pharmacogenetic information.
Therapeutic drug monitoring & Pharmacokinetic modeling
To determine CsA exposure (AUC0-12h) routine whole blood samples (EDTA-blood) were 
obtained from transplant candidates just before (trough) and 1, 2, 3, 4, 5 and 6 hours after 
drug administration on official study visits. In case the exposure was determined on other 
visits to the outpatient clinic, samples were drawn just before and 2 and 3 hours after 
drug administration. Whole blood concentrations were determined with fluorescence 
polarization immunoassay (Axsym®, Abbott Laboratories) in the laboratories of the three 
participating centers. 
Pharmacokinetic parameters of interest were AUC0-12h, CsA clearance and CsA dose. 
These pharmacokinetic parameters were derived using a previously published population 
pharmacokinetic model for CsA [29]. 
Pharmacogenetics
Renal transplant recipients (n=302) were genotyped for genetic variants in the relevant 
genes PPP3CA and PPP3CB and in the genes ABCB1, CYP3A5, CYP3A4, CYP2C8 and 
NR1I2. Primarily due to early drop-out of patients or low quality of the collected material, 
genetic information could not be obtained from all participants. 
PPP3CA and PPP3CB SNPs were selected based on tagging SNPs for PPP3CA and 
PPP3CB haplotypes. Haploblocks in PPP3CA and PPP3CB were set using HAPMAP CEU 
population data covering variability in the gene area, without extra basepairs, with the 
haploblock definition of Gabriel et al. in Haploview [24]. Haploblocks were constructed 
for the CEU population since 86% of our population of transplant recipients is Caucausian 
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(Table 1). Next, it was verified whether the selected SNPs were able to reflect haplotype 
variability in other populations (Japanese, African-American). The SNPs that best 
reflected genetic variability among all ethnic groups consisted of 5 SNPs for the PPP3CA 
gene (rs13146281, rs7665292, rs2201677, rs10031159, rs13117493) and 3 SNPs for the 
gene PPP3CB (rs12644, rs12775630, rs3763679). 
In addition, four single SNPs in ABCB1 were determined, in the promoter region T-129C 
(rs3213619) and a haplotype consisting of T3435C (rs1045642), C1236T (rs1128503) 
and G2677T (rs2032582). For the CsA metabolic pathway were determined: CYP3A5*1 
(rs776746), CYP3A5*6 (rs10264272) CYP3A4*22 (35599367) and CYP2C8*3, the 
latter using 2 SNPs (rs10509681, rs11572080). Genetic variability in the nuclear factor 
pregnane-X-receptor (NR1I2) was based on 2 SNPs, A+7635G (rs6785049) and G-24113A 
(rs2276706). 
DNA was isolated from EDTA-blood samples with MagNA Pure Compact DNA Isolation 
kit (Roche Diagnostics, Almere, The Netherlands). DNA concentrations were quantified 
on the nanodrop (Isogen, IJsselstein, The Netherlands). Taqman assays were obtained from 
Applied Biosystems (Applied Biosystems, Nieuwerkerk aan den IJssel, The Netherlands). 
SNP genotyping was performed with the LightCycler 480 II Real-Time PCR System 
(Roche Diagnostics, Almere, The Netherlands). All assays were performed according to 
protocols provided by the manufacturer. Genotyping was performed in a blinded fashion, 
without knowledge of the clinical data. As a quality control, 10% of the patient samples en 
genotype assays were analyzed in duplicate. As negative controls water was used. Overall, 
no inconsistencies in genotypes were observed. 
Genotype distributions are presented in Table 3. The success rates for all genotyping 
analyses were higher than 97%. Genotype frequencies for 15 of 19 SNPs were in Hardy-
Weinberg equilibrium (P >0.05), while CYP3A5 rs776746, NR1I2 rs2276706 and PPP3CA 
rs7665292, PPP3CB rs12644 were not in Hardy-Weinberg equilibrium. However, these 
genotype frequencies are similar to frequencies for Caucasians in previous reports and 
similar to the reported frequencies in the NCBI dbSNP database. Therefore, data were 
allowed for analysis.
Haplotypes in our population were set with gPLINK (http://pngu.mgh.harvard.edu/purcell/
plink/), whereas no phase uncertainty in the defined haploblocks and haplotypes (Rh2> 
0.98) was seen. The haploblock definition for ABCB1 included 1236C>T, 2677G>A/T, 
and 3435C>T (Table 2), for PPP3CA gene it included rs13146281, rs7665292, rs2201677, 




The binary endpoint for delayed graft function (yes/no) was analyzed with a proportional 
odd model. Dropout was not included in the analysis since DGF only occurred directly 
after transplantation.
Subclinical rejection
The binary endpoint for subclinical rejection (yes/no) was analyzed with a proportional 
odd model. Patients that dropped-out during the first 6 months were included in the 
analysis to avoid over-prediction of subclinical rejection. The base model for patients with 
a biopsy at 6 months was defined by:
Y = (1-Pdo)*(PSCR*SCR + (1-PSCR)*(1-SCR))
With Y the likelihood of the model, Pdo the probability of dropping out and PSCR as the 
probability of SCR. The variable SCR is a binary outcome with SCR=1 if SCR is present 
and SCR=0 if SCR is absent. For individuals with a premature study-end (drop-out), the 
likelihood of the model is Y = Pdo. For the analysis of rejection treatment on the development 
of SCR a sub analysis was performed on the 50 patients who had experienced an acute 
rejection in the first 6 months. The model parameters for the analysis of DGF and SCR 
were estimated by maximizing its likelihood using the Laplacian method. Throughout 
the model building process, an altered model was chosen over a precursor model if the 
difference in the objective function (OF), defined as -2 times the log-likelihood, was 
>3.84 (P < 0.05, with 1 degree of freedom, assuming χ2 distribution) . All pre-selected 
covariates were evaluated one by one in the base model. Subsequently, selected covariate 
relationships were evaluated by forward inclusion and backward deletion procedure.
Acute Rejection – Time To Event 
The time at which first acute allograft rejection occurred was recorded and for the patients 
who did not experience an acute rejection the time to dropout or end of study was recorded 
and treated as a censored observation. The time to the acute rejection was analyzed using 
a parametric survival model. The model was developed in two steps: First a base model 
was built to describe the time to first acute rejection with taking the drop out into account 
(right-censoring). Secondly, it was investigated if covariates could influence the time to 
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first acute rejection. To describe the time to the first acute allograft rejection, a parametric 
survival function according to the following equation (equation 1) was used:
 (1)
With h(t) as the hazard, and S(t) as the survival, which is a function of the cumulative 
hazard within the time interval between time zero and time t describing the probability 
of not experiencing an acute rejection (“surviving”) within this interval. The base model 
was developed by exploring different functions for the hazard h(t), varying from time 
independent constant hazard functions (e.g. exponential) to more complex functions 
such as Weibull, Gompertz and log-logistic distributions. Of the preselected covariates 
potential covariates were selected after a stepwise approach: In a first step, a graphical 
analysis was performed to select potential covariates that could be investigated in a full 
covariate analysis. To this end for each covariate Kaplan-Meier plots, stratified per group, 
were inspected visually. In case of continuous covariates, data was divided in quartiles, 
resulting in equal number of subjects in each quartile. In a second step, based on the 
graphical analysis, covariates were selected to be carried forward to the single addition 
step. The selected covariates were added to the model one-by-one, and were retained in 
the model if the drop in OF > 6.63 (p<0.01, assuming χ²-distribution). In a third step, 
forward inclusion, the covariates that were selected were added one after each other in 
ranking order of significance. The covariates were retained in the model if drop in OF 
was larger than 6.63 (p<0.01). In a fourth step, backward deletion, each covariate that was 
included in the full model, based on the forward inclusion step, was removed. This step 
was repeated until each remaining covariate caused an increase of at least 10.8 points in 
OF. The covariates were retained in the model if increase in OF >10.8 (p<0.001) to correct 
for multiple testing. The nonlinear mixed effect modelling package NONMEM (v7.2.1, 
Icon Development Solutions, Ellicott City, MD) was used for modelling, using PsN toolkit 
3.4.2 and Piranã version 2.8.0 as modelling environment [30]. Results were analysed using 
statistical software package R (v2.15.2) and RStudio (v0.97.248; Boston, MA, USA). 
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Results
Patient characteristics are provided in Table 1. At the time of transplantation 361 renal 
transplant recipients were included and a 6-month protocol biopsy was obtained from 
275 (76%) patients. Reasons were mainly non-medical (withdrawal of consent), return 
to dialysis, insufficient graft function or patient death. There were no relevant differences 
in the relevant demographic or transplant characteristics. Overall DGF was observed in 
14% of the patients (28% in case of a deceased donor kidney, including those after cardiac 
death) and subclinical acute rejection was observed in 18% (n = 50) of protocol biopsies. 
The prevalence of SCR was higher in male recipients and patients with a history of acute 
rejection (Table 2). 
Patients were genotyped for the polymorphisms in genes encoding the cytochrome P450 
3A5 3A4 and 2C8 enzymes, P-glycoprotein and the calcineurin protein. Haplotypes and 
genotypes are summarized in Table 3. Besides these pharmacogenetic factors, inadequate 
systemic drug exposure is a potential important pharmacological risk factor for SCR as 
well. CsA exposure was monitored throughout the study period and the change in AUCs 
over time after transplantation is presented in Figure 1.
Exposure was found to be higher than the predefined target value in the first 6 weeks 
in the majority of the transplant recipients. After 6 weeks, when exposure to CsA was 
reduced, the CsA-AUC was kept within a range of roughly 2000-4500 µg*h/L (target 3250 
µg*h/L) for most patients. 
In univariate analysis the covariates related to the incidence of DGF (Table 4) and SCR 
were identified (Table 5).
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Table 1: Clinical characteristics.
Characteristic  Inclusion at the time of transplantation
Inclusion at transplantation (n) 361
Recipient age (yr) 51 ± 13
Recipient gender (% male) 63
Race (% Caucasian) 86
Diabetes at baseline (%) 42 (12%)
Primary kidney disease
 Polycystic kidney disease 78
 Glomerulonephritis,-sclerosis 77
 Hypertension 60
 Urological origin 26
 Diabetic nephropathy 18
 interstitial disease 11
 etiology uncertain (e.c.i.) 14
 other 77
cold ischemia (h) of cad donor 17
donor age (yr) 49 ± 13
donor type:
 living donor, related 76
 living donor, unrelated 93
 deceased donor, heart beating 121
 deceased donor, non-heart beating 70
HLA-mismatches:
 Class 1 mismatces 1.94 ± 1.15
 Class 2 mismatches 0.84 ± 0.63
Delayed graft function (%; living donor excl.) 28
Patients with at least 1 BPAR (%) 13.85
Patients treated with ATG (%) 34
serum creatinine at baseline (µmol/L) 770 ± 277
serum creatinine at week 2 (µmol/L) 246 ± 244
serum creatinine at week 4 (µmol/L) 145 ± 62
serum creatinine at month 2 (µmol/L) 138 ± 70
serum creatinine at month 6 (µmol/L) 129 ± 39
Patients with a 6 months biopsy 276
Drop-out (no biopsy) reasons:
 Withdrawal of consent 55
 Graft loss, dialysis or eGFR < 15 ml/min 18
 Patient death 7
 Infection 2
 Intolerability to immunosuppressive drugs 1
 Other 2
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Table 2: Demographic and transplant related factors within the groups with and without biopsies displaying 
subclinical acute rejection (SCR). 
Characteristics at 6 months SCR  
  Absent (n=225) Present (n=50)
Recipient age (yr) 51 ± 13 49 ± 12
 gender (male, %) 64 78
 race (Caucasian ,%) 87 86
Donor age (yr) 51 ± 12 48 ± 14
 age > 60 yrs (%) 14 18
HLA class I mismatches 1.98 ± 1.16 1.70 ± 1.20
HLA class II mismatches 0.80 ± 0.64 0.84 ± 0.58
Delayed graft function (living donor excluded,%) 27 25
Recipients with a previous BPAR (%) 8 16%
Renal function (mean ± SD)
 serum creatinine at baseline 754 ±257 865 ± 364
 serum creatinine at week 2 234 ± 227 312 ± 320
 serum creatinine at week 4 142 ± 65 160 ± 44
 serum creatinine at month 2 132 ± 58 173 ± 111









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1: AUC0-12h in time after transplantation. Target AUC (horizontal striped lines) was 5400 µg*h/L up to 6 
weeks after transplantation and 3250 µg*h/L thereafter.
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Table 3: Haplotype and genotype frequencies in renal transplant recipients for the genes coding for calcineurin 
alpha (PPP3CA) and beta (PPP3CB), CYP2C8, P-glycoprotein (ABCB1), CYP3A5 and Pregnane-X-Receptor 
(NR1I2).
PPP3CA PPP3CB CYP2C8 ABCB1 ABCB1
haplotype haplotype haplo *3 haplotype T-129C
n=282   n=288   n=295   n=290   n=300  
CTCCT 0.52 CAC 0.8 CT 0.81 CCG 0.44 TT 0.91
CCACT 0.18 TAT 0.08 TC 0.18 TTT 0.38 TC 0.09
ACACT 0.12 CTC 0.06 TCG 0.13
ACCTG 0.11 TAC 0.05 CTG 0.02
ACCTT 0.04 CTT 0.02
CTCCG 0.02
CYP3A5 CYP3A5 CYP3A4 NR1I2 NR1I2
*1 *6 *22 A+7635G G-24113A
n=300   n=300   n=302   n=302   n=301  
GG 0.81 GG 0.99 CC 0.88 AA 0.35 GG 0.32
GA 0.16 GA 0.01 CT 0.11 AG 0.48 GA 0.54
AA 0.03 TT 0.01 GG 0.17 AA 0.14
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Table 4: Factors with significant effect on the incidence of delayed graft function.
Covariaat Incidence of DGF Δ OF/LL P-value
BASE-model* 14%
Deceased donor -63.408 <0.00001
 if yes 27%
 if no 0.6%
Cold ischemic time > 12 hr # -36.515 <0.00001
 if yes 26%
 If no 7%
PPP3CB -genotype #, no TAC block 15% -5.142 0.0234
 carriers of TAC 35%
 
* ∆OF/LL >3.84 (P<0.05, chi-square test), # Based on a smaller dataset due to missing data. N.S. not significant.
Of the pharmacological factors, only PPP3B was related to the occurrence of DGF. Carriers 
of a at least one TAC block had a higher incidence of DGF (35% vs 15%). The only other 
covariate related to DGF was a deceased kidney donor (27% versus 0.6% of living donors) 
and a cold ischemic time over 12 hours (26% versus 7% if not). 
No pharmacological factors were related to SCR. In order of relevance, the most significant 
covariates related to the prevalence of SCR were: a previous acute rejection episode and 
recipient of a kidney from a deceased donor. A history of acute rejection increased the 
incidence of SCR to 38% versus 16% without acute rejection. Receiving a deceased donor 
kidney was associated with an SCR prevalence of 24% versus 13% in recipients with a living 
donor kidney. After including the information on patients without a protocol biopsy (the 
context that every patient was intended-to-be-biopsied) factors could be identified related 
to not having a protocol biopsy performed at 6 months (“dropping-out of the study”). 
Covariates related to an increased risk of dropping-out were a previous acute rejection 
episode, a deceased donor kidney, female sex and the ABCB1 TTT-haplotype (Table 5). In 
case patients did not carry a TTT-haplotype drop-out was 10%, otherwise 19%. 
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Table 5: Factors with significant effects on either the incidence of subclinical acute rejection or the incidence of 
drop-outs.






Δ OF/LL * P-value
BASE-model* 18% 24%
Previous acute rejection 
episode
-6.645 0.0099 -16.829 0.0000
 if yes 38% 48%
 if no 16% 20%
Type of Donation -5.489 0.0191 -7.473 0.0063
 if deceased 24% 29%
 If living 13% 17%
Gender -3.814 0.0508 -6.926 0.0085
 male 21% 19%
 female 12% 31%
-4.388 0.0362
ABCB1 TTT-genotype#
 no TTT block N.S. 10%




 if yes 34% N.S.
 if no 15%       N.S.  
∆OF >3.84 (P<0.05, chi-square test), # Based on a smaller dataset due to missing data. N.S. not significant.
In the next step, these above mentioned factors were combined in a multivariable approach 
(Tables 6 and 7). For DGF only a deceased kidney donor remained significantly related in 
the multivariate analysis with an incidence of 28%. The highest risk category for SCR was 
identified with the final model, identifying SCR prevalence at 6 months of 47% in case 
of a deceased donor kidney and a history of (treated) acute rejection. In contrast, living 
donation without acute rejection resulted in a SCR prevalence of 11%. 
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Table 6: Multivariate analysis of DGF: forward inclusion/backward deletion.
Model absolute OF ΔOF P-value
forward inclusion
BASE-model 297.324
 AND effect deceased donor on DGF 233.916 - 63.408 <0.00001
 AND effect cold ischemic time on DGF * 231.415 - 2.501 0.1338
backward deletion
FINAL-model 233.916
 MINUS effect deceased donor on DGF 297.324 63.408 <0.00001
∆OF/LL >6.64 (P<0.01, chi-square test), * Dropped from the final model.
Table 7: Multivariate analysis of SCR: forward inclusion/backward deletion.
Model absolute OF ΔOF P-value
forward inclusion
BASE-model 654.297
 AND effect previous acute rejection on drop out 637.468 -16.829 0.0000
 AND effect recipient gender on drop-out 628.991 - 8.477 0.0036
 AND effect donation type on drop-out 620.677 - 8.314 0.0039
 AND effect previous acute rejection on SCR 614.032 - 6.645 0.0099
 AND effect donation type on SCR 608.458 - 5.574 0.0182
backward deletion
FINAL-model 608.458
 MINUS effect donation type on SCR 614.032 5.574 0.0182
 MINUS effect previous acute rejection on SCR 620.032 6 0.0143
 MINUS effect donation type on drop-out 628.991 8.959 0.0028
 MINUS effect recipient gender on drop-out 637.468 8.477 0.0036
 MINUS effect previous acute rejection on drop out 654.297 16.829 0.0000
* ∆OF >3.84 (P<0.05, chi-square test).
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During the study period patients dropped-out and recipients with a deceased donor 
kidney, also had the highest drop-out rate, 60% versus 27% with or without acute rejection, 
respectively. After splitting the results according to gender as additional risk factor for 
dropping-out, female recipients displayed a drop-out rate of 70% and males 51% in case 
of a deceased donor kidney and previous acute rejection. For comparison after living 
donations, without a previous acute rejection, drop-out rate were 19% (females) versus 
10% (males), respectively. In the multivariate analysis the ABCB1 TTT-haplotype was 
deliberately left out due to the small effect (P=0.04, Table 4) on drop-out, as well as the fact 
that the genotypes were not available for all individuals. 
Finally in a sub analysis with patients that experienced at least one acute rejection episode 
(n=50) the effect of the type of rejection treatment on prevention of subsequent SCR was 
investigated. These results are presented in Table 8. Rejection treatment that included 
ATG resulted in a significantly (P<0.05) lower prevalence of SCR (13% versus 50%).
Table 8: Sub analysis of rejection treatment and incidence of SCR in patients experiencing acute rejection.
Model Incidence of SCR ΔOF P-value
BASE-model 38%
Rejection treatment with least MPNS and ATG -4.052 0.0441
 if yes 13%
 if no 50%
 
* ∆OF >3.84 (P<0.05, chi-square test).
In the time to first acute rejection analysis 3 patients had to be excluded because they 
dropped out of the study before start of the six month observation period. In some of 
the patients, more than one acute rejection was observed; Due to the limited number 
of these observations the analysis took only occurrence of a first acute rejection episode 
into account. Based on the objective function and the simulated Kaplan-Meier plots, 
a Gompertz model described the time to first acute rejection most adequately. The 
equations used for the hazard function (Equation 2) for the survival function (Equation 
3) are shown below:
 (2)
    
    (3)
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With λ describing the scale and γ describing the shape of the survival curve. The Kaplan 
Meier plots showed adequate agreement between the observed and the simulated time to 
rejection. Furthermore the drop-out was adequately described by a log-logistic model.
Based on graphical non-parametric Kaplan Meier plot analysis of the different covariates 
11 covariates were selected for parametric covariate analysis with the model; body mass 
index and CSA exposure (AUC0-12h) as continuous covariates and DGF, PPP3CB variant 
TAT, Pre-existing diabetes mellitus (DM), CYP3A5*1 genotype, 5 different HLA-mismatch 
categories (HLAMISS defined as 2 or more HLA DR mismatches or at least 1 HLA-B 
and 1 HLA DR mismatch), age category and underlying disease as categorical covariates 
(immunological vs non immunological). These covariates were tested for influence on the 
scale and the shape parameters of the survival curve. The results of the univariate analysis 
are presented in Table 9.
Delayed graft function and CYP3A5*1 had a significant effect on the scale parameter of the 
survival curve. Age category had a significant effect on the shape parameter of the survival 
curve, older patients had a decreased risk of developing early acute rejection. After forward 
inclusion and backward deletion only DGF remained a significant risk factor for the time 
to acute rejection (Table 10). In Figure 2 the Kaplan Meier plot shows the difference in 
survival (freedom of acute rejection) in the two groups: with or without DGF. The survival 
model prediction shows adequate match with the observed data. Patients experiencing 
DGF after transplantation had an increased risk of developing early acute rejection.
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Table 9: Univariate analysis of time to first AR.
Model ΔOF P value
Continuous covariates
BMI on λ (linear) * -1.06 0.3032
Cyclosporine AUC0-12h
AUC on λ -0.642 0.4230
AUC on γ -0.823  0.3643
Categorical covariates
DGF on λ # -12.33  0.0004
DGF on γ -1.34 0.2470 
DM on λ -0.71 0.3994
DM on γ -0.12 0.7290
PPP3CB - TAT on λ -4.65 0.0311
PPP3CB - TAT on γ -3.8 0.0513
CYP3A5*1 on λ # -8.36 0.0038
CYP3A5*1 on γ # -7.04 0.0080
HLA mismatch CLASS II on λ -4.57 0.0325
HLAMISS on λ -3.67 0.0554
HLAMISS on γ -2.72 0.0991
HLA mismatch-A on λ -1.74 0.1871
HLA mismatch-A on γ -3.53 0.0603
HLA mismatch-B on λ -3.93 0.0474
HLA mismatch-B on γ -3.84 0.0500
HLA mismatch-DR on λ -4.57 0.0325
HLA mismatch-DR on γ -3.46 0.0629
Age category on λ # -8.16 0.0028
Age category on γ # -8.95 0.0028
Underlying disease on λ -0.72 0.3961
Underlying disease on γ -5.24 0.0221
*  Continuous covariates were tested for linear, loglinear, allometric an Emax relationship, the relationship with 
the largest ∆OF is shown. # selected for multivariate analysis ∆OF >6.64 (P<0.01) N.S. not significant.
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Table 10: Multivariate analysis of time to first AR. 
Model absolute OF ΔOF P-value
forward inclusion
Basic survival 745.62
AND effect DGF on λ 733.293 -12.327 0.0004
AND effect AGEcat on γ 724.646 -8.647 0.0033
AND effect CYP3A5*1 on λ 718.273 -6.373 0.0116
AND effect AGEcat on λ 722.759 -1.887 0.1695
AND effect CYP3A5.1 on γ 722.92 -1.726 0.1889
backward deletion
Final survival model 724.646
MINUS effect AGECAT as covariate on γ 733.293 8.647 0.0033
MINUS effect DGF as covariate on λ 736.7 12.054 0.0005
* ∆OF >6.64 (P<0.01) forward inclusion, ∆OF >10.8 (P<0.001 ) backward deletion (chi-quare test).
Figure 2: Survival plot of fraction of patients without acute rejection during the study showing a clear difference 
between patients with (red line) and without DGF (black line).The predicted survival according to the developed 
survival model is showed by the green open circles.
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Discussion
This analysis on a relatively large homogenous group of standard to low risk transplant 
recipients participating in the run-in phase of a multicenter, randomized clinical trial 
on quadruple therapy with basiliximab, prednisolone, mycophenolate sodium and CsA 
with controlled systemic drug exposure, aimed to identify pharmacological risk factors 
for DGF, AR and SCR 6 months after renal transplantation. Especially, the variability in 
CsA exposure and/or genetic variability in genes encoding calcineurin, P-glycoprotein and 
CYP3A5 were of interest. The incidence of AR and SCR with controlled and early reduced 
systemic CsA-exposure within 6 months was found to be 14% and 18%, respectively. In this 
context pharmacological factors, including exposure and genetic variability in the selected 
genes, were not found to be related to the risk for DGF, AR or SCR. Receiving a kidney from 
a deceased donor was the dominant risk factor for DGF, with DGF being the primary risk 
factor for time to first AR. For SCR the most important risk factors were a previous acute 
rejection episode, and being recipient of a deceased donor kidney. These factors were also 
associated with a lower 6-months protocol biopsy rate (overall reduction of 24%). Other 
factors related to “dropping-out” were female sex and carrying a copy of the ABCB1 TTT-
haplotype. The incidence of biopsy drop-out was the lowest for patients without a copy 
of the ABCB1 haplotype. Finally a significant relationship (P<0.05) was found between 
rejection treatment including ATG and a lower subsequent prevalence of SCR.
The results of this study confirm previous findings and of Nankivell et al. [7,31], in that 
DGF was associated with an increased risk of early acute rejection and patients with 
acute rejection constituted the dominant risk factor for subsequent SCR. The prevalence 
of SCR depends on time after transplantation and the center policy on the use/type of 
induction/maintenance immunosuppressive therapy and the immunologic risk profile of 
the recipients [32], complicating comparison of different studies. SCR in early protocol 
biopsies was found to be associated with HLA-matching [9,31,33], prior acute rejection 
episode [31], donor age [9] and donor source [15,33]. Although CsA exposure was 
not related to the incidence of SCR at 6 months, it is relevant to note that the present 
analysis was performed on a CsA exposure (AUC0-12h) controlled population of standard 
to low risk kidney transplant recipients. Exposure was relatively high the first 6 weeks 
after transplantation (generally over 5400 µg*h/L) and, after early reduction maintained 
between 2000 and 4500 µg*h/L thereafter.
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This is the first report on the genetic variability in the genes coding for calcineurin 
isoforms, PPP3CA and PPP3CB. No relationship between the genetic variability in these 
genes and the time to AR or the prevalence of SCR was found. In this study we determined 
genetic variability in two genes coding for calcineurin, the target protein of CNIs. PPP3CB 
could be primarily of relevance since this gene principally encodes the calcineurin present 
in cells of the immune system, whereas PPP3CA is thought to be more relevant in other 
tissues including renal tubular epithelial cells. Variability in the PPP3CA gene within 
kidney donors would be more relevant for renal toxicity and perhaps DGF. To investigate 
these theoretical genetic risk factors we determined haploblocks in both genes, but in the 
current cohort genetic variability in PPP3CB was not related to time to first AR, DGF or 
the prevalence of SCR. The selected haplotype combination reflects the overall variability 
in the calcineurin gene, but may not specifically represent variability in the structure of 
the actual calmodulin and calcineurin binding parts, responsible for the susceptibility 
for CsA as previously hypothesized [16]. In addition, expression of this protein may be 
regulated by other (nuclear) factors. 
No relationship could be identified between any of the selected genes in drug transport 
(ABCB1), metabolism (CYP3A5, CYP3A4, CYP2C8) and the regulation of these genes 
(PXR - NR1I2). Carrying at least one copy of the ABCB1 TTT-haplotype, however, was 
related to an almost 2-fold higher drop-out rate for a 6-month protocol biopsy. At least 
theoretically, these patients may be prone to a higher frequency of adverse events, since 
the TTT-haplotype is associated with lower P-glycoprotein activity. This is independent 
from kidney survival, where the ABCB1 genotype of the donor may be of higher relevance 
[17,20]. A combined donor-recipient homozygosity for the C3435T variant in ABCB1 was 
associated with chronic allograft damage [34]. In accordance with our results no relation 
has been found between tacrolimus, carrying the CYP3A5*1 allele and AR or SCR, acute 
rejection [35,36]. 
The findings of the sub analysis of rejection treatment on the prevalence of subsequent 
SCR suggest confirms the previously reported low prevalences observed with induction 
therapy with depleting antibodies in patients cohort dominated by living donor kidney 
transplant recipients. 
Early minimization of CsA or tacrolimus is increasingly applied an attempt to reduce 
toxicity and to improve long term outcome [37–39]. While there is still debate whether 
SCR should be treated as acute rejection episode, it is generally accepted that persistent 
or recurrent SCR constitutes a potential threat to (functional) survival of the transplanted 
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kidney [8,10,15,40]. To safely taper CNI therapy within the immunosuppressive regimen 
after renal transplantation the risk of acute rejection should be minimized. It is generally 
assumed that CNI minimization or withdrawal is safest if a protocol biopsy shows no 
subclinical rejection [14,38,41] and exposure to the remaining drug(s) is individualized 
and adequate. There are several lines of evidences to support this notion. Inadequate MPA 
exposure and SCR were independent risk factors for subsequent acute rejection after early 
CNI withdrawal [42]. Less early as well as late acute rejection episodes occurred after 
treating SCR in early protocol biopsies with high dose steroids [43]. Maintaining adequate 
controlled CNI exposure in a triple immunosuppressive regimen was as effective in 
preventing late acute rejection [10]. Despite (predominantly borderline) SCR in a relevant 
proportion of 6 month biopsies, no significant differences for renal function or severity of 
fibrosis in sequential biopsies were observed [10]. 
The integrated approach used in this study, combining demographic characteristics, 
transplant-related factors together with detailed drug-exposure and variability in genetic 
parameters in genes related to pharmacokinetics as well as pharmacodynamics, is very 
powerful to detect relationships with clinical events and identified DGF as a risk factor for 
early acute rejection. Moreover, a history of acute rejection recipients of kidneys from a 
deceased donor were identified as the dominant risk factors for inflammation in 6-month 
protocol biopsies despite controlled systemic drug exposure. Although, effects of exposure 
and genetics could not be identified in this analysis, likely this approach can be successful 
in identifying risks of late acute (cellular or humoral) rejection, chronic nephrotoxicity, or 
other forms of drug-related toxicity, in transplant recipients. Indeed, kidneys from donors 
carrying the ABCB1 variant haplotype 1236T/2677T/3435T have been associated with 
inferior graft survival (hazard ratio 9.3) and renal function [20], while donors carrying 
the 3435TT genotype were associated with nephrotoxicity (odds ratio 13.4) [17]. Such 
a conclusive analysis should at least include genetic variability in the genes ABCB1, 
CYP3A5, PPP3CA of the donor.
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General discussion and future perspectives
210 Chapter 10
Introduction
With acute rejection rates lowered to 10-20% but limited progress with regard to long-
term survival a new challenge lies ahead in optimizing immunosuppression in renal 
transplantation [1]. Individualizing and fine-tuning current immunosuppressive regimens 
is now the most promising strategy to improve long term graft survival for renal transplant 
recipients. The current maintenance immunosuppressive drugs, calcineurin inhibitors 
(CNIs), are known for their efficacy but also for their toxicity such as new onset diabetes 
mellitus, neurotoxicity and renal toxicity especially in the higher dose ranges [2]. Efficacy 
of CNI minimizing or even CNI free strategies shortly after transplantation are currently 
widely investigated [3–5]. Less nephrotoxic regimens including mTOR inhibitors have 
been developed during the last decade, but on the other hand new serious side effects, 
relative high discontinuation rates and/or intolerability postpone wide implementation 
[4,6]. Although strict therapeutic drug monitoring is implemented some patients remain 
at risk for serious side effects and rejection. Identifying these patients before initiation 
of therapy could help prevent therapy failure. The main challenge is to find the right 
immunosuppressive regimen and exposure at the right time for individual patients. 
This thesis is constructed out of a number of different analyses to further optimize 
maintenance immunosuppressive therapy for renal transplant recipients to prolong long-
term graft survival, starting with a comparison of the most used analytical methods for 
therapeutic drug monitoring of everolimus, followed by evaluations of potential predictive 
biomarkers for everolimus pharmacokinetics and pharmacodynamics and finally also 
potential predictive biomarkers for calcineurin inhibitor pharmacokinetics and dynamics 
are explored.
Therapeutic drug monitoring techniques
Because of its highly variable pharmacokinetics and narrow therapeutic window 
everolimus therapeutic drug monitoring (TDM) is essential for preventing serious side 
effects and rejection [7]. Currently a variety of analytical methods to perform TDM are 
available [8–10], and methods may differ in accuracy and specificity. Whether these 
differences are clinically relevant is an important question. Because of high protein binding 
and to distribution into erythrocytes whole blood is the matrix of choice for everolimus 
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TDM [11]. The two widely used analytical techniques for everolimus blood concentration 
measurement, fluorescence polarization immuno assay (FPIA) and liquid chromatography 
tandem mass spectrometry (LC-MS/MS), were compared in chapter 3 of this thesis. The 
findings showed that these two methods are not in agreement. Everolimus concentrations 
determined by FPIA are, on average, 23% higher than LC-MS/MS. However, the variability 
found between FPIA and LC-MS/MS could be twofold for concentrations lower than 
15 µg/L or AUC0–12h. This suggests a relatively large effect on variability of FPIA versus 
LC-MS/MS when monitoring everolimus trough concentrations. The large variability in 
concentrations determined with FPIA can lead to clinically relevant differences in dosing 
advice compared with LC-MS/MS despite using a correction factor of 23%. The within-
patient variability for trough concentrations appeared to be higher using the FPIA method 
[12], most likely caused by nonspecific binding of the antibodies [13] and crossreactivity 
of metabolites, which are actually present in relatively high concentrations before the 
next dose [14,15]. The variability in differences in dosage advice showed that the risk of 
suboptimal dosage advice is present and clinically relevant. In general LC-MS/MS is a 
more specific, more stable, and more accurate method for everolimus TDM compared to 
FPIA and is able to simultaneously measure several immunosuppressive drugs in a single 
run. However the most important limitations for broad introduction of LC-MS/MS for 
everolimus TDM are the need for a high initial capital investment and highly trained 
technicians for operation and maintenance. Centralization of sample measurements in 
combination with dried blood spot methodology might be a solution to this problem. 
While pharmacodynamic monitoring instead of pharmacokinetic monitoring in theory 
should give a more accurate insight on the mTOR inhibition and clinical effects a suitable 
method has not yet been found and implemented. Other innovative methods of measuring 
concentrations at the site of action like PBMCs could potentially give a more precise view 
at the level of immunosuppression but are currently under development and not yet 
accepted in clinical practice. Therefore TDM of everolimus whole blood concentrations 
using LC-MS/MS currently is still the method of choice. 
Variability in pharmacokinetics of everolimus 
Everolimus is metabolized by CYP3A4, CYP3A5, CYP2C8 and is a substrate for 
P-glycoprotein (P-gp), and is characterized by its high inter patient variability. The nuclear 
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pregnane X receptor (PXR) mediates expression of CYP3A4 and multi drug resistance 
proteins (MDR1 and MDR2) and could therefore potentially influence everolimus 
pharmacokinetics [16–18]. Monitoring area under the blood concentration versus time 
curve (AUC) instead of trough concentration is often more informative. However, AUC 
monitoring when using trapezoidal calculations remains laborious for both patients 
and the clinic. Limiting sampling strategies based on Bayesian estimation could be 
solution to this problem. A limitation of TDM is that during the critical period of the 
first days after transplantation or conversion to another immunosuppressive regimen 
the exposure cannot be influenced. Getting the initial dose right is therefore very 
important. Especially drugs with a long elimination half-life such as everolimus are at 
risk of under or overexposure because correcting them takes more time. Reaching target 
exposure is as soon as possible after drug initiation is essential, however currently no 
factors for everolimus initial dose differentiation have been identified. Pharmacogenetics, 
when looking at polymorphisms coding for metabolizing enzymes which lead to altered 
drug metabolism could be a potential factor as previously shown for tacrolimus [19]. 
These factors could potentially shorten the time to reach target exposure. To address 
the above mentioned problems the research described in chapter 4 was performed. 
Pharmacometrics, which uses mathematical models based on physiology, pharmacology 
and disease for quantitative analysis of interaction between drugs and patients was used 
to build a population pharmacokinetic model, a limited sampling model and evaluate 
potential factors influencing pharmacokinetics (covariates). The pharmacokinetics 
of everolimus of (primarily Caucasian) renal transplant patients using everolimus 
and prednisolone was best described by a two-compartmental model with first order 
absorption and lag time. Everolimus pharmacokinetics was not significantly influenced by 
genetic polymorphisms in coding genes for the metabolizing enzymes CYP3A5, CYP2C8, 
ABCB1 and PXR or drug transporter ABCB1. Therefore, the currently known single 
nucleotide polymorphisms (SNPs) are not able to predict everolimus systemic exposure 
to a clinically relevant extent and shorten the time to reach target exposure. In addition, 
demographic covariates such as total body weight, age, sex, hematocrit, albumin, length, 
body mass index, body surface area, lean body weight, underlying disease, co-medication 
and ethnicity did not significantly influence everolimus pharmacokinetics [20]. Ideal body 
weight did significantly correlate with the variability in apparent distribution volume of 
the central compartment and can be physiologically explained by the fact that everolimus 
is for more than 75% partitioned into red blood cells and 75% of the plasma fraction is 
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bound to plasma proteins since length and sex are incorporated in the ideal body weight 
formula [11,21]. In conclusion, no factors for initial dose differentiation of everolimus 
were identified. Weak CYP3A inhibitors such as statins, nifedipine and sulfamethoxazole/
trimethoprim did not have a clinically relevant effects on pharmacokinetics, which 
was in accordance with previous findings [22] although strong CYP3A inhibitors and 
inducers are known to strongly influence everolimus pharmacokinetics [23]. Monitoring 
everolimus during initiation and discontinuation of such drugs is therefore essential. 
Therapeutic drug monitoring of everolimus
The most common way to perform everolimus therapeutic drug monitoring is monitoring 
based on trough concentrations. However, besides the higher impact of assay variability 
[12] when using one marker to predict everolimus systemic exposure, the correlation 
between Ctrough and AUC is not optimal and could in theory lead to therapy failure and 
side effects [24] . Worse predictive performance of a TDM marker can lead to incorrect 
dose adjustments resulting in exposure outside the target range. The developed limited 
sampling model (Chapter 4) is an improvement in terms of inconvenience for patient 
and clinic and predictive performance. Ctrough and C2 monitoring based on the population 
pharmacokinetic model resulted in an improved predictive performance compared to 
Ctrough monitoring. Whether TDM based on trough or AUC0–12h does lead to differences 
the occurrence of hazardous side effects and clinical benefit in long term warrants to be 
investigated more thoroughly before clinicians can be convinced to use AUC monitoring 
instead of trough monitoring. Since the majority of research suggests that tacrolimus does 
not influence everolimus pharmacokinetics, the applicability of the developed model 
might include on tacrolimus + everolimus regimens. Since CNI minimizing and CNI 
free strategies are being actively investigated worldwide [4,5,25–28] there could be an 
increasing interest for implementation of the developed model in clinical practice.
Pharmacodynamics: side effects and everolimus discontinuation
Despite its proven efficacy and close TDM, everolimus is also known for some serious side 
effects with relative high discontinuation rates [6,29]. Leukopenia, thrombocytopenia, 
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hypertriglyceridemia and hypercholesterolemia are the most common side effects of 
mTOR inhibitors [4] and can often be managed with counteracting medication or dose 
reduction [6,30]. Although less common but a potentially life threatening side effect of 
everolimus is non-infectious interstitial pneumonitis. It typically presents itself within 2 to 
6 months after start of therapy [31,32]. The exact mechanism of mTOR inhibitor-induced 
pneumonitis is still unknown, but direct damage to alveolar structures, formation of 
immunogenic molecules that react with specific antibodies, and direct immunologic drug 
responses are suggested as possible mechanisms [33]. A dose relationship may be present 
and is supported findings of by higher incidence in oncology where higher daily doses are 
prescribed [34,35]. Moreover a higher incidence was found in males on sirolimus therapy 
compared to females [36]. Infectious diseases are an important cause of death in renal 
transplant recipients [37,38] and strongly related to excessive and/or long-term clinical 
immunosuppression [39]. Everolimus is associated with a relatively low incidence of viral 
infections as compared to other immunosuppressive groups [40–42]. Everolimus is also 
associated with an increased incidence of new onset diabetes mellitus (NODM) which 
subsequently is associated with increased graft failure and mortality due to cardiovascular 
events [43]. NODM is therefore a serious complication of immunosuppressive therapy 
in transplant recipients which shortens long term survival [44]. Finding risk factors 
for everolimus discontinuation and the mentioned severe side effect could help further 
improve individualized immunosuppressive therapy by excluding patients at high risk 
from everolimus therapy or monitor them more intensively. In chapter 5 and 6 risk factors 
were explored for everolimus-discontinuation and serious side effects in renal transplant 
recipients on dual therapy.
In the case-cohort study (Chapter 5) no clear predisposing factors were identified for non-
infectious interstitial pneumonitis. Pulmonary CT scans revealed an organizing or non-
specific interstitial pneumonitis-like pattern. The course seems benign with disappearance 
of symptoms within one year after discontinuation of the drug. The incidence (12.7%) 
reported was higher than previously reported in renal transplant recipients on mTOR-
inhibitors, varying between 4 and 6.8% [45–47]. In patients treated with everolimus for renal 
cell carcinoma the incidence of non-infectious interstitial pneumonitis has been reported 
to be around 25% [34,35]. This high incidence of non-infectious interstitial pneumonitis 
has been attributed to higher dosage of everolimus in these patients in combination with a 
higher detection level of pneumonitis due to routinely performed pulmonary CT scans. In 
the case cohort study, drug exposure was relatively high with an AUC around 170 μg*h/L 
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and trough levels around 10 μg/ml since everolimus was prescribed as part of a double 
immunosuppressive regimen. However, average everolimus exposure was not higher in the 
cases compared to controls. All patients subjectively recovered within one year, however long-
term outcome after non-infectious pneumonitis remains unclear since at least theoretically 
non-infectious pneumonitis may result in pulmonary fibrosis. Since the presentation of non-
infectious pneumonitis can be insidious or even asymptomatic, performing radiographic 
imaging of the lungs when patients present with dyspnea, cough or fever while on treatment 
with this drug according to the algorithm shown in Chapter 5 is recommended. 
A more sophisticated time to event analysis was used to investigate risk factors for everolimus 
discontinuation and the serious side effects non-infectious interstitial pneumonitis, infection 
and NODM (Chapter 6). Such an approach has advantages compared to non-parametric 
and semi parametric analyses, because it enables inclusion of time-varying covariates and 
allows simulation based on the final model. Results showed that excess exposure during 
the study period and older age were risk factors for everolimus-discontinuation. Since the 
majority of discontinuation was side effect related this is in line with earlier finding that 
certain side effects have previously shown to be dependent on exposure [48,49]. As can 
be concluded from our results, clinicians should prevent renal transplant recipients from 
reaching excess everolimus exposure (i.e. AUC12> 120 -150 µg*h/L), therefore close TDM 
remains warranted. Looking at the high discontinuation rates and low rejection risk we 
can extrapolate an initial target trough level between 6 µg/L and 8 µg/L from this study 
and an initial dose of 2 mg b.i.d. This initial dose might lower the rate of overexposure 
compared to 3 mg which was used in the study. Higher age resulted in a higher risk of 
everolimus-discontinuation probably due to fact that often patients with higher age have 
more comorbidities and senescence of their immune system with changes in T-cell function 
[50] where the immunosuppressive effect of the same immunosuppression exposure might 
be higher. Older patients with more comorbidities also have more difficulty to cope or accept 
additional side effects compared to young patients with no comorbidities.
The risk of experiencing non-infectious pneumonitis was increased by prolonged excess 
exposure. Furthermore renal transplant recipients with a PXR (NR1|2)( -24113G>A): AA 
genotype had a higher risk of developing pneumonitis compared to those carrying the AG 
or GG genotype although the effect seemed to be limited. The increase in risk of patient 
with that was found for patients with PXR (NR1|2) (-24113G>A) AA genotype might be 
related to an increased accumulation of everolimus in the lungs. In experimental animals 
high affinity for lungs and kidney were found for everolimus [51] and could this could 
216 Chapter 10
be the case in humans. PXR is a nuclear receptor whose primary function is to sense 
the presence of foreign toxic substances and in response up regulate the expression of 
proteins involved in the detoxification and clearance of these substances from the body. 
PXR polymorphism could subsequently have an effect on drug transporter activity since 
PXR is able to influence enzyme activity and multi drug transporter proteins [16–18]. 
Infections continue to be an important feature in the first year following both renal and 
heart transplant and occur in around 50% of patients [37]. The incidence of (opportunistic) 
infections is related to the intensity and type of immunosuppression [38]. No significant 
relationships for infection could be identified in the current analysis, but in general 
differences are more pronounced when two different immunosuppressive regimens are 
compared [39,52]. 
Although known from literature, important risk factor for the development of NODM 
include African ethnicity, increased age, obesity, increased number of transplants, donor 
type, a family history of diabetes and the use of prednisolone [53], but none of these 
relationships were strong enough to be detected in this patient cohort. The analysis for 
NODM had some specific limitations; the dataset lacked a significant number of patients 
from African ethnicity, Family history of diabetes was not available in the dataset en could 
therefore not be included in the covariate analysis. Exposure did not seem to affect the 
occurrence of NODM which was in accordance with previous studies [49]. In conclusion, 
the current findings can be used to further optimize everolimus based immunosuppressive 
therapy by preventing excessive drug exposure by strict therapeutic drug monitoring and 
restrict the initial dosing to a maximum of 2 mg b.i.d.
Influence of the most promising single nucleotide polymorphisms 
on maintenance immunosuppressant pharmacokinetics
Pharmacogenetics has only been adopted to a small extent in clinical practice for renal 
transplant recipients. In chapter 7 the influence of the most promising single nucleotide 
polymorphism: CYP3A4*22, CYP3A5*3 variant alleles and its combined clusters on 
the pharmacokinetics of the three main kidney transplant immunosuppressive drugs 
cyclosporine, everolimus and tacrolimus was investigated. Cyclosporine, everolimus and 
tacrolimus are primarily eliminated by CYP3A enzymes [7,54–56] and as shown before 
in in-vitro and in-vivo studies, CYP3A4 is involved in their pharmacokinetics [55,57,58]. 
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CYP3A4 is most likely predominant in cyclosporine and everolimus metabolic clearance 
and CYP3A5 contributes more significantly to tacrolimus metabolic clearance compared 
with CYP3A4 [55,56]. In contrast to CYP3A5, CYP3A4 lacked a reliable genetic marker 
for prediction of CYP3A4 expression which was suitable for dosing adjustments [59,60], 
however CYP3A4*22 was previously marked as a potential reliable marker [61,62]. 
The results presented in chapter 7 demonstrated that carriership of the CYP3A4*22 
allele is significantly associated with a decreased cyclosporine clearance. Carriers of 
the CYP3A4*22 allele showed 15% lower cyclosporine clearance as compared to non-
carriers. In clinical practice this effect is not high enough to justify dose modification 
based on CYP3A4*22, since only an effect of at least 20% on clearance would lead to dose 
adjustments due to considerable degree of intra-individual variability in pharmacokinetics. 
Combining individual SNPs in theory would increase the predictive power of the single 
polymorphisms. However using CYP3A combined genotype of CYP3A4 and CYP3A5 as 
a predictor for cyclosporine, everolimus or tacrolimus clearance does not seem to be an 
improvement compared to the individual polymorphisms. Finally it was also demonstrated 
that patients carrying at least one CYP3A5*1 allele have on average 53% higher tacrolimus 
clearance compared to non-carriers. The difference in tacrolimus clearance between 
CYP3A5*1 carriers and non-carriers found was similar to what was published previously 
[19,63]. Dosing adjustments based on CYP3A5*3 could be indicated to quickly reach target 
exposure, however the variability explained by CYP3A5*3 is limited and the variability 
within the CYP3A5 genotype groups remains significant and therefore close TDM remains 
essential. The absence of a clinically relevant influence of CYP3A5*3 on cyclosporine and 
everolimus pharmacokinetics was in line with previous studies [60,64,65]. In conclusion, 
CYP3A4*22 does not influence cyclosporine, everolimus or tacrolimus pharmacokinetics 
to a clinically relevant extent. Therefore the newly discovered CYP3A4*22 or CYP3A 
combined genotypes are not indicative to be used for dose adjustments in clinical practice 
to further improve immunosuppressive therapy of cyclosporine, tacrolimus or everolimus 
in the investigated patient population. Hepatic microsomal P450 enzymes require P450 
oxidoreductase (POR). Polymorphisms in the gene encoding POR have been linked to 
altered CYP activity [66]. In an additional analysis for everolimus (Chapter 8) the effect of 
POR*28, CYP3A5*3 and their combined genotypes were explored. In contrast to what was 
previously found for tacrolimus [67,68] and in accordance to what was found for sirolimus 
[69] POR*28, or the combination of combination of POR*28 & CYP3A5*3 appeared not to 
be suitable as a biomarker to improve prediction of everolimus exposure.
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Risk factors for delayed graft function, acute rejection  
and sub clinical rejection in a CNI based regimen
Over the past decades acute rejection (AR) rates have decreased dramatically, mainly due 
to calcineurin inhibitor (CNI) based immunosuppressive regimens. One of the dominant 
risk factors , previously identified for AR is delayed graft function (DGF) which is highly 
related to transplant related factors such as vulnerability of the allograft and/or prolonged 
preservation times [70]. Clinical episodes of AR have previously been identified as a risk 
factor for subclinical rejection (SCR) [71]. SCR is by definition histologically defined 
acute rejection and, as such, has been associated with subsequent interstitial fibrosis and 
tubular atrophy and with time progressive deterioration of renal function and inferior 
graft survival. Despite low acute rejection rates in the first year after transplantation 
with current standards for immunosuppressive therapy, long-term outcome after renal 
transplantation has not improved accordingly [72]. In chapter 9, a relatively large 
homogenous group of standard to low risk transplant recipients participating in the run-
in phase of a multicenter, randomized clinical trial on quadruple therapy with basiliximab, 
prednisolone, mycophenolate sodium and CsA with controlled systemic drug exposure 
was analysed, aimed to identify pharmacological risk factors for DGF, AR and SCR 6 
months after renal transplantation. Especially, the variability in CsA exposure and/or 
genetic variability in genes encoding calcineurin, P-glycoprotein and CYP3A5 were of 
interest. The incidence of AR and prevalence of SCR with controlled and early reduced 
systemic CsA-exposure at 6 months was found to be 14 and 18%, respectively. In this 
context pharmacological factors, including exposure and genetic variability in the selected 
genes, were not found to be related to the risk for DGF, AR or SCR. Receiving a kidney 
from a deceased donor was the dominant risk factor for DGF, with DGF being the primary 
risk factor for time to first AR. For SCR the most important risk factors were previous 
acute rejection, and being recipient of a deceased donor kidney. These factors were also 
associated with a lower 6-months protocol biopsy rate (overall reduction of 24%). Other 
factors related to “dropping-out” were female sex and carrying a copy of the ABCB1 TTT-
haplotype. The incidence of biopsy “drop-out” was the lowest for patients without a copy 
of the ABCB1 haplotype. Finally a significant relationship (P<0.05) was found between 
rejection treatment including ATG and a lower subsequent prevalence of SCR. Three 
isoforms for calcineurin have been described: alpha, beta en gamma. Genetic variability 
in two genes coding for calcineurin, the target protein of CNIs were determined. The 
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gene coding for calcineurin beta (PPP3CB) could be primarily of relevance since this 
gene principally encodes the calcineurin present in cells of the immune system, whereas 
the gene coding for calcineurin alfa (PPP3CA) is thought to be more relevant in other 
tissues including renal tubular epithelial cells. Variability in the PPP3CA gene within 
kidney donors would be more relevant for renal toxicity and perhaps DGF. To investigate 
these theoretical genetic risk factors we determined haploblocks in both genes, but in the 
current cohort genetic variability in PPP3CB was not related to time to first AR, DGF or 
the prevalence of SCR. The selected haplotype combination reflects the overall variability 
in the calcineurin gene, but may not specifically represent variability in the structure of the 
actual calmodulin and calcineurin binding parts, responsible for the susceptibility for CsA 
as previously hypothesized [73]. In addition, expression of this protein may be regulated 
by other (nuclear) factors. No relationship could be identified between any of the selected 
genes in drug transport (ABCB1), metabolism (CYP3A5, CYP3A4, CYP2C8) and the 
regulation of these genes (PXR - NR1I2). Carrying at least one copy of the ABCB1 TTT-
haplotype, however, was related to an almost 2-fold higher “drop-out” rate for a 6-month 
protocol biopsy. At least theoretically, these patients may be prone to a higher frequency of 
adverse events, since the TTT-haplotype is associated with lower P-glycoprotein activity. 
This is independent from kidney survival, where the ABCB1 genotype of the donor may 
be of higher relevance [74,75]. A combined donor-recipient homozygosity for the C3435T 
variant in ABCB1 was associated with chronic allograft damage [76]. In accordance with 
our results no relation has been found between tacrolimus, carrying the CYP3A5*1 allele 
and AR or SCR [77,78]. 
The findings of the sub analysis of rejection treatment on the prevalence of subsequent 
SCR confirms the previously reported low prevalence observed with induction therapy 
with depleting antibodies in patients cohort dominated by living donor kidney transplant 
recipients. Early minimization of CsA or tacrolimus is increasingly applied an attempt to 
reduce toxicity and to improve long term outcome [3,79,80]. While there is still debate 
whether SCR should be treated as acute rejection episode, it is generally accepted that 
persistent or recurrent SCR constitutes a potential threat to (functional) survival of the 
transplanted kidney [81–84]. To safely taper CNI therapy within the immunosuppressive 
regimen after renal transplantation the risk of acute rejection should be minimized. It 
is generally assumed that CNI minimization or withdrawal is safest if a protocol biopsy 
shows no subclinical rejection [79,82,85] and exposure to the remaining drug(s) is 
individualized and adequate. 
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The integrated approach used in this last chapter combining demographic characteristics, 
transplant-related factors together with detailed drug-exposure and variability in genetic 
parameters in genes related to pharmacokinetics as well as pharmacodynamics, is very 
powerful to detect relationships with clinical events and identified DGF as a risk factor for 
early acute rejection. Moreover, a history of acute rejection recipients of kidneys from a 
deceased donor were identified as the dominant risk factors for inflammation in 6-month 
protocol biopsies despite controlled systemic drug exposure. Although, effects of exposure 
and genetics could not be identified in this analysis, likely this approach can be successful 
in identifying risks of late acute (cellular or humoral) rejection and calcineurin toxicity, 
in transplant recipients when using genetic information of the donors. Kidneys from 
donors carrying the ABCB1 variant haplotype 1236T/2677T/3435T have previously been 
associated with inferior graft survival and renal function [75], while donors carrying the 
3435TT genotype were associated with nephrotoxicity [74]. Such a conclusive analysis 
should include genetic variability in the genes ABCB1, CYP3A5, PPP3CA of the donor.
Future research perspectives
The balance between high efficacy and a minimum of side effects of immunosuppressive 
treatment is fragile, especially in transplantation were the main immunosuppressive drugs 
have a low bioavailability, a narrow therapeutic index and high inter-patient variability. 
Finding the right immunosuppressive regimen and exposure for the right patient at 
the right time is the main challenge for the future. This thesis aimed to fulfill a part of 
this challenge, however, only small steps forward were made and much more research 
is needed to find the optimal immunosuppressive treatment for the individual patient. 
Finding factors that are predictive for short term (clinical and subclinical rejection) and 
subsequently long term outcome (graft survival) are essential to achieve an increase in 
survival for renal transplant recipients. Transplant characteristics such as donor type, HLA-
DR mismatch, cold ischemic time and donor age are currently still the most predictive 
factors for the initial immunological risk. Although strict therapeutic drug monitoring 
is performed for most drugs still some patients are at risk for rejection or toxicity, 
therefore better biomarkers are needed to guide adequate clinical immunosuppression. 
Ideally a biological marker reflecting the immunological status of an individual should 
be used for monitoring immunosuppressive treatment. Unfortunately pharmacodynamic 
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markers are still not suitable for clinical practice or not available. Currently attempts 
are made to measure immunosuppressive drug concentrations at the site of action like 
PBMCs [86] but research is still in its early stages. Especially drugs that are substrates 
of P-glycoprotein (P-gp) like CNIs and mTOR inhibitors are of interest since P-gp could 
potentially have a large impact on drug disposition in PBMC resulting in differences in 
immunosuppressive effect. On the other hand less invasive biomarkers for early prediction 
of acute rejection as free circulating DNA and donor-specific antibodies are currently also 
under investigation [87,88]. Also promising biomarkers for nephrotoxiticy are under 
development [89]. Combining such biomarkers with a pharmacokinetic model might 
help to find an individual’s unique target concentration range. Pharmacogenetics on 
pharmacokinetic parameters has been of great interest during the past decade in the field 
of renal transplantation, however only a few suitable pharmacogenetic markers predicting 
exposure have been found. Furthermore the additional value of initial dosing based on 
pharmacogenetic markers with respect to long term outcome has not yet been established. 
The focus of pharmacogenetics should be expanded to pharmacodynamics parameters 
like polymorphisms in the mTOR gene or calcineurin gene to identify patients at risk 
for certain side effects or under immunosuppression. All efforts should be pointed at 
finding the optimal immunosuppressive treatment for the individual patient. To make this 
possible more effort should be made for collaboration between research groups. Especially 
in Europe the need for collaboration between clinicians and scientists is essential to gather 
and analyze large datasets needed to evaluate the effect of future biomarkers on patient 
outcome in large patient populations. Subsequently a systems pharmacology approach 
should be used incorporating the most important sources of variability in terms of 
pharmacokinetics and pharmacodynamics.
Conclusions
mTOR inhibitors form a promising new class of immunosuppressive drugs for mainte-
nance immunosuppression in renal transplantation. The available evidence demonstrates 
that IL-2RA induction with an mTOR inhibitor can successfully reduce CNI exposure by at 
least half without a penalty in terms of rejection in low- or moderate-risk de novo transplant 
recipients and may offer renal and antiviral benefits [90]. Besides these advantages, high 
drug-discontinuation rates and some serious side effects have been limiting for broad 
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introduction of mTOR inhibitors into the field of kidney transplantation. Therapy 
should be further optimized be means of finding the right exposure at the right time. 
With this in mind AUC monitoring can become more and more important, especially in 
the Netherlands where active patient participation and at home monitoring with dried 
blood spot technology are important aspects of how transplantation care will be organized 
in the future. This can only be made possible with wide adaptation of pharmacometric 
tools to assure the optimal balance between minimal patient inconvenience and accurate 
monitoring of immunosuppressive therapy. Few single nucleotide polymorphisms have 
been identified to predict exposure of maintenance immunosuppressive drug, with 
CYP3A5*1 allele as the only undisputed and widely adopted predictive marker for 
tacrolimus clearance. Although an increasing amount of transplantation centers currently 
use this marker for initial dose differentiation, long term benefit has not yet been established. 
Therapeutic drug monitoring of immunosuppressive whole blood concentrations is still 
common practice, although more advanced variants such as monitoring intracellular 
(PBMC) drug concentrations slowly emerge, while pharmacodynamic monitoring is 
still not possible but promising new biomarkers are emerging. Pharmacometrics is the 
ideal tool to correlate clinical events to possible predictive factors as shown in chapter six 
and nine of this thesis. These types of analyses should become more widely adapted to 
the transplantation field. Combining available data in the renal transplantation research 
society and searching collaboration with pharmacometricians can assure optimal use 
of the available research data and will increase the chance of improvement of long term 
outcome of the renal transplant recipient population.
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Renal transplantation is currently the best option for patients with end stage renal disease. 
Despite the low acute rejection rates and successful treatment in the first year after 
renal transplantation, long term outcome after renal transplantation remains poor. An 
important factor influencing survival is optimal immunosuppressive treatment. The work 
presented in thesis aimed at optimizing immunosuppressive therapy in renal transplant 
recipients and especially therapy consisting of the mTOR inhibitor everolimus by 
identifying pharmacological and pharmacogenetic factors influencing pharmacokinetics, 
and pharmcodynamics such as side effects and patient outcome. 
The mTOR inhibitors are a relatively new therapeutic group in renal transplantation and 
have shown their efficacy in recent trials. Their main advantage compared to calcineurin 
inhibitors cyclosporine and tacrolimus are their relative lack of nephrotoxicity. In 
Chapter 2, a systematic review describes the knowledge of clinical pharmacokinetics 
and pharmacodynamics of mTOR inhibitors in renal transplantation at the start of 
this PhD project. The narrow therapeutic window of mTOR inhibitors, together with 
high variability in pharmacokinetics, makes therapeutic drug monitoring essential for 
individualizing the dose and thereby preventing toxicity or rejection. For these reasons 
it is very important to use a reliable and accurate bioanalytical assay. In Chapter 3 the 
differences between the mostly used analytical assays of measuring everolimus in whole 
blood and its effect on dosing advice are investigated. Results showed that the analytical 
methods Fluorescent Polarization Immuno Assay (FPIA) and Liquid Chromatography 
tandem Mass Spectrometry (LC-MS/MS) are not in agreement and everolimus blood 
concentration measurement using FPIA results in systematically higher (23% on average) 
everolimus concentrations compared with LC-MS/MS. Furthermore the use of FPIA 
can lead to clinically relevant differences in everolimus dosage advice and higher intra-
patient variability. Therefore LC-MS/MS outperforms FPIA for clinical monitoring and 
intervention of everolimus therapy in adult renal transplant recipients on dual therapy 
with prednisolone. Therapeutic drug monitoring (TDM) of everolimus is performed 
based on either trough or AUC monitoring and pharmacogenetics might be a valuable 
addition to TDM in order to reach the target drug concentration as soon as possible by 
individualizing the initial dose. Especially drugs with a long elimination half-life such as 
everolimus are at risk of under or overexposure because it takes more time to reach steady 
state target concentration. Polymorphisms in genes coding for metabolizing enzymes 
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might therefore be of interest for optimizing immunosuppressive therapy. In Chapter 
4, a population pharmacokinetic model of everolimus in a calcineurin free regimen was 
developed and predictive factors for pharmacokinetics such as pharmacogenetics were 
explored. Everolimus pharmacokinetics was not significantly influenced by genetic 
polymorphisms in coding genes for the metabolizing enzymes CYP3A5, CYP2C8, PXR 
or drug transporter ABCB1 (also known as P-glycoprotein) and these polymorphisms 
are therefore not suitable as a marker for initial dose individualization. Finally a limited 
sampling model was developed which enables physicians to accurately predict everolimus 
exposure with limited patient discomfort and burden. Using Ctrough and C2 as limited 
sampling markers resulted in an improved predictive performance compared to Ctrough 
monitoring. 
Despite its proven efficacy and close TDM, everolimus is also known for some serious 
side effects with relative high discontinuation rates. In Chapter 5 potential risk factors 
such as demographics, underlying disease, transplant related factors, renal function and 
average everolimus exposure for the most severe side effect of mTOR inhibitors, interstitial 
pneumonitis, were evaluated in a case control study. No risk factors could be identified. In 
a more sophisticated time to event analysis (Chapter 6), risk factors for discontinuation 
and the side effects interstitial pneumonitis, infection and new onset diabetes mellitus 
were explored in a population of renal transplant patients on a regimen of everolimus and 
prednisolone dual therapy. Risk factors of everolimus discontinuation of renal transplant 
recipients on a regimen of everolimus and prednisolone dual therapy were constant 
too high everolimus exposure and high age. The initial dose of 3 mg b.i.d used in this 
study might be too high given the high initial exposure, the high discontinuation rate 
and low acute rejection rate. Furthermore, risk factor for the hazardous side effect non-
infectious interstitial pneumonitis were a too high everolimus exposure and PXR (NR1|2)
( -24113G>A): AA genotype. For infection and new onset diabetes mellitus no significant 
covariates were detected. Lower initial dosing and prevention of too high everolimus 
exposure by strict TDM might decrease the high everolimus discontinuation rates and 
the incidence of interstitial pneumonitis. Pharmacogenetics has only been adopted in 
clinical practice to a small extent for renal transplant recipients. In Chapter 7 the most 
promising polymorphisms (CYP3A5*3 and CYP3A4*22) in renal transplantation were 
evaluated for influence on the pharmacokinetics on the maintenance immunosuppressive 
drugs cyclosporine, everolimus and tacrolimus. Results showed that CYP3A4*22 does 
not influence cyclosporine, everolimus or tacrolimus pharmacokinetics to a clinically 
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relevant extent. Furthermore this study confirmed that CYP3A5*3 is only suitable as a 
predictive marker for tacrolimus clearance but close TDM remains essential due to the 
remaining variability between patients with the same genotype. The CYP3A4 and CYP3A5 
combined genotypes do not further improve the predictive performance compared to 
the predictive performance of the polymorphisms alone. Based on our study the newly 
discovered CYP3A4*22 or CYP3A combined genotypes cannot be advised to be used for 
dose adjustments in clinical practice to further improve immunosuppressive therapy of 
cyclosporine, tacrolimus or everolimus. In addition Chapter 8 reports the findings of the 
effect of peroxide reductase (POR) and CYP3A5 polymorphisms and their combination 
on everolimus pharmacokinetics. In contrast to what was found for tacrolimus but in 
accordance with the findings for sirolimus POR*28 polymorphism or the combination 
with the CYP3A5 polymorphism did not have a significant and clinical relevant impact 
on everolimus pharmacokinetics. Despite low acute rejection rates in the first year after 
transplantation with current standards for immunosuppressive therapy, long-term 
outcome after renal transplantation has not improved accordingly. Acute rejection has been 
previously found to be a risk factor for subclinical rejection. Subclinical rejection (SCR) 
is by definition histologically defined acute rejection and, as such, has been associated 
with subsequent interstitial fibrosis and tubular atrophy and with time progressive 
deterioration of renal function and inferior graft survival. In Chapter 9 risk factor were 
identified for delayed graft function, acute rejection and subclinical rejection in patients 
on a cyclosporine based immunosuppressive regimen. The incidence of acute rejection 
(AR) and prevalence of SCR with controlled and early reduced systemic cyclosporine 
exposure within 6 months was found to be 14% and 18%, respectively. Pharmacological 
factors, including exposure and genetic variability in the genes coding for relevant 
pharmacokinetic and pharmacodynamics proteins, were not found to be related to the 
risk for delayed graft function (DGF), AR or SCR. Receiving a kidney from a deceased 
donor was the dominant risk factor for DGF, with DGF being the primary risk factor 
for AR. For SCR the most important risk factors were a previous acute rejection episode, 
and being recipient of a deceased donor kidney. Finally a significant relationship was 
identified between rejection treatment including ATG and a lower subsequent prevalence 
of SCR. Finally in Chapter 10 the results from the performed research are discussed 
and future perspectives are presented. MTOR inhibitors form a promising new class of 
immunosuppressive drugs for maintenance immunosuppression in the field of kidney 
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transplantation and may offer renal and antiviral benefits without increasing the risk of 
acute rejection. Despite these advantages and TDM, mTOR inhibitors are also known for 
high discontinuation rates and some serious side effects. Even with all current options 
of immunosuppression long term outcome for renal transplant recipients is still poor. 
Immunosuppressive therapy should therefore by further optimized by means of finding 
the amount of immunosuppression at the right time. Finding new biomarkers for early 
detection of (subclinical) rejection and toxicity are therefore essential. Pharmacometrics 
is the ideal science for reaching this goal. Research collaborations of pharmacometricians 
and nephrologists should be formed to assure optimal use of the available clinical data to 






Momenteel is niertransplantatie de aangewezen behandeling voor patiënten met 
eindstadium nierfalen. Ondanks de lage incidentie van acute rejectie en succesvolle rejectie 
behandeling in het eerste jaar na niertransplantatie laten de lange termijn uitkomsten 
na niertransplantatie nog te wensen over. Een van de factoren die overleving beïnvloed 
is optimale immunosuppressieve behandeling. Het onderzoek dat in dit proefschrift 
gepresenteerd wordt is gericht op het optimaliseren van immunosuppressieve therapie 
bij niertransplantatiepatiënten en in het bijzonder de immunosuppressieve therapie met 
de mTOR-remmer everolimus. Dit is gedaan door het identificeren van farmacologische 
en farmacogenetische factoren die de farmacokinetiek en dynamiek beïnvloeden, zoals 
bijwerkingen en prognose van de patiënt.
De mTOR-remmers zijn een relatief nieuwe therapeutische groep in het veld van 
niertransplantatie en hebben in recente studies hun effectiviteit aangetoond. Het 
belangrijkste voordeel ten opzichte van de calcineurine remmers ciclosporine en 
tacrolimus is het relatieve gebrek aan nefrotoxiciteit. In Hoofdstuk 2 wordt in een 
systematische review de kennis van de klinische farmacokinetiek en dynamiek van de 
mTOR-remmers bij niertransplantatie aan het begin van dit promotie project beschreven. 
De smalle therapeutische breedte van de mTOR-remmers, in combinatie met een hoge 
variabiliteit in farmacokinetiek, maakt therapeutische geneesmiddel monitoring (TDM) 
van essentieel belang voor het individualiseren van de dosering en daarmee het voorkomen 
van toxiciteit of rejectie. Om deze reden is het zeer belangrijk om een  betrouwbare en 
nauwkeurige bioanalytische bepalingsmethode te gebruiken. In Hoofdstuk 3 zijn de 
verschillen tussen de meest gebruikte analytische bepalingsmethodes voor het meten 
van everolimus concentratie in volbloed en het effect daarvan op het dosering advies 
onderzocht. De resultaten toonden aan dat de analysemethoden Fluorescent Polarization 
Immuno Assay (FPIA) en Liquid Chromatography tandem Mass Spectrometry (LC-MS/
MS) niet één op één uitwisselbaar waren en dat bepaling van everolimus bloedconcentraties 
met behulp FPIA resulteert in systematisch hogere (23% gemiddeld) everolimus 
concentraties in vergelijking met LC-MS/MS. Het gebruik van FPIA als analysemethode 
kan bovendien leiden tot klinisch relevante verschillen in het everolimus dosering advies 
en introduceert tevens hogere intra-patiënt variabiliteit. Om deze redenen is LC-MS/MS 
een geschiktere methode dan de FPIA methode voor de controle van everolimus therapie 
bij niertransplantatie patiënten. 
239Nederlandse samenvatting (Dutch summary)
TDM van everolimus wordt uitgevoerd op basis van ofwel dalspiegels of monitoring van 
de zogenaamde oppervlakte onder concentratie tijd curve (AUC). Farmacogenetica kan 
een waardevolle aanvulling zijn op TDM om de gewenste geneesmiddelblootstelling zo 
snel mogelijk te realiseren door de initiële dosering te individualiseren. Vooral 
geneesmiddelen met een lange halfwaardetijd zoals everolimus lopen het risico om op te 
hoge of te lage blootstelling uit te komen omdat het bereiken van de stabiele doelconcentratie 
meer tijd kost. Polymorfismen in genen die coderen voor metaboliserende enzymen 
kunnen daarom nuttig zijn voor het optimaliseren van immunosuppressieve therapie. In 
Hoofdstuk 4 wordt een populatie farmacokinetisch model van everolimus in een 
immunosuppressief regime zonder calcineurine-remmer ontwikkeld en worden potentieel 
voorspellende factoren voor de farmacokinetiek zoals farmacogenetica verkend. De 
farmacokinetiek van everolimus werd niet significant beïnvloed door genetische 
polymorfismen in coderende genen voor de enzymen CYP3A5, CYP2C8, PXR of de 
geneesmiddel transporter ABCB1 (ook bekend als P-glycoproteïne). Deze polymorfismen 
kunnen daarom niet worden gebruikt voor de individualisering van de initiële everolimus 
dosis. Ten slotte is een zogenaamd limited sampling model ontwikkeld dat artsen in staat 
stelt om de everolimus blootstelling met zo weinig mogelijk ongemak voor de patiënt toch 
nauwkeurig te voorspellen. Door de dalspiegel en een spiegel 2 uur na de gift te gebruiken 
in het ontwikkelde limited sampling model wordt een klinische relevante verbetering van 
de voorspellende prestaties ten opzichte van de dalspiegel monitoring behaald. Ondanks 
de bewezen werkzaamheid en nauwkeurige monitoring van de therapie is everolimus ook 
geassocieerd met een aantal ernstige bijwerkingen en een relatief hoog aantal patiënten 
dat stopt met de therapie. In Hoofdstuk 5 worden potentiële risicofactoren zoals 
demografische factoren, onderliggende ziekte, transplantatie gerelateerde factoren, 
nierfunctie en gemiddelde everolimus blootstelling voor de meest ernstige bijwerking van 
mTOR-remmers, niet-infectieuze interstitiële pneumonitis, geëvalueerd in een case-
control studie. Er werden geen risicofactoren geïdentificeerd in deze analyse. In een meer 
geavanceerde time-to-event analyse (Hoofdstuk 6), werden risicofactoren voor het staken 
van de therapie en de bijwerkingen; niet-infectieuze interstitiële pneumonie, infectie en 
diabetes mellitus onderzocht in een groep niertransplantatiepatiënten die werden 
behandeld met een immunosuppressief regime van everolimus en prednisolon. 
Risicofactoren voor het moeten staken van de everolimus therapie waren een te hoge 
everolimus blootstelling en hoge leeftijd. De initiële dosis van 3 mg tweemaal daags is 
vermoedelijk te hoog gezien de hoge initiële blootstelling, de hoge frequentie van het 
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staken van de therapie en lage incidentie van acute rejectie. Als risicofactoren voor de 
gevaarlijke bijwerking niet-infectieuze interstitiële pneumonitis werd te hoge everolimus 
blootstelling en het PXR (NR1 | 2) (-24113G> A): AA genotype gevonden. Voor het 
optreden van een infectie en het ontstaan  van Diabetes Mellitus werden geen significante 
risicofactoren gevonden. Een lagere initiële dosering en het voorkomen van een te hoge 
everolimus blootstelling door strikte TDM zal de frequentie van het staken van de therapie 
en de incidentie van interstitiële pneumonitis waarschijnlijk verlagen. Farmacogenetica 
wordt momenteel slechts in beperkte mate toegepast in de klinische praktijk bij 
niertransplantatiepatiënten. In Hoofdstuk 7 zijn de meest veelbelovende polymorfismen 
(CYP3A5*3 en CYP3A4*22) die gebruikt zouden kunnen worden bij niertransplantatie 
onderzocht op hun invloed op de farmacokinetiek ciclosporine, everolimus en tacrolimus. 
De resultaten toonden aan dat CYP3A4*22 geen klinisch relevante invloed op heeft op de 
farmacokinetiek van ciclosporine, everolimus of tacrolimus. Verder bevestigde deze studie 
dat CYP3A5*3 alleen voor tacrolimus geschikt is als voorspellende marker voor 
blootstelling. Intensieve TDM blijft echter essentieel vanwege de relatief grote variabiliteit 
tussen patiënten met hetzelfde genotype. Het CYP3A4 en CYP3A5 gecombineerd genotype 
leidt niet tot een relevante verbetering van het voorspellend vermogen in vergelijking met 
het voorspellend vermogen van de individuele polymorfismen. Het nieuw ontdekte 
CYP3A4*22 of CYP3A gecombineerd genotype zijn daarom niet geschikt om te worden 
gebruikt voor de aanpassing van de initiële dosering van ciclosporine, tacrolimus of 
everolimus. Daarnaast worden in Hoofdstuk 8 de bevindingen van de analyse naar het 
effect van peroxide reductase (POR) en CYP3A5-polymorfismen en hun combinatie op de 
farmacokinetiek van everolimus gerapporteerd. In tegenstelling tot wat werd gevonden 
voor tacrolimus, maar in overeenstemming met de bevindingen voor sirolimus blijkt het 
POR*28 polymorfisme of de combinatie met het CYP3A5 polymorfisme niet een 
significante en klinisch relevante invloed op de farmacokinetiek van everolimus hebben. 
Ondanks de lage incidentie van acute rejectie in het eerste jaar na transplantatie die zijn 
behaald met de huidige immunosuppressieve therapie, is de lange-termijn uitkomst niet 
op vergelijkbare wijze verbeterd. Acute rejectie is al eerder geïdentificeerd als een 
risicofactor voor subklinische rejectie (SCR). SCR is histologisch gedefinieerde acute 
rejectie en is als zodanig geassocieerd met opeenvolgende interstitiële fibrose en tubulaire 
atrofie. Dit leidt vervolgens tot progressieve verslechtering van de nierfunctie en een 
slechtere transplantaatoverleving. In Hoofdstuk 9 zijn risicofactoren geïdentificeerd voor 
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het vertraagd op gang komen van het transplantaat (delayed graft function (DGF)), acute 
rejectie (AR) en SCR bij patiënten die werden behandeld met een immunosuppressief 
regime met als basis ciclosporine. De incidentie van AR en SCR binnen 6 maanden onder 
gecontroleerde en vroeg verminderde systemische ciclosporine blootstelling bleek 14% en 
18%, respectievelijk te zijn. Farmacologische factoren zoals ciclosporine blootstelling en 
genetische variabiliteit in de genen die coderen voor relevante farmacokinetische en 
farmacodynamische eiwitten bleken niet gerelateerd te zijn aan het risico op DGF, AR of 
SCR. Het ontvangen van een nier van een overleden donor was de dominante risicofactor 
voor DGF. DGF was vervolgens de primaire risicofactor voor het optreden van AR. Voor 
SCR bleken de belangrijkste risicofactoren een eerdere doorgemaakt acute rejectie-
episode en het ontvangen van donor nier van een overleden donor te zijn. Tenslotte werd 
een significante relatie gevonden tussen de rejectiebehandeling met Anti-Thymocyten 
Globuline (ATG) en een daaropvolgende lagere prevalentie van SCR. Tot slot worden 
(Hoofdstuk 10) de resultaten van al het uitgevoerde onderzoek bediscussieerd en 
vervolgens toekomstperspectieven voor het optimaliseren van immunosuppressieve 
therapie geschetst. mTOR-remmers vormen een veelbelovende nieuwe groep van 
immunosuppressieve geneesmiddelen voor onderhoud immunosuppressie op het gebied 
van niertransplantatie. Ze bieden waarschijnlijk antivirale en nierfunctie sparende 
voordelen, zonder een verhoging van het risico op acute rejectie. Ondanks deze voordelen 
en intensieve monitoring van de therapie, zijn mTOR-remmers ook bekend om het hoge 
aantal patiënten wat deze middelen slecht verdraagt en een aantal ernstige bijwerkingen. 
Zelfs met alle huidige opties van immunosuppressie is de lange termijn uitkomst bij 
niertransplantatiepatiënten is nog steeds matig. Immunosuppressiva dient derhalve verder 
geoptimaliseerd te worden door middel van het vinden van de juiste hoeveelheid 
immuunsuppressie op het juiste moment. Het vinden van nieuwe biomarkers waarmee 
(subklinische) rejectie en toxiciteit vroeg gedetecteerd kan worden zijn daarvoor essentieel. 
Farmacometrie is de ideale wetenschap voor het bereiken van dit doel. Samenwerkings-
verbanden van specialisten in de farmacometrie en nefrologen moeten worden gevormd 
om een optimaal gebruik van de beschikbare klinische onderzoeksgegevens om uiteindelijk 
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